German court rules Pfizer, BioNTech violated Moderna's COVID-19 vaccine patent
- A German court in Duesseldorf on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna.
- 03/05/2025
|
U.S. FDA places clinical hold on BioNTech's malaria vaccine study
- BioNTech said in a regulatory filing on Tuesday the U.S. Food and Drug Administration has placed a clinical hold on an early-to-mid stage trial of its malaria vaccine.
- 03/04/2025
|
FDA Vaccine Panel Meeting To Discuss Flu Shots Reportedly Canceled
- A meeting of the Food and Drug Administration's vaccine advisory committee to discuss the next season's flu vaccine has reportedly been canceled, the second such disruption of a meeting involving vaccine policy experts at the federal level since prominent vaccine skeptic Robert F. Kennedy Jr took over as the Health and Human Services secretary earlier this month.
- 02/27/2025
|
Vaccine Stocks Rise as Chinese Scientists Discover a New Coronavirus
- Stocks of MRNA, PFE, NVAX and BNTX rose in anticipation that a new virus in China could trigger another pandemic.
- 02/24/2025
|
BioNTech to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on March 10, 2025
- MAINZ, Germany, February 24, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the fourth quarter and full year 2024 on Monday, March 10, 2025. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (1:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.
- 02/24/2025
|
What Makes BioNTech (BNTX) a New Buy Stock
- BioNTech (BNTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 02/13/2025
|
Vaccine, packaged food stocks fall as Kennedy moves closer to health secretary job
- Shares of vaccine makers and packaged food companies fell on Tuesday after President Donald Trump's pick for U.S. health secretary, Robert F. Kennedy Jr., moved closer to the job after a favorable vote by a Senate panel.
- 02/04/2025
|
Vaccine stocks fall as Senate panel advances RFK Jr.'s nomination for HHS secretary
- Shares of vaccine companies fell after a Senate panel voted to advance Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services to the full chamber.
- 02/04/2025
|
BioNTech Completes Acquisition of Biotheus
- MAINZ, Germany, February 3, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the completion of the acquisition of Biotheus (“Biotheus”), a clinical-stage biotechnology company dedicated to the discovery and development of novel antibodies to address unmet medical needs of patients with oncological or inflammatory diseases. The acquisition was announced on November 2024 and builds on the successful collaboration on the late-stage clinical asset BNT327, an investigational bispecific antibody targeting PD-L1 and VEGF-A, and other bispecific antibody candidates.
- 02/03/2025
|
3 Dirt-Cheap Stocks to Buy in a Market That's Priced for Perfection
- How expensive is the stock market right now? The S&P 500 Shiller CAPE ratio is near its second-highest level ever.
- 01/22/2025
|
Wall Street Analysts Predict a 25.59% Upside in BioNTech (BNTX): Here's What You Should Know
- The average of price targets set by Wall Street analysts indicates a potential upside of 25.6% in BioNTech (BNTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 01/17/2025
|
BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
- MAINZ, Germany, January 14, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today will present its 2025 strategic priorities and progress on the Company's pipeline of mRNA therapeutics, immunomodulators, and targeted therapies at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California.
- 01/14/2025
|
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
- This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 billion by 2028. Every year, the FDA and EMA approve dozens of anticancer drugs, so Seeking Alpha readers should be careful when making decisions.
- 01/13/2025
|
BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst
- On Thursday, Truist initiated coverage on BioNTech SE BNTX, a famed COVID-19 vaccine maker, in collaboration with Pfizer Inc PFE.
- 01/10/2025
|
BioNTech initiated with a Buy at Truist
- Truist initiated coverage of BioNTech with a Buy rating and $172 price target. BioNTech is an oncology company "at heart, even though it was the COVID vaccine that made it a household name," the analyst tells investors in a research note. The firm says that with the pandemic in the rear-view mirror, investor focus is increasingly shifting to BioNTech's oncology business. It says 2025 is set up with potentially stock-moving read-outs for key assets, presenting "ample opportunity" for BioNTech to grow into the price target.
- 01/09/2025
|
5 Predictions for the Stock Market in 2025 -- and Which Stocks Will Soar the Most If They're Right
- Nearly one year ago, I made four predictions about the stock market in 2024. I thought the S&P 500 would generate positive returns but lower than in 2023.
- 01/04/2025
|
BioNTech enters settlement with US agency, UPenn over COVID vaccine royalties
- BioNTech has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University of Pennyslvania over the payment of royalties related to its COVID-19 vaccine, the company said in filings on Friday.
- 12/27/2024
|
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
- Investing in biotech stocks usually isn't for the faint of heart. These stocks tend to be highly volatile because of the inherent risks of developing new drugs.
- 12/18/2024
|
US FDA lifts partial clinical hold on BioNTech cancer drug study
- BioNTech SE said on Friday it has been informed by its partner OncoC4 that the U.S. Food and Drug Administration has lifted the partial clinical hold on its late-stage trial studying its drug for a type of lung cancer.
- 12/13/2024
|
2 Healthcare Stocks to Buy Hand Over Fist and 1 to Avoid
- I've long viewed healthcare as one of the best sectors for long-term investors because everybody requires healthcare products and services sooner or later. With aging populations in the U.S. and other major countries, the demand will almost certainly increase over the next decade and beyond.
- 12/11/2024
|
2 No-Brainer Stocks to Buy Before the End of 2024
- I think the stock market's valuation has become frothy. And I'm in good company; Warren Buffett's actions show that he shares this opinion.
- 12/09/2024
|
Why Is BioNTech Stock Trading Higher On Friday?
- On Thursday, Duality Biologics revealed the first data from a global Phase 1/2a trial of BNT324/DB-1311, which it co-developed with BioNTech SE BNTX.
- 12/06/2024
|
5 Top Stocks to Buy in December
- The end of the year can spur myriad feelings when deciding which stocks are the best buys.
- 12/04/2024
|
BioNTech Stock Has Been Hit Hard Since RFK Jr.'s Nomination. Why This Analyst Upgraded It.
- Evercore ISI analyst Cory Kasimov upgrades the German drugmaker's stock to Outperform from In Line.
- 11/19/2024
|
Analysts Turn Bullish on BioNTech Stock Amid Volatility
- BioNTech SE ADR (NASDAQ:BNTX) stock is up 2.8% to trade at $825.41 at last glance, after an Evercore ISI upgrade to "outperform" from "in-line.
- 11/19/2024
|
BioNTech and Moderna at vanguard of new treatment wave - but which is best?
- The mRNA (messenger RNA) technology that powered the rapid development of COVID-19 vaccines is now driving a broader revolution in medicine. According to Berenberg, this innovative approach has the potential to transform the treatment of multiple ailments, particularly cancer and infectious diseases.
- 11/19/2024
|
Vaccine Maker Stocks Slump After RFK Jr. Nominated as HHS Head
- In the 2024 presidential election's latest impact on the stock markets, shares of several vaccine makers were down Friday morning following the nomination of Robert F. Kennedy Jr. to head the Department of Health and Human Services.
- 11/15/2024
|
European And US Vaccine Stocks Are Under Pressure - Here's WHy
- Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services.
- 11/15/2024
|
BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock Up
- BioNTech inks a deal to acquire Biotheus and gain full global rights to a bispecific antibody, BNT327/PM8002, being studied for various oncology indications.
- 11/14/2024
|
BioNTech buys China's Biotheus to support oncology strategy
- German drugmaker BioNTech has agreed to acquire Chinese biotech company Biotheus to support its oncology strategy and gain full global rights to the bispecific antibody candidate BNT327, it said on Wednesday.
- 11/13/2024
|
BioNTech to Acquire Biotheus to Boost Oncology Strategy
- MAINZ, Germany, November 13, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Biotheus (“Biotheus”) today announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage biotechnology company dedicated to the discovery and development of novel antibodies to address unmet medical needs of patients with oncological or inflammatory diseases.
- 11/13/2024
|
BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential
- Goldman Sachs has upgraded BioNTech SE BNTX, citing the company's BNT327, an immuno-oncology asset in clinical development across multiple solid tumors.
- 11/09/2024
|
BioNTech Q3 Earnings Review: Good Quarter, Strong Promise -- But Still A Hold
- BioNTech SE's stock saw a spike in September due to positive data from Summit Therapeutics' ivonescimab, which has a similar mechanism to BioNTech's BNT327. BioNTech's Q3 earnings showed improved revenues and profit, largely driven by its COVID-19 vaccine, Comirnaty, which remains a significant revenue source. Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a “Hold” rating.
- 11/06/2024
|
BioNTech SE (BNTX) Q3 2024 Earnings Call Transcript
- BioNTech SE (NASDAQ:BNTX ) Q3 2024 Earnings Conference Call November 4, 2024 8:00 AM ET Company Participants Michael Horowicz - Director, Investor Relations Ugur Sahin - Chief Executive Officer & Co-Founder Özlem Türeci - Chief Medical Officer & Co-Founder Jens Holstein - Chief Financial Officer Ryan Richardson - Chief Strategy Officer Conference Call Participants Tazeen Ahmad - Bank of America Securities Daina Graybosch - Leerink Partners Suzanne van Voorthuizen - VLK Terence Flynn - Morgan Stanley Yaron Werber - TD Cowen Jessica Fye - JPMorgan Chase Cory Kasimov - Evercore ISI Luke Shumway - BMO Capital Markets Ellie Merle - UBS Yifeng Liu - HSBC Bank Plc Simon Baker - Redburn Atlantic Manos Mastorakis - Deutsche Bank Jay Olson - Oppenheimer Operator Welcome to BioNTech's Third Quarter 2024 Earnings Call. I would like to hand the call over to Michael Horowicz, Director of Investor Relations.
- 11/04/2024
|
BioNTech surprises with Q3 profit driven by strong vaccine sales
- BioNTech SE reported a surprising profit for the third quarter, achieving earnings of €0.81 ($0.88) per diluted share, far exceeding analyst expectations of a loss of €1.84. The Mainz, Germany-based company also posted sales of €1.2 billion, nearly three times higher than anticipated.
- 11/04/2024
|
BioNTech Variant-adapted COVID-19 Vaccines Do Well In Q3
- On Monday, BioNTech SE BNTX reported third-quarter revenues of 1.244 billion euros (or $1.36 billion), up from 895.3 million euros a year ago.
- 11/04/2024
|
BioNTech lowers full-year revenue outlook on COVID-19 seasonality, inventory write-downs
- German drugmaker BioNTech on Monday lowered its guidance for full-year revenue, citing COVID-19 uptake and price levels, inventory write-downs and Pfizer charges.
- 11/04/2024
|
BioNTech Announces Third Quarter 2024 Financial Results and Corporate Update
- Conference call and webcast scheduled for November 4, 2024, at 8:00 a.m. EST (2:00 p.m. CET)
- 11/04/2024
|
BioNTech to Host Innovation Series R&D Day on November 14, 2024
- MAINZ, Germany, October 31 , 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), will host an edition of the Company's Innovation Series R&D Day at 10:30 a.m. Eastern Standard Time (16:30 p.m. CET) on Thursday, November 14, 2024 in New York City, U.S.
- 10/31/2024
|
BioNTech to Report Q3 Earnings: Is a Beat in the Cards?
- On BNTX's third-quarter 2024 earnings call, investors' focus is likely to be on the updates related to its oncology pipeline.
- 10/25/2024
|
BioNTech's Oncology Gamble: High Stakes, Big Potential
- BioNTech's oncology assets, including BNT327/PM8002, show promising results, with a notable 39.3% ORR in PD-L1-negative EGFR-mutated NSCLC patients. BioNTech's stock has risen by 24% since March, outperforming the S&P 500, driven by optimism in their oncology pipeline. Despite a partial FDA hold on BNT316/ONC-392 for NSCLC, other trials and treatments remain unaffected, signaling potential for resolution.
- 10/21/2024
|
BioNTech to Report Third Quarter 2024 Financial Results and Corporate Update on November 4, 2024
- MAINZ, Germany, October 21, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2024 on Monday, November 4, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.
- 10/21/2024
|
Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents
- Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's High Court.
- 10/08/2024
|
BioNTech (BNTX) Presents at Innovation Series: AI Day
- BioNTech SE (NASDAQ:BNTX ) Company Conference Call October 1, 2024 9:00 AM ET Company Participants Karim Beguir - Chief Executive Officer, InstaDeep Uğur Şahin - Chief Executive Officer, BioNTech Ryan Richardson - Chief Strategy Officer, BioNTech Nacef Labidi - Head of Infrastructure, InstaDeep Alex Laterre - Head of Research, InstaDeep Alex Graves - Research Scientist, InstaDeep Bora Guloglu - Research Scientist, InstaDeep Julia Gimbernat - Product Manager, InstaDeep Arnu Pretorius - Research Scientist, InstaDeep Youssef Ben Dhieb - Senior ML Engineer, InstaDeep Thomas Pierrot - Research Scientist, InstaDeep Maren Lang - Senior Director, Bioinformatics R&D, BioNTech Marie Lopez - Research Engineer Team Lead, InstaDeep Daniel Rothenberg - Associate Director, Proteomics, BioNTech Michael Rooney - Director, Computational Biology, BioNTech Nicolas Lopez Carranza - Head of BioAI, InstaDeep Hippolyte Jacomet - Research Engineer, InstaDeep Sven Coutandin - Director, Global R&D Automation, BioNTech David Drakard - Senior Research Engineer, InstaDeep Michael Dahms - Director, Digitization R&D Labs, BioNTech Conference Call Participants Sam Fazeli - Bloomberg Intelligence Harry - Time Magazine Ian Johnston - Financial Times Unidentified Speaker - Karim Beguir Hi everyone. Welcome to AI Day.
- 10/03/2024
|
BioNTech Highlights AI Capabilities and R&D Use Cases at Inaugural AI Day
- LONDON, United Kingdom, October 1, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), alongside its artificial intelligence (“AI”) subsidiary InstaDeep Ltd . (“InstaDeep”), today presents an overview of its AI approach during an edition of the Company's Innovation Series, AI Day.
- 10/01/2024
|
PFE & BNTX Get Positive CHMP Opinion for Updated COVID-19 Jab
- The Committee for Medicinal Products for Human Use recommends marketing authorization for Pfizer and BioNTech's updated version of mRNA COVID-19 jab, Comirnaty.
- 09/23/2024
|
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
- NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization for the companies' Omicron KP.2-adapted monovalent COVID-19 vaccine (COMIRNATY® KP.2) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The European Commission wil.
- 09/20/2024
|
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
- Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron KP.2-adapted COVID-19 vaccine generates a substantially improved response against multiple circulating Omicron JN.1 sublineages as did the Omicron JN.1-adapted COVID-19 vaccine authorized by the European Commission in July 2024 Doses will be ready to ship to applicable European Union member states as soon as possible upon European Commission authorization NEW YORK and MAINZ, GERMANY, SEPTEMBER 20, 2024 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) has recommended marketing authorization for the companies' Omicron KP.2-adapted monovalent COVID-19 vaccine (COMIRNATY® KP.2) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The European Commission (“EC”) will review the CHMP's recommendation and is expected to make a final decision soon.
- 09/20/2024
|
BioNTech Is More Than a Covid-19 Stock. It's Having a Great September.
- Recently BioNTech has been boosted a wave of enthusiasm over another company's cancer drug, which has turned the biopharma industry upside down.
- 09/19/2024
|
How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery
- BioNTech stock has climbed 25% over four days as the German biotech rides a round of cancer treatment success from Summit Therapeutics.
- 09/17/2024
|
BioNTech to Host AI Day as an Edition of its Innovation Series on October 1, 2024
- MAINZ, Germany, September 17, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”), alongside its artificial intelligence (“AI”) company InstaDeep Ltd. (“InstaDeep”), will host an AI Day, an edition of BioNTech's “Innovation Series”, at 09:00 a.m. EDT (3:00 p.m. CEST) on Tuesday, October 1st, 2024 in London, United Kingdom. The event will provide an overview of BioNTech's and InstaDeep's AI strategy and capabilities, and the application of AI in BioNTech's pipeline and internal processes.
- 09/17/2024
|
Trade It or Fade It: The week's big biotech moves
- Jared Holz, Mizuho, joins 'Fast Money' to talk his playbook on recent biotech movers.
- 09/13/2024
|
BioNTech (BNTX) Stock Jumps 5.8%: Will It Continue to Soar?
- BioNTech (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
- 09/13/2024
|
BioNTech's Low Valuation, Many Shots On Goal Make It A Buy
- BioNTech shares surged 13% after Summit Therapeutics reported positive data on ivonescimab, a bispecific antibody similar to BioNTech's PM8002. BioNTech's PM8002 antibody is similar to Summit's ivonescimab. Despite declining Covid-19 vaccine revenue and safety concerns about those shot, BioNTech's low valuation and promising pipeline make it a buy for risk-tolerant, long-term investors.
- 09/11/2024
|
BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024
- MAINZ, Germany, September 05, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected assets from its multi-platform oncology pipeline at the European Society for Molecular Oncology (“ESMO”) Congress 2024 in Barcelona, Spain from September 13-17, 2024. The oral and poster presentations will feature programs across BioNTech's clinical pipeline, including mRNA-based cancer vaccines, next-generation immunomodulators and targeted therapy approaches.
- 09/05/2024
|
BioNTech BNT116 Lung Cancer mRNA Vaccine Clinical Trials Initiated
- Currently More Than 5 Lung Cancer Vaccines Based On mRNA Platform Are Under Clinical Trials Says Kuick Research Currently More Than 5 Lung Cancer Vaccines Based On mRNA Platform Are Under Clinical Trials Says Kuick Research
- 08/25/2024
|
Genmab: Strong H1 2024 Performance, Partner BioNTech Gives Up On Acasunlimab
- Genmab's stock continues to struggle despite the strong progress of the company's commercial portfolio in the first half of the year. Epkinly is now FDA-approved for third-line+ follicular lymphoma, which should boost its revenue growth rates in the following quarters. BioNTech gave up on co-development of acasunlimab, but Genmab is undeterred and expects to start a phase 3 trial by the end of the year.
- 08/23/2024
|
Lung cancer patient is first in UK to receive experimental vaccine
- A lung cancer patient has become the first in the UK to receive a new experimental vaccine to help his body fight the disease.
- 08/22/2024
|
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
- NEW YORK and MAINZ, GERMANY, August 22, 2024 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved the supplemental Biologics License Application for individuals 12 years of age and older (COMIRNATY® (COVID-19 Vaccine, mRNA)), and granted emergency use authorization for individuals 6 months through 11 years of age (Pfizer-BioNTech COVID-19 Vaccine) of the companies' Omicron KP.2-adapted 2024-2025 Formula COVID-19 vaccine. This season's vaccine is for use as a single dose for most individuals 5 years of age and older. Individuals 5 years of age and older with certain kinds of immunocompromise previously vaccinated with Pfizer and BioNTech COVID-19 vaccines or children under the age of 5 who have not already completed a three-dose series with previous formulas of a COVID-19 vaccine may be eligible to receive additional doses.
- 08/22/2024
|
BioNTech: Clinical Hold Removal Pushes ADC Development Program Forward
- Partial clinical hold of BioNTech SE's BNT326/YL202 for the treatment of patients with solid tumors in phase 1 study was lifted by the FDA. The primary endpoint of ORR of BNT111 in combination with Libtayo, for the treatment of patients with anti-PD-1/anti-PD-L1 relapsed/refractory or unresectable stage III or IV melanoma, met with statistical significance. Positive results obtained from an open-label phase 2 study, using BNT311 + Keytruda for the treatment of patients with relapsed/refractory metastatic non-small cell lung cancer; 12-month overall-survival [OS] rate of 69%.
- 08/20/2024
|
BioNTech says FDA lifts partial hold on its cancer drug trial
- BioNTech on Monday said the U.S. Food and Drug Administration (FDA) has lifted a partial clinical hold on an early stage study of its experimental cancer drug.
- 08/19/2024
|
Pfizer and BioNTech's Combo Shot Missed the Mark. Is It Time to Sell?
- Pfizer and BioNTech recently reported top-line results from a trial of its combination vaccine that was meant to protect against the flu and COVID-19. The partners' combination shot failed to achieve non-inferiority when compared to an approved flu vaccine.
- 08/19/2024
|
Pfizer, BioNTech Combination Flu and COVID-19 Shot Misses 1 of 2 Endpoints
- Shares of Pfizer (PFE) and American depositary receipts (ADRs) of BioNTech (BNTX) dropped in intraday trading Friday following disappointing results from a late-stage study of the drugmakers' combined COVID-19 and flu vaccine in adults.
- 08/16/2024
|
Pfizer, BioNTech COVID-19-flu combination drug meets 1 of 2 trial objectives
- Pfizer Inc. PFE, -0.59% and BioNTech SE BNTX, +2.83% said Friday a Phase 3 trial of their COVID-19-influenza vaccine candidate met one of its two objectives. The companies said the candidate showed “comparable” responses against the SARS-CoV-2 virus when compared with their licensed COVID-19 vaccine, which was one objective.
- 08/16/2024
|
Pfizer, BioNtech say combined flu-COVID vaccine misses a main goal of Phase 3 trial
- Pfizer and BioNTech said a late-stage trial of their experimental mRNA vaccine to protect against influenza and COVID-19 found the combination shot failed to meet one of the study's two main goals and they are evaluating next steps.
- 08/16/2024
|
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
- NEW YORK and MAINZ, Germany, August 16, 2024 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced top-line results from their Phase 3 clinical trial to evaluate the companies' combined mRNA vaccine candidate against influenza and COVID-19 in healthy individuals 18-64 years of age. The combination candidate consists of Pfizer's mRNA-based influenza vaccine candidate with the companies' licensed COVID-19 vaccine. The Phase 3 trial measured two primary immunogenicity objectives (immunogenicity against SARS-CoV-2 as well as immunogenicity against influenza A and B), of which one was met. In a separate Phase 2 trial, Pfizer evaluated trivalent (“tIRV”) influenza mRNA standalone vaccine candidates which demonstrated robust immunogenicity in individuals 18-64 years of age. The companies are evaluating adjustments to the combination vaccine candidate aimed at improving immune responses against influenza B and will discuss next steps with health authorities.
- 08/16/2024
|
3 Biotech Stocks With Promising Drug Pipelines: August 2024
- Investing in biotech stocks with promising pipelines has to be the most exciting area of the market. A successful drug approval can not only unveil a blockbuster treatment worth billions of dollars, but it can literally change people's lives for the better.
- 08/08/2024
|
BioNTech Q2 Earnings Review: No Needle-Moving Catalysts Despite Oncology Promise
- BioNTech SE reported Q2 2024 earnings yesterday, with a significant decrease in revenues from Comirnaty compared to previous years. The company reaffirmed guidance for 2024, for revenues of $2.7bn — $3.4bn, but is expecting a loss-making year due to increased costs. The cash position remains healthy at nearly $20bn, which helps to support a $19.5bn market cap valuation at the present times.
- 08/06/2024
|
BioNTech SE (BNTX) Q2 2024 Earnings Call Transcript
- BioNTech SE (NASDAQ:BNTX ) Q2 2024 Earnings Conference Call August 5, 2024 8:00 AM ET Company Participants Victoria Meissner - Vice President, Strategy & Investor Relations Ugur Sahin - Chief Executive Officer & Co-Founder Özlem Türeci - Chief Medical Officer & Co-Founder Jens Holstein - Chief Financial Officer Ryan Richardson - Chief Strategy Officer Conference Call Participants Daina Graybosch - Leerink Partners Yaron Werber - TD Cowen Tazeen Ahmad - Bank of America Securities Etzer Darout - BMO Capital Markets Yifeng Liu - HSBC Bank Plc Jessica Fye - JPMorgan Chase Cory Kasimov - Evercore ISI Chris Shibutani - Goldman Sachs Simon Baker - Redburn Atlantic Eliana Merle - UBS John Newman - Canaccord Genuity Manos Mastorakis - Deutsche Bank Operator Welcome to BioNTech's Second Quarter 2024 Earnings Call. I would like to hand the call over to Dr. Victoria Meissner, Vice President of Strategy and Investor Relations.
- 08/05/2024
|
BioNTech's Loss Quadruples as COVID-19 Vaccine Demand Falls
- American depositary receipts (ADRs) of BioNTech (BNTX) fell Monday after the COVID-19 vaccine maker's second-quarter loss quadrupled on falling demand for the shots, and as it ended an agreement with biotech firm Genmab to develop a lung cancer drug.
- 08/05/2024
|
BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products
- Monday, BioNTech SE BNTX reported deeper losses in the second quarter of 2024, with an EPS loss of $(3.62) or (3.36) euros, missing the consensus of (1.89) euros and higher than (79) cents in the second quarter of 2023.
- 08/05/2024
|
BioNTech's stock slides 4% after earnings fall short of estimates as COVID vaccine falls slide
- BioNTech SE's stock BNTX, +1.65% fell 4% early Monday, after the company's second-quarter earnings fell short of estimates amid a continued slide in sales of its COVID-19 vaccine. The company had a net loss of 807.8 million euros ($883.5 million), or $3.36 a share, for the quarter, wider than the los of EUR109.4 million, or 79 cents a share, posted in the year-earlier period.
- 08/05/2024
|
BioNTech widens loss to 807.8 mln euro in second quarter
- Losses at Germany's BioNTech quadrupled year-on-year in the second quarter, the company said on Monday, as it banks on a strategy shift towards new cancer treatments following a sharp drop-off in sales of its COVID-19 vaccine.
- 08/05/2024
|
BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update
- Announced positive data from multiple mRNA cancer vaccine clinical trials, including topline results from the ongoing Phase 2 evaluating FixVac candidate BNT111 Launched updated variant-adapted COVID-19 vaccine in the European Union (“EU”), received approval in the United Kingdom and initiated rolling supplemental Biologics Licensing Application (“sBLA”) with the United States Food and Drug Administration (“U.S. FDA”) Reiterates guidance for total revenues in the range of €2.5-3.1 billion Reports second quarter 2024 revenues of €128.7 million, net loss of €807.8 million and loss per share of €3.36 ($3.621) Invested €525.6 million or approximately 90% of the Company's total R&D spend in Q2 in non-COVID-19 related activities, mainly oncology and mRNA; investments are in line with the reiterated full-year R&D expense guidance Ended the second quarter of 2024 with €18.5 billion in cash, cash equivalents and security investments Conference call and webcast scheduled for August 5, 2024, at 8:00 a.m. EDT (2:00 p.m.
- 08/05/2024
|
BioNTech's cancer drug meets primary endpoint in Phase 2 trial
- COVID-19 vaccine maker BioNTech's cancer drug candidate BNT111 showed significant improvement in the response rate in patients with advanced melanoma during a Phase 2 trial, the German company said on Tuesday.
- 07/30/2024
|
BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma
- MAINZ, Germany, July 30, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced positive topline data from the ongoing Phase 2 clinical trial (EudraCT No.: 2020-002195-12 ; NCT04526899 ) in patients with unresectable stage III or IV melanoma whose disease had progressed following anti-PD-(L)1-containing treatment. The randomized trial evaluates the clinical activity and safety of the investigational mRNA cancer immunotherapy BNT111 in combination with Libtayo® (cemiplimab), an anti-PD-1 monoclonal antibody being developed by Regeneron, and assesses the two single agents alone.
- 07/30/2024
|
UK regulator authorises Pfizer-BioNTech shot for JN.1 COVID variant
- Britain's health regulator said on Wednesday it has authorised Pfizer and BioNTech's updated COVID-19 vaccine that targets the JN.1 subvariant of the coronavirus for use in infants, children and adults.
- 07/24/2024
|
BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024
- MAINZ, Germany, July 22, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2024 on Monday, August 5, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (2:00 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.
- 07/22/2024
|
3 Nasdaq Stocks to Sell in July Before They Crash & Burn
- When deciding which stocks to invest in, understanding which exchanges they are listed on can make a big difference in long-term performance and perception. For most U.S.-based investors, the two exchanges they hear about the most are the New York Stock Exchange (NYSE) and the Nasdaq.
- 07/02/2024
|
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
- NEW YORK and MAINZ, Germany, June 27, 2024 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization for the companies' Omicron JN.1-adapted monovalent COVID-19 vaccine (COMIRNATY® JN.1) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the World Health Organization (WHO) Technical Advisory Group on COVID-19 Vaccine Composition and the European Medicines Agency's Emergency Task Force (ETF) to update COVID-19 vaccines to target the SARS-CoV-2 variant JN.1 for the 2024-2025 vaccination campaign. ETF stated that “evidence indicates that targeting JN.1 will help maintain the effectiveness of the vaccines as SARS-CoV-2 continues to evolve.” 1, 2
- 06/27/2024
|
BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer
- MAINZ, Germany and SHANGHAI, China, June 24, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Duality Biologics (Suzhou) Co., Ltd. (“DualityBio”) today announced that the U.S. Food and Drug Administration (“FDA”) granted Fast Track designation for BNT324/DB-1311 for the treatment of patients with advanced/unresectable, or metastatic castration-resistant prostate cancer (“CRPC”) who have progressed on or after standard systemic regimens. BNT324/DB-1311 is a next-generation antibody-drug conjugate (“ADC”) candidate targeting the transmembrane glycoprotein B7-H3, an immune checkpoint protein which is overexpressed in a range of tumor types and has been associated with disease progression and poor prognosis for patients. The candidate is currently being evaluated in an ongoing Phase 1/2 study ( NCT05914116) in patients with advanced solid tumors.
- 06/24/2024
|
Why Is Pfizer Partner BioNTech Stock Trading Lower On Monday?
- BioNTech SE's BNTX partner MediLink Therapeutics (Suzhou) Co., Ltd says the FDA has placed a partial clinical hold on the Phase 1 trial.
- 06/17/2024
|
US FDA puts partial clinical hold on BioNTech's early-stage study of cancer drug
- Germany's BioNTech SE said in a regulatory filing on Monday the U.S. Food and Drug Administration has placed a partial clinical hold on an early-stage study of its experimental cancer drug.
- 06/17/2024
|
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
- COPENHAGEN, Denmark & MAINZ, Germany--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and BioNTech SE (Nasdaq: BNTX) today announced initial data from the Phase 2 GCT1046-04 trial (NCT05117242) evaluating acasunlimab (DuoBody-PD-L1x4-1BB), an investigational bispecific antibody also known as GEN1046/BNT311, as monotherapy and in combination with pembrolizumab in patients with PDL(1)-positive mNSCLC who had disease progression following one or more prior lines of anti-PD(L)1 containing treatment. The.
- 06/01/2024
|
New U.S. bird-flu case is first with respiratory symptoms, CDC says
- A new human bird-flu case identified in a Michigan dairy worker is the first in the U.S. to involve acute respiratory symptoms, the Centers for Disease Control and Prevention said Thursday.
- 05/30/2024
|
BioNTech wins up to $145 mln in CEPI support for African mRNA vaccine plants
- COVID-19 vaccine maker BioNTech won up to $145 million in funding from a global coalition against infectious diseases to build a production network in African countries for messenger-RNA based shots.
- 05/29/2024
|
BioNTech and CEPI Expand Partnership to Strengthen Africa's mRNA Vaccine Ecosystem
- MAINZ, Germany/OSLO, Norway, May 29, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech”, “the Company”) and the Coalition for Epidemic Preparedness Innovations (“CEPI”) are expanding their strategic partnership to contribute to building a sustainable and resilient end-to-end African vaccine ecosystem. CEPI is committing up to US $145 million1 to support BioNTech to establish mRNA vaccine R&D, clinical and commercial-scale manufacturing capabilities at the Company's facility in Kigali, Rwanda. These capabilities will contribute to efforts to better prepare for potential future epidemic and pandemic threats in Africa.
- 05/29/2024
|
MediLink Therapeutics announces a multi-target TMALIN® ADC technology platform license agreement with BioNTech, expanding their global strategic partnership
- SUZHOU, China, May 26, 2024 /PRNewswire/ -- MediLink Therapeutics (Suzhou) Co., Ltd. ("MediLink"), a clinical-stage biotech company, today announces a new strategic collaboration with BioNTech SE (Nasdaq: BNTX, "BioNTech"), a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases, under which BioNTech will receive an exclusive option to an exclusive global license to apply MediLink's TMALIN® antibody-drug conjugate (ADC) platform, for several novel targets chosen by BioNTech.
- 05/26/2024
|
Why Vaccine Stocks Rallied This Week
- H5N1 bird flu was detected this week in Michigan and Australia. It's the first detection in humans since March, when news of an outbreak in cattle emerged.
- 05/24/2024
|
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
- MAINZ, Germany, May 21, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected programs from the Company's diversified immuno-oncology pipeline at the American Society of Clinical Oncology (“ASCO”) Annual Meeting in Chicago, Illinois, from May 31 to June 4, 2024. Moreover, in support of the Company's ongoing CAR-T cell and individualized mRNA programs, BioNTech will also present epidemiological and real-world data from two observational studies in patient populations for which product candidates are being developed in the Company's respective clinical programs.
- 05/21/2024
|
Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announced Term
- Planegg/Martinsried, May 21, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of differentiated T cell immunotherapies for solid tumors and BioNTech SE (Nasdaq: BNTX, “BioNTech”) have announced that their collaboration to advance T cell receptor (TCR) immunotherapies against cancer will extend beyond the initial three-year term outlined at the signing of the agreement in February 2022. This extension will enable ongoing and future work required to potentially generate novel TCRs directed against multiple newly nominated antigen targets that could further expand the BioNTech warehouse of TCR candidates.
- 05/21/2024
|
Moderna wins case in patent dispute with Pfizer, BioNTech over COVID shot, FT reports
- Moderna has won a case at the European Patent Office in its dispute with Pfizer and BioNTech over its COVID-19 vaccine, the Financial Times reported on Friday.
- 05/17/2024
|
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
- MAINZ, Germany, May 17, 2024 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech” or the “Company”) held its Annual General Meeting (“AGM”) today, May 17, 2024. A total of 87.51 per cent of the share capital was represented at the virtual assembly. There were 14 items on the agenda of the AGM. All resolutions proposed on the agenda items put to the vote at today's AGM were approved by a large majority of the shareholders.
- 05/17/2024
|
BioNTech SE (BNTX) Q1 2024 Earnings Call Transcript
- BioNTech SE (NASDAQ:BNTX ) Q1 2024 Earnings Conference Call May 6, 2024 8:00 AM ET Company Participants Victoria Meissner - VP, Strategy & IR Ugur Sahin - Co-Founder & CEO Ozlem Tureci - Chief Medical Officer & Co-Founder Jens Holstein - CFO Ryan Richardson - Chief Strategy Officer Conference Call Participants Tazeen Ahmad - Bank of America Daina Graybosch - Leerink Partners Akash Tewari - Jefferies Jessica Fye - JPMorgan Brendan Smith - TD Cowen Etzer Darout - BMO Capital Terence Flynn - Morgan Stanley William Maughan - Canaccord Hartaj Singh - Oppenheimer Ellie Merle - UBS Simon Baker - Redburn Atlantic Yifeng Liu - HSBC Suzanne Van Voorthuizen - VLK Operator Welcome to BioNTech's First Quarter 2024 Earnings Call. I would like to hand the call over to Dr. Victoria Meissner, Vice President of Strategy and Investor Relations.
- 05/06/2024
|
BioNTech's Outlook Gives Vaccine Maker a Shot in the Arm
- American depositary receipts (ADRs) of BioNTech (BNTX) were down less than 1% in intraday trading Monday after the COVID-19 vaccine maker shrugged off losses and tumbling sales in the first quarter, giving a positive outlook for the year.
- 05/06/2024
|
BioNTech Slides After Reporting Losses As Covid Vaccine Sales Take A Hit
- BioNTech stock fell early Monday after the German biotech reported wider-than-expected losses and short Covid vaccine sales.
- 05/06/2024
|
BioNTech Revenue Falls Sharply on Reduced Covid Vaccine Sales
- The pharmaceutical company posts a first-quarter loss of €1.31 a share, a swing from year-earlier profit of €2.05.
- 05/06/2024
|
BioNTech says 90% of 2024 revenues will accrue at end of year
- Germany's BioNTech , whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, said on Monday that almost all of its expected 2024 revenues would come in at the end of the year.
- 05/06/2024
|
BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
- Advancing toward goal of ten or more potentially registrational trials running by the end of 2024: first patient dosed in Phase 3 clinical trial evaluating BNT323/DB-1303 in HR+ HER2-low chemotherapy-naïve metastatic breast cancer patients, and a second Phase 3 trial with BNT323/DB-1303 in recurrent endometrial cancer planned to start soon Presented clinical data at the American Association for Cancer Research (“AACR”) Annual Meeting for individualized and off-the-shelf mRNA-based cancer vaccine candidates based on iNeST and FixVac platforms, including three-year follow-up data of an investigator-initiated trial in patients with resected pancreatic ductal adenocarcinoma (“PDAC”) Planning to share additional clinical data from multiple clinical programs at the American Society of Clinical Oncology (“ASCO”) Annual Meeting, including bispecific antibodies BNT311/GEN1046 (acasunlimab) and BNT327/PM8002 and antibody-drug conjugate (“ADC”) BNT326/YL202 Continued development and commercial preparation for a 2024 season variant-adapted COVID-19 vaccine First quarter 2024 revenues of €187.6 million, net loss of €315.1 million an d loss per share of €1.31 ($1.421) Maintained strong financial position with €16.9 billion in cash, cash equivalents and security investments Conference call and webcast scheduled for May 6, 2024, at 8:00 a.m. EDT (2:00 p.m.
- 05/06/2024
|
Why Earnings Season Could Be Great for BioNTech (BNTX)
- BioNTech (BNTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 05/03/2024
|
BioNTech (BNTX) to Report Q1 Earnings: Is a Beat in Store?
- On BioNTech's (BNTX) first-quarter 2024 earnings call, investors' focus is likely to be on the updates related to its pipeline development now that the pandemic is over.
- 04/30/2024
|
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
- GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines.
- 04/25/2024
|
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
- MAINZ, Germany, April 22, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2024 on Monday, May 6, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (2:00 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.
- 04/22/2024
|
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
- MAINZ, Germany, April 7, 2024 - BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced three-year follow-up data from a Phase 1 trial with the mRNA-based individualized neoantigen-specific immunotherapy (“iNeST”) candidate autogene cevumeran (also known as BNT122, RO7198457) in patients with resected pancreatic ductal adenocarcinoma (“PDAC”). The data show that in 8 out of 16 patients autogene cevumeran elicited an immune response up to three years post administration measured by activated T cells. The persistence of T cels was associated with a longer median recurrence-free survival in cancer vaccine responders.
- 04/07/2024
|
The 3 Best Bargain Stocks to Buy in Q2 2024
- Best bargain stocks to buy is a simple but tricky concept. Whenever shares trade lower than an established multiple, whether that by earnings, sales, book or some other metric, there might be a reason for it.
- 03/31/2024
|
3 Biotech Stocks to Buy for the Next Bull Run: March 2024
- As we step into March 2024, the spotlight is turning towards the biotech sector, with investors searching for biotech stocks to buy. Biotech stocks are ready to soar after a period of under-performance relative to the broader market.
- 03/26/2024
|
BioNTech gets US agency notice over default on COVID vaccine royalties
- BioNTech said on Monday the U.S. National Institutes of Health has sent a notice to the German company regarding default on the payment of royalties and other amounts related to its COVID-19 vaccine.
- 03/25/2024
|
BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions
- BioNTech's Q4 earnings shows a significant revenue drop and profitability concerns, with expectations of continued vaccine demand decline. Despite short-term challenges, BioNTech's mRNA technology and pipeline, including COVID/flu vaccines and oncology, highlight long-term potential. Financials suggest a strong balance sheet, but projected R&D expenses indicate potential future cash burns.
- 03/20/2024
|
BioNTech SE (BNTX) Q4 2023 Earnings Call Transcript
- BioNTech SE (BNTX) Q4 2023 Earnings Call Transcript
- 03/20/2024
|
BioNTech Earnings Fall Short of Estimates. The Stock Is Down.
- The pharmaceutical firm has been hit hard as demand for Covid-19 vaccines plunged.
- 03/20/2024
|
BioNTech Q4 earnings: COVID franchise to remain a notable cash contributor in 2024
- BioNTech SE (NASDAQ: BNTX) is down nearly 5.0% in premarket on Wednesday after reporting disappointing financial results for the fourth quarter. BioNTech stock down on muted guidance The stock is being hit because $BNTX did not issue an impressive guidance either.
- 03/20/2024
|
BioNTech's stock sinks after earnings fall below expectations, hurt by writedowns of vaccine inventory
- Shares of BioNTech SE BNTX, +1.22% dropped 4.4% in premarket trading Wednesday, after the Germany-based biotechnology company reported fourth-quarter results that fell sharply to miss expectations, weighed down by inventory writedowns by COVID-19 vaccine collaboration partner Pfizer Inc. PFE, -0.32% Net profit for the quarter to Dec. 31 dropped to EUR457.9 million ($496.5 million), or EUR1.90 a share, from EUR2.28 billion, or EUR9.26 a share, in the same period a year ago. That missed the FactSet consensus for earnings per share of EUR2.37.
- 03/20/2024
|
After earnings plunge, BioNTech pins hopes on cancer drug launches
- Germany's BioNTech , whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, reported on Wednesday a plunge in 2023 revenue and earnings as its focus shifts towards cancer drug development.
- 03/20/2024
|
This Biotech Stock Plunged 20% but Wall Street Expects a 195% Recovery
- Investing in biopharmaceutical stocks comes with more risks than some other types of stocks.
- 03/15/2024
|
BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024
- MAINZ, Germany, March 11, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected candidates from its oncology pipeline at the American Association for Cancer Research (“AACR”) Annual Meeting 2024 in San Diego, California, from April 5-10, 2024. The oral and poster presentations will feature BioNTech's investigational mRNA-based cancer vaccine and novel investigational antibody-drug conjugate (“ADC”) approaches.
- 03/11/2024
|
3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success
- Biotech stocks have always been high-risk and high-reward, with the futures and fortunes of companies often decided with a single successful drug trial or Federal Drug Administration (FDA) approval. The right company can yield extravagant returns for the lucky or prudent investor.
- 03/06/2024
|
BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 20, 2024
- MAINZ, Germany, March 6, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the full year and fourth quarter 2023 on Wednesday, March 20, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.
- 03/06/2024
|
Hidden Gems: 7 Oversold Stocks Ready for a Major Rebound
- Ordinarily, you'll want to avoid excessively red-stained ideas. Although certain exceptions might be made for these oversold stocks ready for rebound.
- 03/04/2024
|
It's Time! 3 Dodgy Pharma Stocks to Sell in February
- Much like Big Tech companies ride the AI hype, pharma stocks are counting on valuation boosts from big drug hits and FDA approvals. This anticipation, however, brings to light the importance of discerning which pharma stocks to sell, as not all will sustain their high-growth promises, potentially generating double-digit profits in the short term.
- 03/04/2024
|
3 Pharma Stocks to Sell in February Before They Crash and Burn
- The pharma industry has developed some real blockbusters between novel vaccines and weight loss drugs over the past few years. This has increasingly led investors to view pharma stocks as a promising growth industry after years of underperformance, but many are top pharma stocks to sell.
- 02/02/2024
|
Top 10 stocks to buy in 2024
- 2023 was an incredibly strong year for U.S. stocks but many believe the S&P 500 will push further up in the new year. To play that continued strength, our experts have picked top 10 stocks to buy in 2024.
- 01/16/2024
|
BioNTech SE (BNTX) 42nd Annual J.P. Morgan Healthcare Conference (Transcript)
- BioNTech SE (BNTX) 42nd Annual J.P. Morgan Healthcare Conference (Transcript)
- 01/09/2024
|
BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics
- BioNTech is diversifying its portfolio beyond its COVID-19 vaccine, focusing on antibody-drug conjugates (ADCs) and novel vaccines. The company has acquired MediLink Therapeutics' ADC technology and is targeting HER3 protein-related tumors in cancer treatment. Despite a decline in revenue and profit, BioNTech remains financially robust with strong cash reserves and a solid current ratio.
- 12/28/2023
|
BioNTech's COVID-19 Success Paves The Way For A Strong Drug Pipeline
- BioNTech and Pfizer's COVID-19 vaccine, COMIRNATY, generated $36.8 billion in sales in 2021, making it the highest-selling pharmaceutical product in a single year. BioNTech's stock has faced challenges due to competition and declining COVID-19 demand, leading to the stock dropping 29% this year. However, it has a promising pipeline of therapies in ongoing trials and the potential for recurring revenue from annual COVID-19 booster shots.
- 12/23/2023
|
3 Stocks Down 30% or More This Year That Wall Street Expects to Skyrocket in 2024
- BioNTech's pipeline should take center stage going forward. JD.com is dirt cheap after a big sell-off.
- 12/18/2023
|
Barron's Favorite 10 Stocks for 2024
- Barron's annual list of unloved stocks ranges from tech giant Alibaba to miner Barrick to auto rental stalwart Hertz Global.
- 12/15/2023
|
BioNTech Vs. Moderna: Navigating The mRNA Landscape
- Moderna and BioNTech are pioneering companies in mRNA technology, known for their fast development of highly effective COVID-19 vaccines. Both companies have the potential to transform the treatment landscape for various diseases, including cancer and infectious diseases. Both companies hold late-stage assets that pave the road for near-term growth.
- 11/22/2023
|
BioNTech says European Patent Office has declared Moderna patent invalid
- COVID-19 vaccine maker BioNTech said on Tuesday the European Patent Office has declared as invalid an mRNA patent that has been invoked by Moderna in litigation about alleged an patent violation by BioNTech and its partner Pfizer.
- 11/21/2023
|
3 Biotech Stocks You'll Regret Not Buying Soon: November 2023
- Biotechnology is a booming industry recently focused on synthetic biology, biomanufacturing and gene editing. Biotech is seen as the key to the future, as it has the potential to cure diseases and save many lives.
- 11/14/2023
|
7 Underappreciated Biotech Stocks to Pick Up on the Cheap
- Amid some rising questions for the economy, value-seeking investors may want to consider underappreciated biotech stocks. As a sector that, while not immune to broader pressures, generally manages to march to its own beat, the underlying innovation may offer an alternative upside pathway.
- 11/09/2023
|
BioNTech SE (BNTX) Q3 2023 Earnings Call Transcript
- BioNTech SE (NASDAQ:BNTX ) Q3 2023 Earnings Call Transcript November 8, 2023 8:00 AM ET Company Participants Victoria Meissner - VP, Strategy & IR Ugur Sahin - Co-Founder & CFO Ozlem Tureci - Chief Medical Officer & Co-Founder Jens Holstein - CFO Ryan Richardson - Chief Strategy Officer Conference Call Participants Daina Graybosch - Leerink Partners Tazeen Ahmad - Bank of America Chris Shibutani - Goldman Sachs Yaron Werber - TD Cowen Jessica Fye - JPMorgan Bill Maughan - Canaccord Genuity Simon Baker - Redburn Atlantic Ellie Merle - UBS Operator Welcome to the BioNTech Third Quarter 2023 Update Call. I would like to hand the call over to Dr. Victoria Meissner, Vice President of Strategy and Investor Relations.
- 11/06/2023
|
BioNTech Posts a Profit, While Cutting Its Full-Year COVID Vaccine Sales Outlook
- BioNTech (BNTX) slashed its outlook for sales of its COVID-19 vaccine, but its American depositary receipts (ADRs) jumped over 4% in early trading Monday after the biotech firm posted a surprise profit as it lowered expenses.
- 11/06/2023
|
Tesla, Organigram, BioNTech, Dish, Bumble, FreshPet, Berkshire Hathaway – Stocks on the move
- Dish Network (NASDAQ:DISH), down 10% to $4.94, reported a drop in third-quarter revenue amid declining pay-TV subscribers, triggering a loss for its fiscal third quarter. The US owner of the direct-broadcast satellite provider Dish said in a statement that pay-TV subscribers decreased by roughly 64,000 in Q3, compared to a net increase of approximately 30,000 in the year-ago quarter.
- 11/06/2023
|
BioNTech slashes revenue outlook amid lower Covid vaccine sales
- BioNTech SE has lowered its forecast for this year's Covid-19 vaccine sales by 20%, becoming the latest drugmaker to adjust its expectations in the post-pandemic era. The German company said it now expects 2023 vaccine sales of around €4 billion, down from previous guidance of €5 billion.
- 11/06/2023
|
3 No-Brainer Stocks to Buy for Under $100 Right Now
- AstraZeneca's slump presents a great buying opportunity. BioNTech's future prospects go well beyond COVID-19.
- 10/28/2023
|
7 Undervalued Stocks That Analysts Love Right Now
- Ahead of possible volatility in the market, investors may find some measure of confidence in undervalued stocks. From a psychological perspective, companies that sit well outside the well-beaten path offer the perception that they trade below their intrinsic value.
- 10/26/2023
|
Pfizer and BioNTech announce positive data in early trial of flu/COVID combination vaccine
- Pfizer Inc. PFE and German partner BioNTEch SE BNTX announced positive results from a Phase 1/2 trial of their combined mRNA flu/COVID vaccine on Thursday in adults aged 18 to 64. The vaccine candidates were compared to a licensed influenza vaccine and the companies' omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine given at the same visit.
- 10/26/2023
|
Pfizer, BioNtech say flu-COVID shot generates immune response
- Pfizer and German partner BioNTech said on Thursday that their vaccine to prevent flu and COVID-19 generated a strong immune response against the virus strains in early- to mid-stage trials.
- 10/26/2023
|
Is BioNTech Stock a Buy Now?
- BioNTech's coronavirus portfolio isn't doing as well as last year. The company has a rich pipeline, but few of its products are in late-stage studies.
- 10/25/2023
|
BioNTech to Report Third Quarter Financial Results and Corporate Update on November 6, 2023, And to Host Innovation Series Day on November 7, 2023
- MAINZ, Germany , October 23, 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2023 on Monday, November 6th, 2023. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. ET (2.00 p.m. CET) to report its financial results and provide a corporate update for the third quarter 2023.
- 10/23/2023
|
7 Stocks That Are Heading for a Train Wreck
- One of the big slogans favored by CNBC pundit Jim Cramer is, “There's always a bull market somewhere.” I believe that's true.
- 10/19/2023
|
Paxlovid contract renegotiation pushed Covid business over the edge, says BMO's Evan Seigerman
- Evan Seigerman, BMO Capital Markets analyst, joins 'Closing Bell: Overtime' to discuss Pfizer and BioNTech cutting guidance amid Covid sales falling, the weight loss boom, and more.
- 10/16/2023
|
Vaccine Stocks—Including Pfizer, Moderna, BioNTech And Novavax—Slide Amid Plummeting Demand
- Pfizer slashed its revenue forecasts on Friday amid falling demand for its Covid vaccine and antiviral drug Paxlovid.
- 10/16/2023
|
Pfizer and BioNtech take big write-downs on Covid jab stocks
- Covid vaccine developer BioNTech is to take a write-down of up to €900 million on its stocks of jabs following a similar provision by partner Pfizer last week. Pfizer had said that the write-offs relate to raw materials purchased during the pandemic, as well as Covid-19 vaccine doses adapted to non-XBB.1.5 variants.
- 10/16/2023
|
Pfizer shares fall on guidance cut, weighing on BioNTech and Moderna stocks, and other shares on the move
- Shares of Lululemon Athletica Inc. LULU, +1.00% rallied more than 5% after index provider S&P Dow Jones Indices said the stock will join the S&P 500 index SPX on Wednesday.
- 10/16/2023
|
BioNTech will likely take 900 mln eur write-off on Pfizer-partnered vaccines
- Germany's BioNTech on Monday said it would likely take write-downs of up to 900 million euros ($947 million) in the third quarter after its partner Pfizer reported similar charges on their COVID-19 vaccine business last week.
- 10/16/2023
|
BioNTech to Present Multiple Program Updates Across Modalities at ESMO Congress 2023
- MAINZ, Germany, October 16, 2023 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data across its oncology pipeline, covering multiple solid tumor types and novel mechanisms of action, at the European Society for Molecular Oncology (“ESMO”) Congress 2023 in Madrid, Spain from October 20-24, 2023. The updates will feature oral and poster presentations for five candidates of BioNTech's clinical pipeline across the Company's drug classes, which comprise mRNA-based immunotherapies, cell therapies, protein-based therapeutics, and small molecules.
- 10/16/2023
|
7 Innovator Stocks Primed for Exceptional Growth
- Artificial intelligence. New pharmaceutical drugs.
- 10/10/2023
|
3 Stocks to Buy in October That Could Soar More Than 40% Over the Next 12 Months, According to Wall Street
- BioNTech's pipeline is loaded with promising candidates. PayPal Holdings is dirt cheap and is delivering solid earnings growth.
- 10/01/2023
|
Why Pfizer and BioNTech Stocks Zoomed Higher Today
- While people in this country aren't rushing in masses to get updated COVID booster vaccines, take-up has been encouraging. Many are worried about an apparent resurgence in the affliction.
- 09/29/2023
|
Undervalued Biotech Stocks Shine: Pfizer and BioNTech Show Resilience
- In the ever-evolving world of the stock market, uncovering potential gold mines is paramount for smart investing. One promising area to consider is undervalued biotech stocks.
- 09/28/2023
|
German court suspends mRNA patent trial against BioNTech
- A German court on Thursday suspended a patent trial against BioNTech over the use of mRNA technology in the COVID-19 vaccine developed by the German company together with its U.S. partner Pfizer.
- 09/28/2023
|
With New COVID-19 Boosters in Tow, Which Is the Better Buy: Pfizer, BioNtech, or Moderna Stock?
- Facing significant patent cliffs, Pfizer is putting faith in new launches. Moderna has nearly doubled its pipeline in three years.
- 09/20/2023
|
BioNTech partners with CEPI to advance development of mpox vaccine
- Germany's BioNtech said on Monday it is entering into a partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of its mpox vaccine.
- 09/18/2023
|
FDA Approves Pfizer & Moderna's New COVID Booster Vaccines
- Pfizer (PFE)/ BioNTech (BNTX), and Moderna's (MRNA) updated mRNA vaccines are now approved for individuals 12 years of age and older and are authorized under emergency use for individuals 6 months through 11 years of age.
- 09/12/2023
|
FDA Approves New Covid Vaccines To Target Latest Strains
- The updated booster shots arrive as new coronavirus variants circulate.
- 09/11/2023
|
US FDA authorizes updated COVID vaccines
- The U.S. health regulator on Monday authorized updated COVID-19 vaccines that closely match the Omicron variants that are circulating, starting the process to deploy the shots this month.
- 09/11/2023
|
3 Stocks to Buy For the COVID Resurgence
- The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting on updated COVID-19 vaccines at a meeting scheduled for September 12, 2023.
- 09/07/2023
|
UK joins EU in approving XBB.1.5 jab from Pfizer-BioNTech, but others subvariants are emerging
- An updated Covid-19 vaccine made by Pfizer Inc (NYSE:PFE) and BioNTech has been approved by the UK medical regulator, amid a rise in new variants and subvariants of the virus. The new Pfizer-BioNTech vaccine targets the Omicron XBB.1.5 subvariant, which was approved in the European Union last week, was given approved by the UK Medicines & Healthcare products Regulatory Agency (MHRA) on Tuesday, to be given to anyone aged six months or above.
- 09/06/2023
|
UK regulator approves updated Pfizer-BioNTech COVID vaccine
- The UK drug regulator said on Tuesday it has approved an updated COVID-19 vaccine by Pfizer and its German partner BioNTech that targets only the Omicron XBB.1.5 subvariant.
- 09/05/2023
|
BioNTech: Not Just Another Jab In The Arm
- BioNTech's Q2 2023 revenues significantly decreased due to declining COVID-19 vaccine sales, but the company holds $15.3B in cash reserves. The company's pipeline includes COVID-19 vaccine developments and promising oncology initiatives. The emergence of new COVID-19 variants highlights the potential for ongoing vaccine demand, but public trust and acceptance are crucial.
- 09/01/2023
|
Pfizer, BioNTech updated COVID vaccine to treat new variants gets CHMP recommendation use in Europe
- Pfizer Inc. PFE, -0.25% and BioNTech SE BNTX, +0.58% said Wednesday that its updated COVID-19 vaccine, which is tailored to the new Omicron XBB.1.5 variant has been recommended to receive marketing approval by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The recommendation is for the updated vaccine to be administered as a single dose to those who are at least five years old, regardless of COVID vaccination history.
- 08/30/2023
|
Covid Hospitalizations Jump. So Could Vaccine Demand.
- Drugmakers like Pfizer and Moderna tamped down expectations. Now, cases are increasing.
- 08/22/2023
|
U.S. Govt to Urge Citizens to Get New COVID-19 Shots
- Shares of COVID-19 vaccine makers soared after reports suggest that the Biden administration will start a campaign urging citizens to vaccinate themselves with updated shots vaccine in the upcoming fall.
- 08/22/2023
|
Why Moderna, BioNTech SE, and Novavax Surged Today
- Last week, Moderna and BioNTech partner Pfizer said their new COVID vaccines work against the current dominant strain of omicron growing across the U.S. Today, the Biden administration announced a campaign for citizens to get the new boosters this fall.
- 08/21/2023
|
Covid vaccine stocks jump as new variants emerge ahead of fall shot rollout
- Novavax, Moderna, Pfizer and its partner BioNTech are slated to roll out new shots designed to target the omicron subvariant XBB.1.5 this fall.
- 08/21/2023
|
The 3 Most Undervalued Biotech Stocks to Buy Now: August 2023
- The events of the last few years have made biotech investing look easier than it is. But, investing in biotech is not for the faint of heart.
- 08/17/2023
|
Why BioNTech Stock Was Sinking Today
- The company fell far short of analyst revenue estimates in its latest-reported quarter. It also flipped to a loss on the bottom line.
- 08/07/2023
|
BioNTech SE (BNTX) Q2 2023 Earnings Call Transcript
- BioNTech SE (NASDAQ:BNTX ) Q2 2023 Earnings Conference Call August 7, 2023 8:00 AM ET Company Participants Victoria Meissner - VP, Strategy & IR Ugur Sahin - Co-Founder & CFO Ozlem Tureci - Chief Medical Officer & Co-Founder Jens Holstein - CFO Ryan Richardson - Chief Strategy Officer Conference Call Participants Daina Graybosch - Leerink Partners Tazeen Ahmad - Bank of America Chris Shibutani - Goldman Sachs Brendan Smith - TD Cowen Terence Flynn - Morgan Stanley Bill Maughan - Canaccord Simon Baker - Redburn Operator Welcome to BioNTech's Second Quarter 2023 Update Call. I would like to hand the call over to Dr. Victoria Meissner, Vice President of Strategy and Investor Relations.
- 08/07/2023
|
BioNTech Revenue Plunges on Falling Demand for COVID-19 Vaccines
- American Depositary Receipts of BioNTech sank as COVID-19 vaccine demand waned and sales of its vaccine plunged.
- 08/07/2023
|
Biotech Stock Hits 2-Year Low as Vaccine Sales Decline
- BioNTech SE (NASDAQ:BNTX) is sinking to two-year lows today, after plunging Covid vaccine sales weighed on the company's second-quarter results.
- 08/07/2023
|
BioNTech stock declines as revenue topples on lower demand for Covid vaccine
- BioNTech has reported a sharp decline in second-quarter revenue and swung to a loss as demand for COVID-19 vaccines fell, sending its shares lower in Monday pre-market trading on the Nasdaq. The German company, which developed a vaccine with Pfizer, reported revenue of €168 million for the period to June 30, 2023, from €3.2 billion a year earlier.
- 08/07/2023
|
BioNTech Stock Falls. The Covid-19 Vaccine Maker Misses Revenue Estimates.
- Sales drop by more than expected in the second quarter, but BioNTech says its new 'variant-adapted Covid-19 vaccine' is still on track.
- 08/07/2023
|
BioNTech reduces drug development spend as COVID vaccine sales plunge
- Germany's BioNTech , Pfizer's partner on COVID-19 vaccines, cut its drug development budget for this year after quarterly revenues were hurt by a plunge in pandemic-related demand.
- 08/07/2023
|
BioNTech stock drops after revenue falls well short of expectations, but affirms 2023 COVID vaccine revenue view
- Shares of BioNTech SE BNTX, -0.16% dropped 2.4% toward a three-month low in premarket trading Monday, after the Germany-based biotechnology company, which developed a COVID-19 vaccine with partner Pfizer Inc. PFE, +0.06%, reported second-quarter revenue that fell well short of expectations, while swinging to a net loss that beat forecasts. The company reported a net loss of EUR190.4 million ($208.8 million), or EUR0.79 a share, after net income of EUR1.67 billion, or EUR6.45 a share, in the year-ago period.
- 08/07/2023
|
Disney, UPS, and More Stocks to Watch This Week
- Earnings season rolls along this week, with reports also due from Paramount, Eli Lilly, Wynn Resorts, and many more. And look out for crucial inflation indicators in economic data to be released at week's end.
- 08/06/2023
|
BioNTech: Unraveling A Bargain, A Hidden Opportunity In Market Misjudgments
- A leading immunotherapy innovator with a focus on oncology and infectious diseases. With a strong pipeline and capable management, the company is likely to continue its success in the long run. A projected decline in vaccine revenues is likely to affect upcoming Q2 2023 figures, but the company's profitability outlook remains favorable in the big picture. BioNTech demonstrates an exceptional cash balance while maintaining manageable total liabilities.
- 08/04/2023
|
BioNTech to Report Second Quarter 2023 Financial Results and Operational Update on August 7, 2023
- MAINZ, Germany , July 24, 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2023 on Monday, August 7th, 2023. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. EDT (2.00 p.m. CEST) to report its financial results and provide a corporate update for the second quarter 2023.
- 07/24/2023
|
Why These 7 Stocks Are the Best Ways to Play Biotech Right Now
- Best biotech stocks represents a concept that, no matter what, the market cycle fundamentally delivers relevance. Now, let me back up by stating that no individual company offers a guarantee of success to investors.
- 07/11/2023
|
New Strong Buy Stocks for July 11th
- BLBD, BNTX, EC, TIMB and HIVE have been added to the Zacks Rank #1 (Strong Buy) List on July 11, 2023.
- 07/11/2023
|
Pfizer/BioNTech initiate application with EU regulator for updated COVID vaccine
- Pfizer and partner BioNTech said on Friday they have initiated an application to the European Medicines Agency (EMA) for authorization of updated COVID-19 vaccine targeting Omicron subvariant XBB.1.5.
- 06/23/2023
|
BioNTech: Navigating Post-Pandemic Challenges With Innovative Therapies And Bold Strategies
- BioNTech's Q1 2023 revenues decreased to $1,404.7 million due to a drop in global COVID-19 vaccine sales, but the company has a strong immunotherapy pipeline for future growth. The company's financial metrics show mixed results, with strong profitability and low debt levels but negative stock momentum. Despite the risks and challenges, BioNTech's robust fundamentals, promising pipeline, and commitment to innovation make it a "Buy" recommendation for investors.
- 06/18/2023
|
FDA Panel Endorses Updating COVID Jab to Target XBB Strain
- An FDA panel unanimously recommends updating COVID vaccines to target one of the currently dominating XBB strains of the virus.
- 06/16/2023
|
BioNTech vaccine hearing postponed after complaint over bias
- The first hearing in a German court case against BioNTech over alleged side effects of its COVID-19 vaccine was postponed by a court on Monday.
- 06/12/2023
|
BioNTech faces first German lawsuit over alleged COVID vaccine side effects
- BioNTech will go to court on Monday to defend itself against a lawsuit from a German woman who is seeking damages for alleged side effects of its COVID-19 vaccine, the first of potentially hundreds of cases in the country.
- 06/11/2023
|
3 Ugly Stocks That Actually Hide Beautiful Potential
- While the market theoretically prices in all publicly available information for all securities, the sheer volume of opportunities available breathe life into underrated stocks with potential. Put another way, the below enterprises are Wall Street's equivalent of brown guacamole.
- 06/05/2023
|
BioNTech (BNTX) Up on Initial Data From Lung Cancer Antibody
- BioNTech (BNTX) announces positive initial data evaluating BNT316/ONC-392 to treat metastatic non-small cell lung cancer.
- 06/05/2023
|
Why Shares of BioNTech Rose Friday
- BioNTech's shares have fallen this year, along with its revenue. The company said it expects $5 billion in 2023 revenue from its COVID-19 vaccine, Comirnaty.
- 06/02/2023
|
BioNTech Surges On This Promising Update In Its Bid To Take On Bristol Myers In Lung Cancer Treatment
- BioNTech said Friday almost a third of patients with a hard-to-treat form of lung cancer responded to its treatment — and BNTX stock popped.
- 06/02/2023
|
BioNTech says drug from OncoC4 partnership shows promise in mid-stage trial
- BioNTech said on Friday that a new cancer immunotherapy candidate that it is working on with U.S. partner OncoC4 Inc was shown to shrink tumours in close to 30% of participants in a mid-stage lung cancer trial.
- 06/02/2023
|
7 Deeply Undervalued Growth Stocks to Buy in June
- Typically, securities may be less appreciated by the market because they stink, which means several proposals for best undervalued growth stocks for June might not make the cut. At the same time, betting on the same ship as everyone else presents its own risks.
- 06/01/2023
|
BioNTech is proceeding with COVID-shot in line with WHO guidance
- Germany's BioNTech said it was on track to introduce a COVID-19 shot by the early fall in the northern hemisphere that is adapted to currently dominant virus variants in line with recommendations by the World Health Organization.
- 05/25/2023
|
Report of new COVID wave in China pushes shares of vaccine makers higher
- Dr. Kavita Patel, fmr. White House health policy director, joins 'Fast Money' to discuss the latest reports of a possible uptick of COVID cases in China, the immunity situation in the country, and the impact an outbreak could have on U.S. companies.
- 05/23/2023
|
2 Undervalued Stocks to Buy for Potentially Massive Gains in the Next 10 Years
- Certain biotechs that hit it big early during the pandemic are now undervalued. BioNTech is preparing for a rapid pace of new drug launches.
- 05/23/2023
|
7 Safe Stocks to Buy for an Economic Downward Spiral
- For those that want to stay in the market during these ambiguous times, investors should consider safe stocks to buy. Basically, as Wall Street rotates away from risk-on assets, companies exclusively tied to growth and little else run the risk of suffering sharp losses.
- 05/16/2023
|
BioNTech: Hold Out For More Data (Rating Downgrade)
- Since initial coverage, BioNTech stock has lost $6 billion in value. BNTX's first quarter revenues were $5.6 billion less than 2022.
- 05/12/2023
|
As COVID public health emergency ends, ‘whack-a-mole' virus won't be easy to track
- As the U.S. COVID-19 public health emergency comes to an end on Thursday, the fight against COVID goes on–-and some new challenges begin for those who hope to keep the virus at bay.
- 05/10/2023
|
BioNTech braces for weak Q2 as Covid vaccine demand subsides
- BioNTech is facing a weak second quarter of 2023 as demand for Covid vaccines wane throughout the warmer summer months. Analysts at Canaccord have noted the drug maker's “seasonal administration pattern” that favors the fall.
- 05/10/2023
|
BioNTech Stock Jumps As Covid Vaccine Sales, Profits Beat Expectations
- BioNTech handily beat first-quarter profit expectations and delivered better-than-expected sales, leading BNTX stock to jump Monday. The post BioNTech Stock Jumps As Covid Vaccine Sales, Profits Beat Expectations appeared first on Investor's Business Daily.
- 05/08/2023
|
BioNTech reports strong 1Q earnings; expands focus beyond Covid-19 vaccines
- Covid-19 vaccine maker BioNTech SE has reported better-than-expected earnings, exceeding analyst estimates for the first quarter. Sales of €1.28 billion ($1.4 billion) surpassed the €1.1 billion average estimate, while earnings per share reached €2.05, well above the projected $0.69.
- 05/08/2023
|
BioNTech Revenue Falls. Why the Stock Is Climbing Anyway.
- BioNTech's first-quarter revenue falls from a year earlier as demand for Covid-19 vaccines wanes but still tops analysts' estimates.
- 05/08/2023
|
BioNTech's stock jumps 4.3% premarket after earnings fall but top estimates
- BioNTEch SE's stock BNTX rose 4.3% in premarket trade Monday, after the German biotech posted far stronger-than-expected first-quarter earnings, even as profit and revenue tumbled on lower demand for its COVID vaccine co-developed with Pfizer Inc. PFE. Mainz-based BioNTEch said it had net profit of 502.2 million euros, or 2.05 a share, for the quarter, down from EUR3.699 billion, or EUR14.24 a share, in the year-earlier period.
- 05/08/2023
|
Earnings Previews: BioNTech, Tyson Foods, Warner Bros Discovery
- In the first half-hour of Thursday's trading, the Dow Jones industrials were down 0.38%, the S&P 500 traded 0.35% and the Nasdaq 0.31% lower.
- 05/04/2023
|
FDA authorizes Pfizer-BioNTech booster for young kids with compromised immune systems
- The U.S. Food and Drug Administration late Friday authorized Pfizer Inc. PFE and BioNTech SE BNTX COVID-19 bivalent vaccine for immunocompromised children. The shot, which would be a fourth dose in most cases, can be given to children older than 6 months through 4 years of age who have previously received the vaccine's three doses, the FDA said.
- 04/28/2023
|
Top Biotech Stocks For Q2 2023: First Gem Is BioNTech
- Top Biotech Stocks For Q2 2023: First Gem Is BioNTech.
- 04/25/2023
|
BioNTech to Report First Quarter 2023 Financial Results and Operational Update on May 8, 2023
- MAINZ, Germany , April 24, 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2023 on Monday, May 8th, 2023. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. EDT (2.00 p.m. CEST) to report its financial results and provide a corporate update for the first quarter 2023.
- 04/24/2023
|
7 Low-PE Ratio Blue-Chip Stocks Offering Both Quality and Value
- While the concept of acquiring low-PE ratio blue-chip stocks (that is, industry-leading stalwarts that feature low price-earnings ratios relative to their sectors) appeals on paper, investors need to be cautious. You can't just buy companies based on any one single metric.
- 04/19/2023
|
FDA Gives Nod for Using Bivalent Jab for All COVID Vaccinations
- To simplify the COVID-19 vaccination schedule for all individuals, the FDA authorizes using bivalent COVID-19 vaccines for all doses administered to individuals aged six years and older.
- 04/19/2023
|
BioNTech FY22 Earnings Review - 5 Questions Answered After Today's Results
- BioNTech announced its Q422 and FY22 earnings today, and also provided FY23 guidance. Revenues were ~$18.7bn, thanks to its share of revenues from sales of the Comirnaty COVID vaccine it co-developed with Pfizer. Net profit was >$10bn.
- 03/27/2023
|
Why Shares of BioNTech Slumped Monday
- BioNTech's guidance points to a big drop in revenue this year. The company is using its cash reserves to fund 24 clinical trials.
- 03/27/2023
|
BioNTech stock slumps on worse-than-expected drop in revenue
- Don't Miss: Valley of Hype: The culture that built Elizabeth Holmes WATCH HERE: https://youtu.be/Sb179GLPNYE
- 03/27/2023
|
BioNTech shares slip on gloomy Covid vaccine sales outlook
- The shares initially fell by 6.4% to an intraday low of $119.98 a share before recovering most of those losses in late morning trading.
- 03/27/2023
|
BioNTech Is Ripe For A Rebound In 2023
- BioNTech (NASDAQ: BNTX) got a substantial boost from the pandemic and its mRNA vaccine, developed with Pfizer (NYSE: PFE). The stock has seen a substantial correction since then due to slowing COVID sales, but the bottom is in.
- 03/27/2023
|
BioNTech Stock Crumbles After 2023 Outlook Misses By Almost $3 Billion
- BioNTech said Monday it expects roughly $5.4 billion in sales of its Covid shot this year, missing views and leading BNTX stock to tumble. The post BioNTech Stock Crumbles After 2023 Outlook Misses By Almost $3 Billion appeared first on Investor's Business Daily.
- 03/27/2023
|
BioNTech Stock Is Falling. Blame the Covid Vaccine Outlook.
- The German biotech that partnered with Pfizer to develop a Covid-19 vaccine expects fewer vaccinations and lowered levels of boosting this year.
- 03/27/2023
|
BioNTech stock falls as earnings beat expectations, but show falling demand for COVID-19 vaccines
- The U.S.-listed shares of BioNTech SE BNTX, -0.92% fell 2.7% in premarket expectations, as profit and revenue beat expectations but fell from a year ago due to lower demand for COVID-19 vaccines, and indicated demand would fall further. Net income fell to EUR2.28 billion ($2.45 billion), or EUR9.26 a share, from EUR#.17 billion, or EUR12.18 a share, in the year-ago period.
- 03/27/2023
|
The Cream Of The Crop: 5 Biotech Stocks That Outrank 91% Of All Stocks
- The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
- 03/24/2023
|
7 Blue-Chip Stocks Sitting in the Sweet Spot
- Although blue-chip stocks often carry a reputation for being lumbering giants that might not kill your portfolio but certainly won't do it any favors, specific stalwarts can get the business done. In other words, these enterprises hit the sweet spot: they're tied to well-established businesses that also offer double-digit (percentage) upside potential, as determined by Wall Street analysts.
- 03/23/2023
|
Earnings Previews: BioNTech, Carnival
- In early trading Thursday, the Dow Jones industrials were up 0.25%, the S&P 500 up 0.62% and the Nasdaq up 1.21%.
- 03/23/2023
|
BioNTech inks deal with OncoC4 to develop cancer treatments
- BioNTech SE BNTX, -1.76% will pay $200 million to the privately held OncoC4 Inc. as part of a deal to develop and commercialize OncoC4's monoclonal antibody treatment that is being tested in several cancers. OncoC4 is also eligible for milestone payments and royalties, though the terms were not disclosed in the news release.
- 03/20/2023
|
7 Stocks Set to Soar When the Market Recovers
- While time in the market generally beats out timing the market, it's understandable that some investors may want to hold off on looking for stocks to buy. After all, equities continue to digest the sudden failure of a handful of financial institutions.
- 03/16/2023
|
FDA updates authorization of BioNTech, Pfizer's bivalent booster for young children
- The Food and Drug Administration on Tuesday said children between the ages of 6 months and 5 years old can now get a booster dose of BioNTech BNTX and Pfizer's PFE COVID-19 bivalent vaccine. The third shot should come no sooner than two months after the primary series of three shots.
- 03/15/2023
|
BioNTech to Report Full Year and Fourth Quarter 2022 Financial Results and Operational Update on March 27, 2023
- MAINZ, Germany , March 13, 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the full year and fourth quarter 2022 on Monday, March 27th, 2023. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. EDT (2.00 p.m. CEST) to report its financial results and provide a corporate update for the fourth quarter and full year 2022.
- 03/13/2023
|
Roquefort develops a fifth programme using a technology pioneer by Moderna and BioNTech
- Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) said has developed a new platform of potential anti-cancer messenger RNA (mRNA) therapeutics, expanding the company's portfolio to five in-house programmes. The initiative consists of four pre-clinical putative treatments focusing on the company's MDK, or Midkine, target - a protein that plays a key role in the development and progression of cancer.
- 03/08/2023
|
BioNTech on the verge of UK trials of cancer vaccine - here's our two-minute guide
- BioNTech plans to begin clinical trials for its cancer vaccines in the UK this year, according to the company's CEO, Ugur Sahin quoted in the German press. The drug developer, which is best known for its COVID-19 vaccine developed with Pfizer, is deciding which types of cancer it will test its personalised immunotherapies on and where the trials will be conducted.
- 02/20/2023
|
The 3 Most Undervalued Growth Stocks for Your February Buy List
- Undervalued growth stocks are often overlooked by investors, they can offer significant potential for capital appreciation. One way to identify undervalued growth stocks is to look for companies with high revenue and earnings growth, but low price-to-earnings (P/E) ratios.
- 02/06/2023
|
Better Buy: Novavax or BioNTech Stock?
- The two companies, known for their vaccines, could see their businesses benefit from a yearly COVID-19 shot.
- 02/04/2023
|
The 7 Most Undervalued Biotech Stocks to Buy in February 2023
- You don't have to be particularly astute to recognize the importance of the most undervalued biotech stocks to buy. Fundamentally, the enterprises that undergird these names operate on the cutting edge of medical science.
- 02/02/2023
|
Mergers and Acquisitions in 2023 Off To A Strong Start
- Mergers and acquisitions are a normal part of business, but 2023 has already presented many opportunities across the biotech industry. The M&A surge seems to be driven by two major transactions: the $6 billion sale of LHC Group Inc. (Nasdaq: LHCG) to UnitedHealth (NYSE: UNH) and the $8 billion sale of Signify Health Inc. (NYSE: SGFY) to CVS Health Co. (NYSE: CVS).
- 01/27/2023
|
Ranking The 10 Largest Biotechs By Pipeline
- The pipeline is the heart of all drug discovery companies, leading to all growth in the future. As such, understanding the relative strength of a pipeline by comparing to peers can lead to investment insights.
- 01/11/2023
|
BioNTech SE (BNTX) JP Morgan Annual Healthcare Conference - (Transcript)
- BioNTech SE (NASDAQ:BNTX ) JP Morgan Annual Healthcare Conference January 10, 2023 12:45 PM ET Company Participants Ugur Sahin - Chief Executive Officer & Co-Founder Ryan Richardson - Chief Strategy Officer Conference Call Participants Jessica Fye - JPMorgan Jessica Fye Great. Good morning, everyone.
- 01/11/2023
|
BioNTech makes £562 million foray into AI as it swoops for UK start-up
- BioNTech, the biotech company known for its role in developing a COVID-19 vaccine, has agreed to acquire UK-based artificial intelligence (AI) start-up InstaDeep for £562 million. The deal, the German group's biggest yet, comes after a multi-year collaboration with InstaDeep, which led to the development of an early warning system to predict future variants of the SARS-CoV-2 virus.
- 01/11/2023
|
BioNTech acquires Tunisian-born and U.K-based AI startup InstaDeep for £562M
- German-based biotech company BioNTech SE is set to acquire InstaDeep, a Tunis-born and U.K.-based artificial intelligence (AI) startup InstaDeep for up to £562 million (~$680 million) in its largest deal yet.
- 01/10/2023
|
BioNTech to acquire AI company
- BioNTech SE BNTX, -0.89% said Tuesday that it plans to acquire InstaDeep Ltd., a privately held provider of artificial intelligence and machine learning, for £362 million ($439.2 million), with milestone payments up to £200 million ($242.6 million).
- 01/10/2023
|
BioNTech cancer treatments deal is a coup for the government and a challenge for the NHS
- BioNTech has signed a deal with the UK government to enrol up to 10,000 patients in clinical trials by the end of 2030 for personalised cancer therapies.
- 01/06/2023
|
Cancer Vaccine Trials—Using Same mRNA Tech Behind Covid Shots—Could Launch In U.K. This September
- BioNTech, which worked with Pfizer to build an mRNA Covid vaccine, has partnered with the U.K. to turn the technology towards cancer and plans to treat 10,000 people by 2030.
- 01/06/2023
|
BioNTech says it will start cancer vaccine trials in the UK from September
- The company aims to test 10,000 personalized mRNA therapies, including cancer vaccines, between September 2023 to the end of the decade.
- 01/06/2023
|
UK government inks landmark deal with BioNTech to create cancer vaccine
- The UK government is partnering with BioNTech to enrol up to 10,000 patients in clinical trials for advanced cancer treatments, according to the Financial Times, BioNTech, which developed the best-selling Covid-19 vaccine in partnership with Pfizer, will open a research and development centre in Cambridge, employing 75 staff, as well as an office in London, the paper said. The company is working on personalised cancer vaccines that aim to utilise patients' immune systems to fight tumours, and may also potentially invest in manufacturing in the UK in the future.
- 01/06/2023
|
BioNTech: Covid Market Expansion Plus CAR-T Therapy Improvements
- For the 3 months ending September 30, 2022, BioNTech SE produced $3.65 billion in revenues for its Covid-19 vaccine Comirnaty. BioNTech has potential for Covid-19 market expansion with an enhanced spike protein vaccine plus many other vaccine candidates being advanced.
- 01/03/2023
|
Why BioNTech Was a Sickly Stock This Week
- The world is trying hard to get past the coronavirus pandemic, and investors are trying hard to get past coronavirus stocks.
- 12/30/2022
|
100 Best Stocks Of 2022: Oil Stocks And Medicals Shine
- Medical and energy companies, including oil stocks, lead the list of the 100 best stocks in 2022. The post 100 Best Stocks Of 2022: Oil Stocks And Medicals Shine appeared first on Investor's Business Daily.
- 12/30/2022
|
Are Investors Undervaluing BioNTech (BNTX) Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 12/29/2022
|
3 Big Drug, Biotech Stocks to Boost Your Portfolio in 2023
- Here we discuss three big drug and biotech companies, Sanofi (SNY), GSK (GSK) and BioNTech (BNTX), which may prove to be good bets for your portfolio next year.
- 12/28/2022
|
BioNTech to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Mainz, Germany, December 28, 2022 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that CEO and Co-founder Prof. Ugur Sahin, M.D., will present a corporate overview and update at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 9:45 am PST / 12:45 pm ET.
- 12/28/2022
|
The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond
- Major indices such as the S&P 500 and the Nasdaq Composite may have plunged by double-digits during 2022, but certain areas of the stock market performed strongly throughout the year. One of those areas is among the hottest healthcare stocks.
- 12/18/2022
|
Pfizer and BioNTech fast tracked by FDA for combined COVID, flu vaccine
- Yahoo Finance's Anjalee Khemlani joins the Live show to discuss China's reopening challenges as COVID cases rise as well as the latest surrounding Pfizer and BioNTech's combined COVID and flu vaccine.
- 12/16/2022
|
BioNTech Announces Plans for Taiwan Clinical Trial Hub
- BioNTech SE (NASDAQ:BNTX) announced plans today for a clinical trial hub in Taiwan for its MRNA-based cancer immunotherapies.
- 12/16/2022
|
BioNTech upgraded to buy on high hopes for combined flu/COVID vaccine and oncology pipeline
- Bank of America analysts upgraded BioNTech SE stock to buy from hold on Thursday, citing excitement about its mRNA technology and the outlook for a combined flu/COVID vaccine and oncology vaccines that are currently in various stages of development.
- 12/15/2022
|
All You Need to Know About BioNTech SE Sponsored ADR (BNTX) Rating Upgrade to Buy
- BioNTech SE Sponsored ADR (BNTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 12/13/2022
|
Is BioNTech (BNTX) Stock Undervalued Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 12/13/2022
|
FDA Approves Pfizer, Moderna's Omicron COVID Jabs in Younger Kids
- Amid a rise in seasonal respiratory illnesses in younger children across the country, the FDA broadens the label of authorized bivalent Omicron BA.4/BA.5-adapted vaccines to include children as young as six months.
- 12/09/2022
|
Pfizer and BioNTech get FDA fast track designation for single-dose COVID and flu vaccine candidate
- Pfizer Inc. PFE, +3.07% and German partner BioNTech SE BNTX, +5.64% said Friday they have received fast track designation from the U.S. Food and Drug Administration for a single-dose-mRNA-based vaccine candidate targeting both COVID and flu. The companies already announced that they are in early-stage trials to review the safety and immunogenicity of their combined vaccine among healthy adults.
- 12/09/2022
|
3 Stocks Making Big Midday Moves
- Below we are taking a look at three popular stocks making move in today's trading, just on the heels of several earnings releases and an exciting approval from the Food & Drug Administration (FDA).
- 12/08/2022
|
Pfizer, BioNTech ask FDA to authorize bivalent COVID vaccine in young children
- Pfizer Inc. PFE, -0.77% and BioNTech SE BNTX, -1.63% said Monday that they asked the Food and Drug Administration to authorize their updated COVID-19 vaccine as the third dose for children between the ages of 6 months and 5 years old. Children in this age group receive three doses as their primary series of shots.
- 12/05/2022
|
BioNTech, Vertex Pharmaceuticals And Other Big Biotechnology Stocks From Benzinga's Most Accurate Analysts - Beam Therapeutics (NASDAQ:BEAM), BioNTech (NASDAQ:BNTX)
- Although US stocks closed mixed on Thursday, but healthcare stocks recorded gains, gaining over 0.2% in the previous session. Biotechnology stocks were among the top performers in the sector, adding around 0.5% on Thursday.
- 12/02/2022
|
BioNTech SE Sponsored ADR (BNTX) Just Overtook the 20-Day Moving Average
- Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?
- 11/29/2022
|
7 Stocks on the Perfect 10 List
- A stock that scores a perfect 10 should be on every investor's list of stocks to buy. Any company that receives full marks on quality, value, or growth are stocks I'd considering a perfect 10.
- 11/23/2022
|
Pfizer and BioNTech updated booster shows strong results against new omicron sublineages in fresh analysis of data
- A fresh analysis of data on the immune response generated by the bivalent COVID-19 booster showed strong results against the newer omicron sublineages, Pfizer and German partner BioNTech said Friday.
- 11/18/2022
|
New Pfizer-BioNTech Covid Vaccine Is More Effective Than The Original, Study Shows
- An estimated 68% of Americans are fully vaccinated.
- 11/18/2022
|
Pfizer and BioNTech say bivalent booster increases neutralizing antibodies against new omicron variants
- Pfizer Inc. PFE, +0.58% and German partner BioNTech SE BNTX, +0.82% said Friday a new analysis of data reviewing the immune response created by the omicron BA.4/BA.5 adapted bivalent COVID vaccine showed strong results against newer omicron sublineages, including BA.4.6, BA.2.75.2, BQ.1.1 and XBB.1. The data, which has been posted on the preprint server bioRxiv, show that the booster induces a greater increase in neutralizing antibody titers than the companies' original COVID-19 vaccine against these emerging omicron sublineages.
- 11/18/2022
|
Pfizer, BioNTech Take Next Step Toward A Pan-Covid Vaccine — But Is The Demand There?
- Pfizer and BioNTech said Thursday they've started testing a next-generation Covid shot, but the vaccine stocks tumbled. The post Pfizer, BioNTech Take Next Step Toward A Pan-Covid Vaccine — But Is The Demand There?
- 11/17/2022
|
Moderna Surges On New Omicron Data, Pulling Pfizer, BioNTech Along For The Ride
- Moderna stock popped Monday after the company said its bivalent Covid booster led to a 15-fold jump in omicron-blocking antibodies. The post Moderna Surges On New Omicron Data, Pulling Pfizer, BioNTech Along For The Ride appeared first on Investor's Business Daily.
- 11/14/2022
|
Pfizer, BioNTech BA.4/BA.5-adapted booster gets CHMP recommendation for 5-11 year olds in EU
- Pfizer Inc. PFE, +1.81% and Germany-based partner BioNTech SE BNTX, -3.39% said Thursday that their booster dose of the omicron BA.4/BA.5-adapted bivalent COVID vaccine for 5-to-11 year olds was recommended for marketing authorization in the the European Union. The EU will review the recommendation from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP), and is expected to make a decision "soon.
- 11/10/2022
|
This COVID-19 Vaccine Stock Has More to Offer
- The vaccine revenue was nice, but it's time to look ahead.
- 11/10/2022
|
BioNTech SE (BNTX) Q3 2022 Earnings Call Transcript
- BioNTech SE (NASDAQ:BNTX ) Q3 2022 Earnings Conference Call November 7, 2022 8:00 AM ET Company Participants Sylke Maas - Vice President, Investor Relations & Strategy Ugur Sahin - Chief Executive Officer & Co-Founder Ozlem Tureci - Chief Medical Officer & Co-Founder Jens Holstein - Chief Financial Officer Ryan Richardson - Chief Strategy Officer Conference Call Participants Tazeen Ahmad - Bank of America Chris Shibutani - Goldman Sachs Jessica Fye - JPMorgan Daina Graybosch - SVB Leerink Ellie Merle - UBS Simon Baker - Redburn Operator Welcome to the BioNTech Third Quarter 2022 Update Call. I would like to hand the call over to the Vice President of Investor Relations and Strategy, Sylke Maas.
- 11/07/2022
|
BioNTech beats on earnings despite waning COVID vaccine demand
- COVID19 Yahoo Finance's Anjalee Khemlani joins the Live show to discuss third-quarter earnings for BioNTech and news that the biotechnology company is raising the lower end of its full-year outlook for 2022.
- 11/07/2022
|
BioNTech Takes A Hit Despite Doubling Profit Views, Raising 2022 Outlook
- BioNTech doubled third-quarter profit expectations Monday and raised its full-year outlook for Covid vaccine sales — but BNTX stock toppled. The post BioNTech Takes A Hit Despite Doubling Profit Views, Raising 2022 Outlook appeared first on Investor's Business Daily.
- 11/07/2022
|
BioNTech Issues Bright Revenue Outlook. But The Stock Sinks After Profit Drop.
- BioNTech said it now expects full-year Covid-vaccine revenue of €16 billion-€17 billion, from €13 billion-€17 billion previously.
- 11/07/2022
|
BioNTech profit and revenue fall sharply from year-ago period but top estimates
- BioNTech SE BNTX, +6.24% said Monday it had net income of $1.784 billion euros, or EUR6.98 a share, in the third quarter, down from EUR6.087 billion, or EUR12.35 a share, in the year-earlier period. Revenue fell to EUR3.461 billion from EUR6.087 billion a year ago.
- 11/07/2022
|
The Big Pharma Giants Are Down
- It's evident that big pharma giant Moderna (NASDAQ: MRNA) is going through troubled times. Worse, it's dragging other big Pharma giants with it.
- 11/06/2022
|
This Key Piece Of News Could Sparked BioNTech, Moderna — And Could Stoke Demand For Covid Boosters
- Covid vaccine stocks surged Friday after a new study suggested an added benefit of the updated omicron-targeting boosters. The post This Key Piece Of News Could Sparked BioNTech, Moderna — And Could Stoke Demand For Covid Boosters appeared first on Investor's Business Daily.
- 11/04/2022
|
Pfizer-BioNTech bivalent booster shows higher immune response, but new COVID cases climb back above 40,000 a day
- First the good news: Pfizer Inc. and Germany-based partner BioNTech SE said updated trial data for their omicron BA.4/BA.5-adapted bivalent booster showed a “substantially higher” immune response in adults than the original COVID-19 vaccine.
- 11/04/2022
|
BioNTech Stock Boosted on Vaccine Buzz
- Stocks in China are abuzz with reopening rumors this week, leading investors to speculate on their subsequent rallies and whether or not they will be short-lived.
- 11/04/2022
|
Pfizer, BioNTech stocks rally after announcing positive trial data on BA.4/BA.5 bivalent booster shot
- Pfizer Inc. PFE, -0.21% and Germany-based partner BioNTech SE BNTX, +2.64% said new data from a Phase 2/3 trial showed that the booster for companies' omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine demonstrated a "robust neutralizing immune response" after one month. The companies said immune responses for those getting the booster were "substantially higher" than for those who only received the original COVID-19 vaccine, with similar safety and tolerability profiles.
- 11/04/2022
|
BioNTech stock surges toward 3-month high after report China agrees to approve its COVID vaccine for foreigners
- Shares of Germany-based BioNTech SE BNTX, +2.64% surged 5.1% toward a three-month high in premarket trading Friday, after The Wall Street Journal reported that China agreed to approve the biotechnology company's COVID-19 vaccines for foreign residents in China. Pfizer Inc.'s stock PFE, -0.21% climbed 1.5% ahead of the open, as BioNTech had partnered with the U.S. drug giant to develop COVID-19 vaccines.
- 11/04/2022
|
China Agrees to Approve BioNTech's Covid-19 Vaccine for Foreigners, German Chancellor Says
- China agreed to approve BioNTech's Covid-19 vaccines for foreign residents in China, German Chancellor Olaf Scholz said in a news conference in Beijing, after he met Chinese leader Xi Jinping.
- 11/04/2022
|
COVID: Pfizer and BioNTech study efficacy of combo COVID-flu vaccine
- Yahoo Finance's Anjalee Khemlani discusses Pfizer and BioNTech's study of a combination COVID and flu vaccine, plus the availability of COVID-flu tests at Quest Diagnostics.
- 11/03/2022
|
BioNTech Shares Up On Hope For Combined Flu, Covid Shot
- Pfizer and BioNTech started testing a combined flu and Covid vaccine on Thursday, helping BNTX stock pare earlier Moderna-inspired losses. The post BioNTech Shares Up On Hope For Combined Flu, Covid Shot appeared first on Investor's Business Daily.
- 11/03/2022
|
Is BioNTech a Good Long-Term Buy?
- BioNTech has a burgeoning oncology portfolio up its sleeve.
- 10/27/2022
|
BioNTech to Report Third Quarter 2022 Financial Results and Operational Update on November 7, 2022
|
Why Are Vaccine Stocks MRNA, PFE, BNTX, NVAX Up Today?
- Stocks were set to open lower today, but the market seems to have found its groove. Everything from tech stocks to vaccine stocks are moving higher.
- 10/21/2022
|
FDA Allows Emergency Use of Omicron-Based COVID Jabs in Kids
- Anticipating a surge of COVID-19 infections later this year, the FDA broadens the label of authorized Omicron-based BA.4/BA.5 adapted bivalent boosters to include children as young as five years.
- 10/14/2022
|
Pfizer and BioNTech report positive data in trial of omicron-targeting bivalent booster in individuals aged 18 and older
- Pfizer Inc. PFE, +0.26% and German partner BioNTech SE BNTX, +5.53% said Thursday early data from a Phase 2/3 clinical trial of their omicron BA.4/BA.5-adapated bivalent booster showed positive results in treating individuals aged 18 and older. The data collected 7 days after administering a 30-ug booster dose showed a “substantial increase” in neutralizing antibodies.
- 10/13/2022
|
Why Pfizer Partner BioNTech SE Shares Are Trading Higher - BioNTech (NASDAQ:BNTX)
- BioNTech SE - ADR (NASDAQ: BNTX) shares are trading higher by 5.37% to $136.45 going into the close of Wednesday's trading session after the FDA granted Emergency Use Authorization to the company's 10-µg booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine.
- 10/12/2022
|
CDC officially recommends new boosters for young children
- The Centers for Disease Control and Prevention officially signed off on allowing children as young as 5 years old to get an updated COVID-19 booster shot. CDC Director Rochelle Walensky signed the decision memo on Wednesday afternoon, the same day that the Food and Drug Administration expanded the authorizations for Moderna Inc. MRNA, +7.75% and BioNTech SE BNTX, +4.97% /Pfizer Inc.'s PFE, +0.66% updated COVID-19 boosters.
- 10/12/2022
|
FDA Authorizes New COVID Boosters for Kids
- Like Moderna's and Pfizer's updated vaccines for adults, the child doses target newer strains of COVID-19.
- 10/12/2022
|
Pfizer, BioNTech stocks surge after FDA grants emergency use of BA.4, BA.5 adapted booster shots in children
- Shares of Pfizer Inc. PFE, +1.99% climbed 2.2% and BioNTech SE BNTX, +4.87% hiked up 5.5% in morning trading Wednesday, after the companies said the U.S. Food and Drug Administration has granted Emergency Use Authorization (EUA) for its omicron bivalent COVID-19 booster vaccine for children aged 5 through 11. The drug makers said pending recommendation from the Centers for Disease Control and Prevention (CDC), the 10-ug booster doses, adapted for the BA.4 and BA.5 subvariants, will be shipped immediately.
- 10/12/2022
|
Income Plus Low Volatility Makes This Fund A Safe Haven
- Are you looking for a relatively safe mutual fund haven amid current market carnage? Check out Madison Covered Call & Equity Income Fund (MENYX).
- 10/12/2022
|
Covid-Related Sales Boost BioNTech, Moderna and Gilead
- Covid-related product sales helped make BioNTech SE ( BNTX , Financial), Moderna Inc. ( MRNA , Financial), Gilead Sciences Inc. ( GILD , Financial) and Regeneron Pharmaceuticals Inc. ( REGN , Financial) the most productive biopharma companies in 2021, according to a Fierce Pharma ranking.
- 09/27/2022
|
7 Vaccine Stocks to Sell ASAP Now That the ‘Pandemic's Over'
- As people acclimatize to the new normal, it's time to look at some vaccine stocks to sell. Instead of relying primarily on vaccines and antiviral drugs, the government let people manage infections.
- 09/27/2022
|
Pfizer and BioNTech seek FDA EUA for omicron-targeting booster for use in children aged 5 to 11
- Pfizer Inc. PFE, -1.10% and German partner BioNTech SE BNTX, -1.27% said Monday they have submitted an application to the U.S. Food and Drug Administration seeking an emergency use authorization for their bivalent vaccine booster for use in children aged 5 to 11 years of age. The application is for a 10-ug booster dose of the vaccine targeting omicron BA.4 and BA.5 subvariants, which have become dominant in the U.S and around the world.
- 09/26/2022
|
Vaccine Stocks: Down but Not Out?
- Whether the pandemic is over or not, plenty of people are still looking for protection against COVID-19.
- 09/19/2022
|
Why Are Vaccine Stocks MRNA, PFE, NVAX, BNTX Down Today?
- It's a mixed day for the stock market, but it's not a good day for vaccine stocks. Across the board, these names are getting sold.
- 09/19/2022
|
Moderna, BioNTech, and Novavax plunge after President Biden says the COVID-19 pandemic 'is over'
- "The pandemic is over. We still have a problem with COVID. We're still doing a low of work on it. But the pandemic is over," Biden said.
- 09/19/2022
|
Vaccine stocks Pfizer, BioNTech, Moderna and Novavax slide after Biden says pandemic is over
- Stocks of the three key vaccine makers fell sharply Monday, after President Joe Biden said the pandemic is over, in an interview with "60 Minutes" that aired on Sunday. Moderna Inc. MRNA, -9.41% fell 9.2%, Pfizer Inc. PFE, -1.76% was down 1.7% and its German partner BioNTech SE BNTX, -9.15% was down 8.4%.
- 09/19/2022
|
Why BioNTech, Moderna And Novavax Shares Are Diving - Moderna (NASDAQ:MRNA), BioNTech (NASDAQ:BNTX)
- BioNTech SE - ADR (NASDAQ: BNTX), Moderna Inc (NASDAQ: MRNA) and Novavax, Inc. (NASDAQ: NVAX) are all trading lower during Mo
- 09/19/2022
|
Pfizer, BioNTech COVID vaccine gets CHMP recommendation for 'full' MA for all indications
- Pfizer Inc. PFE, -0.46% and BioNTech SE BNTX, -1.64% said Friday that the Committee for Medicinal Products for Human Use (CHMP) for the European Medicines Agency (EMA) has recommended the companies' COVID-19 vaccine Comirnaty be converted to standard, or "full," Marketing Authorization (MA) from conditional MA for all indications and formulations. The companies said the European Commission (EC) will review the CHMP recommendation and is expected to make a decision "soon.
- 09/16/2022
|
PFE, BNTX and MRNA Omicron Boosters Get Positive CHMP Opinion
- Pfizer (PFE) /BioNTech (BNTX) and Moderna (MRNA) get positive CHMP opinion for Omicron-targeting bivalent booster.
- 09/02/2022
|
Moderna, BioNTech Jump After CDC Green-Lights Updated Covid Boosters
- The CDC green-lighted updated Covid boosters from Pfizer and Moderna, helping vaccine stocks edge higher Friday. The post Moderna, BioNTech Jump After CDC Green-Lights Updated Covid Boosters appeared first on Investor's Business Daily.
- 09/02/2022
|
FDA Authorizes Pfizer, Moderna's Omicron-Based Boosters
- Pfizer (PFE)/BioNTech (BNTX) and Moderna (MRNA) develop the Omicron BA.4/BA.5-adapted bivalent vaccines at the FDA's recommendation.
- 09/01/2022
|
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
- The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
- 08/31/2022
|
After Double-Digit Percentage Declines, Are Vaccine Stocks Buys?
- They still might offer solid long-term opportunities for investors.
- 08/30/2022
|
Could This Move by Moderna Cost Pfizer Billions?
- Moderna's complaint is focused on two critical innovations.
- 08/28/2022
|
Moderna sues Pfizer and BioNTech
- CNBC's Shep Smith reports on a lawsuit filed by Moderna against Pfizer and BioNTech for patent infringement.
- 08/26/2022
|
Moderna Sues Pfizer Over mRNA Technology Used in COVID Vaccines
- Moderna is suing Pfizer and BioNTech over patents it said it filed years ago on the life-saving technology.
- 08/26/2022
|
Moderna sues Pfizer, BioNTech over alleged mRNA patent infringement
- Moderna filed a lawsuit against Pfizer and BioNTech claiming the biopharmaceutical companies infringed on Moderna's patents related to mRNA technology in develop of their COVID-19 vaccine. The lawsuit, to be filed in the U.S.
- 08/26/2022
|
Moderna sets up clash with Pfizer and BioNTech with patent lawsuits in the U.S. and Germany
- Moderna Inc. on Friday filed lawsuits against Pfizer Inc. and German partner BioNTech SE, alleging the pair infringed patents relating to its mRNA platform, a key technology behind all of their COVID vaccines.
- 08/26/2022
|
Moderna sues Pfizer, BioNTech over COVID vaccine patent
- Yahoo Finance's Anjalee Khemlani joins the Live show to discuss Moderna's decision to sue rival vaccine maker Pfizer over the delivery technology used in COVID-19 vaccines.
- 08/26/2022
|
Report finds Americans losing up to $1 billion in wages from long COVID, and Moderna sues Pfizer and BioNTech over mRNA patents
- Some 16 million Americans of working age have long-term COVID and about 2 to 4 million are not working as they struggle with their symptoms, according to a new report from the Brookings Institution.
- 08/26/2022
|
Moderna sues Pfizer and BioNTech for patent infringement over COVID vaccine
- Moderna alleges Pfizer and its German partner BioNTech copied their mRNA technology while developing their COVID-19 vaccine.
- 08/26/2022
|
Moderna Sues Pfizer And BioNTech Over Covid-19 Vaccine
- The company says Pfizer and BioNTech copied Moderna's mRNA technology without its permission.
- 08/26/2022
|
Moderna Claims Pfizer, BioNTech Stole Its Patented Tech In Covid Shot
- Moderna is suing Pfizer and BioNTech for patent infringement, claiming the duo copied its mRNA technology. All three vaccine stocks fell.
- 08/26/2022
|
Moderna sues Pfizer and BioNTech for patent infringement relating to the mRNA platform used to develop COVID vaccines
- Moderna Inc. MRNA, +0.44% said Friday it is suing Pfizer Inc. PFE, +0.99% and German partner BioNTech SE BNTX, +1.59% for infringing patents relating to its mRNA platform, the source of the COVID vaccines developed by the three parties. The suit is to be filed Friday in the U.S. District Court for the District of Massachusetts and the Regional Court of Düsseldorf in Germany.
- 08/26/2022
|
Moderna sues Pfizer/BioNTech for patent infringement over COVID vaccine
- Moderna is suing Pfizer and its German partner BioNTech for patent infringement in the development of the first COVID-19 vaccine approved in the United States, alleging they copied technology that Moderna developed years before the pandemic.
- 08/26/2022
|
Omicron-targeting COVID boosters may be out after Labor Day, and Moderna has joined Pfizer and BioNTech in filing for authorization
- Americans age 12 and older could begin getting omicron-specific COVID-19 boosters soon after Labor Day, according to a new report.
- 08/24/2022
|
Here's Why This Dominant Income Stock Is a Buy
- This company is the undisputed leader in COVID-19 vaccines and treatments.
- 08/24/2022
|
Pfizer-BioNTech Covid Vaccine Is 73% Effective In Young Children, Study Finds
- The three-dose vaccine was most effective in children ages 6 months to 2 years, with a 75.8% efficacy rate, according to the study.
- 08/23/2022
|
Pfizer and BioNTech say data shows COVID vaccine has more than 70% efficacy in small children, and cases now rising in just 7 states
- Pfizer and German partner BioNTech on Tuesday offered updated COVID vaccine data supporting efficacy in children aged 6 months through 4 years of age.
- 08/23/2022
|
Pfizer and BioNTech say COVID vaccine data showed 73.2% efficacy among children aged 6 month to 4 years
- Pfizer Inc. PFE, -0.51% and German partner BioNTech SE BNTX, +0.26% on Tuesday announced updated COVID vaccine data supporting efficacy in children aged 6 months through 4 years of age. The companies said updated analysis from 34 cases occurring at least seven days after a three-dose regimen showed 73.2% vaccine efficacy among children in that age group.
- 08/23/2022
|
Pfizer, BioNTech complete FDA submission for new COVID-19 booster
- Pfizer Inc. PFE, -0.36% and BioNTech SE BNTX, +0.21% said Monday that they formally completed an application asking the Food and Drug Administration to authorize their experimental bivalent COVID-19 booster in those who are 12 years old or older. The new shot equally targets the original strain of the virus and the BA.4 and BA.5 strains.
- 08/22/2022
|
1 Hot Growth Stock to Buy, and 1 to Avoid (For Now)
- Pfizer's diversified portfolio of medicines will ensure it keeps outperforming BioNTech.
- 08/15/2022
|
Is This Battered Growth Stock Still a Buy After Its Latest Stumble?
- Its flagship vaccine product isn't selling as much as it used to.
- 08/11/2022
|
Why BioNTech Was Tumbling Again Today
- Fresh analyst price target cuts dampen investor sentiment on the biotech stock.
- 08/09/2022
|
Why BioNTech Was a Sickly Stock on Monday
- The company's top and bottom lines both declined considerably in the second quarter.
- 08/08/2022
|
BioNTech SE (BNTX) CEO Ugur Sahin on Q2 2022 Results - Earnings Call Transcript
- BioNTech SE (NASDAQ:BNTX ) Q2 2022 Earnings Conference Call August 8, 2022 8:00 AM ET Company Participants Sylke Maas - Vice President, Investor Relations and Strategy Ugur Sahin - Chief Executive Officer and Co-Founder Ozlem Tureci - Chief Medical Officer and Co-Founder Jens Holstein - Chief Financial Officer Ryan Richardson - Chief Strategy Officer Conference Call Participants Matthew Harrison - Morgan Stanley Tazeen Ahmad - Bank of America Daina Graybosch - SVB Securities Zhiqiang Shu - Berenberg Operator Welcome to the BioNTech Second Quarter 2022 Update Call. I would like to hand the call over to the Vice President of Investor Relations and Strategy, Sylke Maas.
- 08/08/2022
|
BioNTech misses earnings expectations, stock falls
- Yahoo Finance Live's Brad Smith discusses how BioNTech stock is trading amid earnings.
- 08/08/2022
|
BioNTech's (BNTX) Earnings & Revenues Miss Estimates in Q2
- BioNTech (BNTX) misses estimates for both earnings and revenues in the second quarter of 2022.
- 08/08/2022
|
Why Is BioNTech (BNTX) Stock Down 7% Today?
- Source: Palatinate Stock / Shutterstock.com BioNTech (NASDAQ: BNTX ) stock is on falling on Monday after the company released poor results for its second quarter of 2022. This saw it report diluted earnings per share of 6.45 euros and revenue of 3.2 billion euros.
- 08/08/2022
|
BioNTech Dives As Second-Quarter Sales, Profit Broadly Miss Forecasts
- BioNTech lagged second-quarter expectations and issued light 2022 guidance on Monday, leading BNTX stock to dive. The post BioNTech Dives As Second-Quarter Sales, Profit Broadly Miss Forecasts appeared first on Investor's Business Daily.
- 08/08/2022
|
Vaccine Targeting Fast-Spreading Omicron Subvariants Could Be Ready For Fall As Pfizer, BioNTech Announce Trials
- BioNTech and its U.S. partner Pfizer have already begun manufacturing Covid-19 boosters that are adapted for multiple Omicron sub variants including BA.1, BA.4 and BA.5.
- 08/08/2022
|
BioNTech expects Omicron-adapted vaccine deliveries as soon as October
- BioNTech expects to begin deliveries of two Omicron-adapted vaccines as soon as October, which will help spur demand in the fourth quarter, said the German biotech firm as it reaffirmed its vaccine revenue guidance for the year on Monday.
- 08/08/2022
|
BioNTech Earnings and Revenue Miss Expectations
- The company reports second-quarter earnings of €6.45 a share on revenue of €3.2 billion.
- 08/08/2022
|
BioNTech stock sinks more than 8% after profit, revenue fall below expectations
- The U.S.-listed shares of Germany-based BioNTech SE BNTX, +1.48% sank 8.2% in premarket trading Monday, after the biotechnology company and Pfizer Inc. PFE, -1.18% partner in developing a COVID-19 vaccine reported second-quarter profit and revenue that fell below expectations but affirmed its full-year COVID-19 revenue outlook. Net income dropped to EUR1.67 billion ($1.70 bln), or EUR6.45 a share, from EUR2.79 billion, or EUR10.77 a share, in the year-ago period.
- 08/08/2022
|
Is a Beat in Store for BioNTech (BNTX) This Earnings Season?
- On BioNTech's (BNTX) second-quarter earnings call, investors are expected to focus on the sales performance of its COVID-19 vaccine, Comirnaty, developed in partnership with Pfizer.
- 08/02/2022
|
Moderna And BioNTech: I Back The Former To Drive Share Price Upside In 2022
- Moderna and BioNTech are the two mRNA giants behind the dominant COVID vaccines SpikeVax and Comirnaty. The two companies have a great deal in common, and the share prices typically track very close to one another.
- 07/29/2022
|
Moderna 2.0: 3 Stocks To Play The Potential Monkeypox Pandemic
- Monkeypox cases are significantly growing during the past few months, especially catalyzed by an increase in international travel. On July 23, WHO declared the Monkeypox spread as a global health emergency, indicating the agency's high degree of concern around the severity of the disease and its spread.
- 07/26/2022
|
BioNTech, Pfizer sue CureVac in U.S. over COVID-19 vaccine patent claims
- COVID-19 vaccine maker BioNTech said on Tuesday that it and partner Pfizer have filed a complaint with the U.S. District Court in Massachusetts, seeking a judgment that they did not infringe U.S. patents held by rival CureVac.
- 07/26/2022
|
BioNTech to Report Second Quarter 2022 Financial Results and Operational Update on August 8, 2022
- Mainz, Germany, July 25, 2022 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2022 on Monday, August 8th, 2022. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. EDT (2.00 p.m. CEST) to report its financial results and provide a corporate update for the second quarter 2022.
- 07/25/2022
|
BioNTech and Pfizer in talks to delay Covid vaccine deliveries amid EU glut
- BioNTech and Pfizer Inc (NYSE:PFE) are reportedly close to reaching an agreement with the European Union to extend Covid-19 vaccine deliveries until 2024, slowing deliveries amid a glut of shots in the bloc. A contract has been signed for up to 1.8bn doses of the messenger RNA (mRNA) shot, including variant-adapted vaccines, though the contract only extends to 2023.
- 07/19/2022
|
Buy BioNTech Stock - Ride The New Wave Of Covid
- Because of geopolitics, we have forgotten COVID, but in vain - the number of new cases is increasing, while the fall season has not even begun. As demand for vaccines picks up in the early fall, shares of vaccine manufacturers could rise again.
- 07/19/2022
|
Does BioNTech SE Sponsored ADR (BNTX) Have the Potential to Rally 48% as Wall Street Analysts Expect?
- The average of price targets set by Wall Street analysts indicates a potential upside of 47.9% in BioNTech SE Sponsored ADR (BNTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 07/12/2022
|
PFE, BNTX's COVID Jab Gets FDA's Full Nod for Adolescents
- Pfizer (PFE) and partner BioNTech's (BNTX) Comirnaty is the first COVID-19 vaccine to receive full approval in the United States for use in adolescents aged 12 years and older.
- 07/11/2022
|
BioNTech sued by CureVac over its mRNA technology
- CureVac (NASDAQ:CVAC) has filed a patent lawsuit in Germany against BioNTech (NASDAQ:BNTX) in what is one of the first court cases in which a company has sued another for using mRNA technology in developing a coronavirus vaccine. According to Germany-based CureVac, it will "assert its intellectual property rights, accumulated over more than two decades of pioneering work in mRNA technology, which contributed to Covid-19 vaccine development", and is seeking "fair compensation" from BioNTech and two subsidiaries.
- 07/06/2022
|
CureVac Files COVID-19 Vaccine Patent Infringement Lawsuit Against BioNTech
- CureVac N.V. (NASDAQ: CVAC) has moved to assert its intellectual property rights, accumulated over two decades of pioneering work in mRNA technology, which contributed to COVID-19 vaccine development.
- 07/05/2022
|
CureVac Sues BioNTech Over mRNA and Covid Vaccines. Pfizer Stock Isn't Spared.
- CureVac says its intellectual property portfolio protects multiple inventions that are considered essential to Pfizer and BioNTech's Covid-19 vaccine.
- 07/05/2022
|
BioNTech stock falls after CureVac files suit, saying COVID vaccine infringes patents
- Shares of BioNTech SE BNTX, +5.63% fell 0.9% in premarket trading Tuesday, after CureVac N.V. CVAC, +4.63% filed in Germany a patent infringement suit against the biotechnology company.
- 07/05/2022
|
FDA Recommends Adding New Omicron Subvariants to COVID Boosters
- In anticipation of a new surge of COVID-19 infections later this year, the FDA recommends that COVID-19 vaccine manufacturers develop bivalent booster vaccines that contain the BA.4/BA.5 Omicron subvariants.
- 07/01/2022
|
Why BioNTech Stock Is Surging
- BioNTech SE (NASDAQ: BNTX) shares are trading higher Thursday after the company and Pfizer Inc (NYSE: PFE) announced a new COVID-19 vaccine supply agreement with the U.S. government. Under terms of the agreement, the two companies will provide the U.S. government with 105 million.
- 06/30/2022
|
This Analyst Says US Government Buying More COVID-19 Vaccines At Higher Prices
- Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) announced a new COVID-19 vaccine supply agreement with the U.S. government. SVB Leerink says that the new contract implies the price per Comirnaty dose is ~$30.50.
- 06/30/2022
|
Why BioNTech Stock Advanced Today
- The U.S. government wants to buy more of its coronavirus vaccine.
- 06/30/2022
|
U.S. to pay $3.2 billion to Pfizer, BioNTech for more COVID-19 vaccines for fall
- Pfizer Inc. PFE, +0.55% and BioNTech SE BNTX, +1.54% said late Wednesday they have inked a new agreement with the U.S. government to supply 105 million doses of their COVID-19 vaccines, including a formulation adapted to target omicron variants, pending approval from the FDA. The two pharma companies said the doses are expected to be delivered as soon as late summer, and continue into the end of the year.
- 06/29/2022
|
FDA recommends updating COVID booster shots to fight Omicron
- Yahoo Finance's Anjalee Khemlani joins the Live show to discuss the FDA's vote to update its COVID-19 boosters.
- 06/29/2022
|
FDA Panel Recommends Modifying COVID Jabs to Target Omicron
- The FDA's VRBPAC committee recommends updated COVID-19 vaccine boosters that target the Omicron variant to improve vaccine effectiveness.
- 06/29/2022
|
FDA advisers recommend Covid fall boosters
- CNBC's Meg Tirrell joins 'Closing Bell: Overtime' to report on FDA advisers recommendation for covid fall boosters.
- 06/28/2022
|
Why BioNTech Stock Rose Today
- Its latest COVID-19 vaccine appears to be effective against the most common viral variants.
- 06/27/2022
|
Pfizer/BioNTech's Updated Omicron-Based COVID-19 Shots Show Improved Response Against Variant
- Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) said the modified vaccine against the omicron coronavirus variant generated a higher immune response. The companies said that 30 µg and 60 µg doses of a shot targeting just the BA.1 omicron subvariant elicited a.
- 06/27/2022
|
7 Biotech Stocks With Key Catalysts Coming in July
- Biotech stocks have suffered significant setbacks during the first half of the year but are likely to bounce back soon The post 7 Biotech Stocks With Key Catalysts Coming in July appeared first on InvestorPlace. More From InvestorPlace $200 Oil Sooner Than You Think – Buy This Now The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn't matter if you have $500 in savings or $5 million.
- 06/27/2022
|
BioNTech breaks ground on first mRNA manufacturing facility in Africa in Kigali, Rwanda
- BioNTech SE BNTX, +0.33% said Thursday it has broken ground on the construction of the first mRNA manufacturing facility in Africa, a plant in Kigali, Rwanda that is expected to employ about 100 workers by 2024. The first of two BioNTainers are expected to be delivered by year-end and the company's malaria vaccine candidate is expected to enter its first in-human trial later in 2022.
- 06/23/2022
|
Got $5,000? These 2 Growth Stocks Are Absurdly Cheap Buys
- You'll get a lot of bang for your buck with these stocks.
- 06/22/2022
|
COVID-19 vaccines slowly begin to roll out for young kids
- Yahoo Finance's Anjalee Khemlani discusses the rollout of COVID vaccines for kids 6 months to 5 years, plus a new test that could indicate when a person needs a booster shot.
- 06/22/2022
|
FDA Authorizes PFE & MRNA's COVID Jabs for 6 Months & Older Kids
- FDA authorizes Pfizer (PFE) and BioNTech's Comirnaty for use in children aged six months through four years. Moderna's (MRNA) Spikevax gains EUA for use in individuals aged 6 months through 17 years.
- 06/20/2022
|
7 Long-Term Stocks to Buy in a Bear Market
- These long-term stocks to buy are from defensive sectors, because now is the time to play defense in your stock investing. The post 7 Long-Term Stocks to Buy in a Bear Market appeared first on InvestorPlace.
- 06/20/2022
|
Covid-19 Vaccinations For Children Starting At Age 6 Months Approved By CDC
- Despite continued skepticism from parents and some scientific advisers, the Centers for Disease Control and Prevention on Saturday recommended Covid-19 vaccines for children as young as 6 months. The ruling means young children could be injected as soon as Tuesday. Covid-19 has been stubbornly resistant to fading away, and new cases are still rising in...
- 06/18/2022
|
CDC Advisers Recommend COVID Vaccines for Kids as Young as 6 Months Old
- Very young children may be able to start receiving shots early next week.
- 06/18/2022
|
CDC Signs Off On Covid Vaccines For Young Children—Shots To Begin Next Week
- Babies as young as 6 months can now get vaccinated.
- 06/18/2022
|
CDC panel recommends COVID-19 vaccine for children as young as 6 months old
- "We've taken a major step forward today," said Dr. Oliver Brooks, one of the members of the advisory panel.
- 06/18/2022
|
CDC advisers recommend COVID-19 shots for children under 5
- U.S. health advisers on Saturday recommended COVID-19 vaccines for infants, toddlers and preschoolers — the last group without the shots.
- 06/18/2022
|
CDC Panel Recommends Covid Vaccines For Young Children
- Shots are expected to start going in arms next week.
- 06/18/2022
|
CDC advisors recommend Covid vaccines for children as young as 6 months
- The CDC committee voted unanimously to recommend the shots for use in infants through preschoolers after two days of meetings that were open to the public.
- 06/18/2022
|
FDA Authorizes Covid Vaccine for Kids 5 and Under
- Covid-19 vaccines for children ages 5 and under from Pfizer Inc. and Moderna Inc. received authorization from US regulators, meaning almost all the American population can soon get pandemic protection. Former FDA Associate Commissioner Peter Pitts says this is a step in the right direction.
- 06/17/2022
|
Moderna, Pfizer stocks edge higher after FDA authorizes COVID vaccines for kids
- Yahoo Finance Live's Brian Sozzi reports that the FDA has authorized Moderna and Pfizer COVID vaccines for children under the age of 5.
- 06/17/2022
|
FDA Approves COVID Vaccines for Kids as Young as 6 Months Old
- Pending the CDC's signoff, both Moderna and Pfizer shots could be available for the youngest children within days.
- 06/17/2022
|
FDA clears Pfizer, Moderna Covid vaccines for young children
- The U.S. FDA has authorized Moderna's and Pfizer's Covid-19 vaccines for kids as young as 6 months. CNBC's Meg Tirrell joins 'Squawk on the Street' with the details.
- 06/17/2022
|
FDA authorizes Pfizer and Moderna COVID-19 vaccines for children as young as 6 months old
- The vaccines will be available for young children once the CDC recommends them, which will likely happen this weekend.
- 06/17/2022
|
FDA authorizes both mRNA vaccines for young children
- The Food and Drug Administration announced Friday that it authorized the COVID-19 vaccines developed by BioNTech SE BNTX, -6.41% /Pfizer Inc. PFE, -2.12% and Moderna Inc. MRNA, -5.80% for children as young as six months old. The regulator said Moderna's two-dose vaccine is now authorized for children between the ages of 6 months old and 17 years old.
- 06/17/2022
|
FDA authorizes Pfizer and Moderna's Covid vaccines for children as young as 6 months
- The White House expects vaccinations to begin as soon as Tuesday.
- 06/17/2022
|
FDA clears COVID-19 vaccines for children under 5
- The U.S. Food and Drug Administration has authorized user of the COVID-19 vaccines from Pfizer and BioNTech, and from Moderna, for kids between 6 months and 5 years of age. The FDA's decision follows a length review process, and the dosage for children under 5 is greatly reduced relative to those for older children and […]
- 06/17/2022
|
Buy BioNTech SE at the low PE of 2.31
- BioNTech SE (NASDAQ:BNTX) is trading at $137.99. The 52-week range has been $121 to $464.
- 06/16/2022
|
Why Pfizer, BioNTech, and Moderna Stocks Are Sinking Today
- Blame it on the overall stock market sell-off.
- 06/16/2022
|
FDA Panel Recommends Pfizer & Moderna COVID Jabs for Young Kids
- The FDA VRBPAC committee unanimously recommends the approval of both Pfizer and BioNTech and Moderna's vaccines for young children, saying the benefits of the vaccines outweigh the risks.
- 06/16/2022
|
Pfizer, BioNTech's COVID Jab Safe in Young Kids Per FDA
- Per the FDA reviewers, the available data supports Pfizer (PFE) and BioNTech (BNTX) vaccine's effectiveness in preventing COVID infection in kids six months to under five years of age as a three-dose primary series.
- 06/13/2022
|
Is This Downtrodden Stock a Value Trap?
- Probably yes, but it could still be a good purchase for investors with the right mindset.
- 06/13/2022
|
100 Billion Reasons to Like This Dominant Healthcare Stock
- This mega-cap stock will become the first in the pharmaceutical industry to reach a major sales milestone.
- 06/06/2022
|
Can the Best-Selling Drugs of 2021 Repeat Their Performance?
- These were the industry's bestsellers last year, but how long can they stay on top?
- 06/05/2022
|
7 of the Best Cheap Stocks to Buy for the Second Half of 2022
- These are the best cheap stocks to invest in now. They all offer compelling buying opportunities in today's volatile market.
- 05/25/2022
|
Pfizer & BioNTech COVID Jab Booster Effective in Kids Under 5
- Pfizer (PFE) and BioNTech (BNTX) state that their three-dose COVID-19 vaccine is 80% effective in children under five years of age.
- 05/24/2022
|
Pfizer/BioNTech say third vaccine dose is 80% effective against Omicron in kids 5 and younger
- Pfizer Inc (NYSE:PFE) and BioNTech SE say their three-dose Covid-19 vaccine for children ages 6 months to 5 years old was 80% effective at preventing illness during the surge of the Omicron variant. According to clinical trial results released Monday, a third vaccine dose was well tolerated by the children, and most side effects were mild to moderate.
- 05/23/2022
|
Why BioNTech Stock Surged Today
- An overall market rebound and Tuesday's authorization of boosters for kids likely propelled the stock higher.
- 05/19/2022
|
FDA Gives Green Signal To Pfizer/BioNTech's COVID-19 Booster For Kids 5-11 Years
- The FDA has authorized a booster shot of Pfizer Inc (NYSE: PFE) and BioNTech SE's (NASDAQ: BNTX) COVID-19 vaccine for children aged 5 to 11. Kids will be eligible for the booster at least five months after completing a primary series with the Pfizer-BioNTech COVID.
- 05/17/2022
|
Why BioNTech Stock Jumped Today
- 5- to 11-year-olds are now eligible to get booster shots of the Comirnaty COVID-19 vaccine.
- 05/17/2022
|
FDA authorizes a booster dose of BioNTech/Pfizer's vaccine for 5 to 11 year olds
- The Food and Drug Administration said Tuesday that children between the ages of 5 and 11 years old can get a booster dose of BioNTech SE and Pfizer Inc.'s PFE, +1.28% COVID-19 vaccine. Children in this age group should wait at least five months after getting the primary series of shots.
- 05/17/2022
|
3 Dirt-Cheap Stocks You Can Buy Right Now
- These stocks are inexpensive yet have solid underlying businesses.
- 05/14/2022
|
Will BioNtech sustain the $140 support level?
- BioNtech SE (NASDAQ: BNTX) is bullish this week, having gained 16.03% to trade at $158. The gains come after the company reported growth in vaccine sales.
- 05/13/2022
|
Why BioNTech Stock Climbed Today
- Global demand for the vaccine maker's COVID-19 drug remains strong.
- 05/09/2022
|
BioNTech SE (BNTX) CEO Ugur Sahin on Q1 2022 Results - Earnings Call Transcript
- BioNTech SE (NASDAQ:BNTX ) Q1 2022 Earnings Conference Call May 9, 2022 8:00 AM ET Company Participants Sylke Maas - VP, IR and Business Strategy Ugur Sahin - Co-Founder & CEO Ozlem Tureci - Co-Founder & Chief Medical Officer Jens Holstein - CFO Ryan Richardson - Chief Strategy Officer Conference Call Participants Matthew Harrison - Morgan Stanley Cory Kasimov - JPMorgan Chase & Co. Christopher Zopf - Goldman Sachs Group Akash Tewari - Jefferies Zhiqiang Shu - Berenberg Daina Graybosch - SVB Leerink Operator Welcome to the BioNTech First Quarter 2022 Update Call. I would like to hand the call over to the Vice President of Investor Relations and Strategy, Sylke Maas.
- 05/09/2022
|
Why BioNTech Stock Is Rising Today
- BioNTech SE (NASDAQ: BNTX) shares are trading higher Monday after the company reported financial results and reaffirmed its 2022 outlook. BioNTech reported first-quarter revenue of 6.37 billion euros ($6.72 billion), which was up from €2.05 billion year-over-year.
- 05/09/2022
|
BioNTech Stock Rises After Reiterating Guidance
- The shares of BioNTech SE (NASDAQ:BNTX) are inching higher ahead of the open, last seen up 0.8% at $137.20, after the pharma giant reported better-than-expected first-quarter earnings, as well as a revenue beat.
- 05/09/2022
|
BioNTech earnings jump after 750 million COVID vaccines invoiced
- BioNTech BNTX, -4.05% , the U.S-listed German biotech, said its first-quarter profit more than tripled to €3.7 billion ($3.9 billion), or €14.24 per share, from €1.13 billion, or €4.39 per share, as revenue jumped to €6.38 billion from €2.05 billion, mostly on its share of COVID-19 vaccine sales from Pfizer and Fosun Pharma as well as direct sales to customers in Germany and Turkey. Analysts polled by FactSet had expected earnings of €9.70 per share on sales of €4.59 billion.
- 05/09/2022
|
BioNTech posts tripled Q1 vaccine sales but still flags full-year decline
- BioNTech said first-quarter sales and earnings more than tripled thanks to demand for the COVID-19 vaccine it developed with Pfizer, but the German biotech firm reaffirmed its forecast for a full-year decline in vaccine sales.
- 05/09/2022
|
BioNTech Earnings and Sales Top Wall Street Forecasts
- BioNTech earns €14.24 a share in the first quarter on revenue of €6.37 billion.
- 05/09/2022
|
Palantir, Plug Power, Novavax, BioNTech, Lordstown: 5 Key Earnings To Watch Today
- The first-quarter reporting season is well and truly underway. Data from Factset show that about 87% of S&P 500 companies have reported their quarterly results, with 79% reporting positive earnings per share, or EPS, surplus, and 74% ringing in revenue upside.
- 05/09/2022
|
Disney, Occidental, Rivian, Palantir, BioNTech, and Other Stocks to Watch This Week
- First quarter earnings reports this week include BioNTech, Palantir, Simon Property Group, Tyson Foods, Electronic Arts, Occidental Petroleum, and Walt Disney. Plus, inflation data.
- 05/08/2022
|
Why BioNTech Stock Crushed the Market Today
- The company launches a two-year share buyback program.
- 05/02/2022
|
Top Pharmaceutical Stocks To Watch In May 2022
- Check out these pharmaceutical stocks in the stock market today.
- 04/30/2022
|
Thinking of Buying BioNTech? Consider These 3 Things First
- There's trouble ahead, but a few new solutions are on the way too.
- 04/29/2022
|
BioNTech, Pfizer say they expect to have COVID-19 vaccine data for young children this quarter
- BioNTech SE BNTX, -2.86% and Pfizer Inc. PFE, -0.42% said Tuesday that they expect to share data from a clinical trial evaluating their COVID-19 vaccines in children between the ages of 6 months and 5 years old sometime before the end of June. The announcement was included in a news release stating that the companies requested Food and Drug Administration authorization for a COVID-19 booster dose in children between the ages of 5 and 11 years old.
- 04/27/2022
|
BioNTech, Pfizer seek FDA authorization of a COVID-19 booster for young children
- BioNTech SE BNTX, -2.24% and Pfizer Inc. PFE, -0.17% said Tuesday that they asked the Food and Drug Administration to authorize a COVID-19 booster dose for children between the ages of 5 and 11 years old. Boosters are already authorized for teens and adults.
- 04/27/2022
|
BioNTech to Report First Quarter 2022 Financial Results and Operational Update on May 9, 2022
- Mainz, Germany, April 26, 2022 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2022 on Monday, May 9th, 2022. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. EDT (2.00 p.m. CEST) to report its financial results and provide a corporate update for the first quarter 2022.
- 04/26/2022
|
Why BioNTech SE Was Surging Today
- The vaccine maker got a dose of good news late last week, and ongoing lockdowns in China perhaps spurred some optimism.
- 04/25/2022
|
What's Happening With BioNTech SE Shares?
- Shares of vaccine companies, including BioNTech SE - ADR (NASDAQ: BNTX), are trading higher amid COVID-19 concerns due to rising cases in China. Rising COVID-19 cases in China's capital Beijing and Shanghai, where enforcement of a strict "zero-COVID" policy is ongoing, have drawn.
- 04/25/2022
|
Does This Vaccine-Maker's Upcoming Share Repurchase Make It a Buy?
- It could be an important sign of a transitional period to come.
- 04/22/2022
|
3 Top Biotech Stocks Ready for a Bull Run
- The hype has died down. Now it's time for science to take over.
- 04/20/2022
|
Pfizer (PFE), BioNTech (BNTX) COVID Booster Effective in Young Kids
- A third dose of Pfizer (PFE) and partner BioNTech's (BNTX) COVID-19 vaccine achieves a significant immune response against the Omicron variant in children aged between 5 years and 11 years.
- 04/18/2022
|
Why BioNTech, Moderna, and Novavax Stocks Are Sinking Today
- Each vaccine stock is moving lower for a different reason.
- 04/18/2022
|
Pfizer/BioNTech Fourth COVID-19 Vaccine Dose Protects Against Omicron For At Least One Month
- A fourth dose of the COVID-19 vaccine from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) provided significant protection against severe disease, hospitalization, and death for at least a month in older individuals. The study was conducted in Israel, when the Omicron.
- 04/18/2022
|
Pfizer and BioNTech say data shows high immune response for COVID booster in children aged 5 to 11
- Pfizer Inc. PFE, -0.02% and German partner BioNTech SE BNTX, +6.06% said Thursday a Phase 2/3 trial of their COVID-19 vaccine booster showed a high immune response in children aged 5-to-11-years old. Data from a sub-analysis of 30 sera from the trial showed a 36-fold increase in neutralizing titers against the omicron variant, which has become dominant globally.
- 04/14/2022
|
Matinas (MTNB) Up on Deal With BioNTech for mRNA Vaccines
- Matinas BioPharma (MTNB) forms an exclusive partnership with BioNTech (BNTX) to develop and advance novel formulations for mRNA vaccines.
- 04/12/2022
|
mRNA Cancer Treatment: Covid Vaccine Giant BioNTech Touts Promising Early Data
- An mRNA vaccine can potentially boost cell treatments used to fight blood cancer and make them more effective in solid tumors, BioNTech said, citing early data.
- 04/11/2022
|
Matinas BioPharma Inks mRNA-Based Vaccine Pact With BioNTech
- BioNTech SE (NASDAQ: BNTX) and Matinas BioPharma Holdings Inc (NYSE: MTNB) have entered into an exclusive research collaboration to evaluate the combination of mRNA formats and Matinas' proprietary LNC platform technology. The companies will collaborate on.
- 04/11/2022
|
3 Top Healthcare Stocks to Buy for April
- When good companies are out of favor is often the best time to buy.
- 04/10/2022
|
3 Breakout Growth Stocks to Buy for the Long Haul
- Investors who can look over the horizon could realize outsize gains.
- 04/09/2022
|
BioNTech: Buy The Dip
- I estimate BioNTech is worth $265 per share, implying a 57% upside potential. BioNTech and Pfizer signed orders to deliver 2.4 billion COVID-19 vaccine doses in 2022. I predict there will be more orders in the next nine months.
- 04/08/2022
|
EU Agencies Doubtful About Need for 2nd COVID Booster
- The European health agencies agreed that the fourth dose of mRNA-based COVID-19 vaccines of Pfizer (PFE)/BioNTech (BNTX) and Moderna (MRNA) may be given to adults 80 years and above.
- 04/07/2022
|
Pfizer/BioNTech's Second COVID-19 Vaccine Booster Provides Short-Lived Protection In Elderly, Israel Study Shows
- An Israel-based study has found that a fourth dose of the Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) vaccine lowered rates of COVID-19 infection among the elderly. However, the protection against disease appeared to be short-lived.
- 04/06/2022
|
5 Top Health Care Stocks To Watch In The Stock Market Today
- Are these health care stocks on your watchlist right now?
- 04/03/2022
|
3 Top Health Care Stocks To Watch Today
- Could these health care stocks be healthy additions to your portfolio?
- 04/01/2022
|
BioNTech SE (BNTX) CEO Ugur Sahin on Q4 2021 Results - Earnings Call Transcript
- BioNTech SE (BNTX) CEO Ugur Sahin on Q4 2021 Results - Earnings Call Transcript
- 03/30/2022
|
BioNTech reports unbelievable YoY growth for its fiscal Q4
- BioNTech SE shares (NASDAQ: BNTX) opened 8% up on Wednesday after the pharmaceutical company handily beat Street expectations for Q4 earnings and revenue. Notable figures in BioNTech Q4 earnings report Net profit printed at €3.17 billion ($3.51 billion), compared to last year's €3.66 million.
- 03/30/2022
|
Why BioNTech Shares Are Surging Today
- BioNTech SE (NASDAQ: BNTX) reported Q4 FY21 revenues of €5.53 billion compared to €345.4 million a year ago, mainly due to high demand for the company's COVID-19 vaccine. BioNTech and its partner Pfizer Inc (NYSE: PFE) delivered approximately 2.6 billion.
- 03/30/2022
|
Dow Jones Newswires: BioNTech reports soaring earnings, revenue on COVID vaccine, plans $1.5 billion in buybacks
- German pharmaceutical company BioNTech SE reported soaring earnings and revenue for the fourth quarter, driven by the Covid-19 vaccine it produces with Pfizer Inc, and said it is starting a share buyback program of up to $1.5 billion over the next two years.
- 03/30/2022
|
BioNTech's Earnings Top Estimates. It Plans a Buyback and Special Dividend.
- BioNTech says it plans to buy back up to $1.5 billion of stock over the next two years. It also will propose to pay a special dividend of €2 a share.
- 03/30/2022
|
Tekla Healthcare Investors: A Dividend Paymaster That Can Compensate For Poor Price Performance
- Tekla Healthcare Investors: A Dividend Paymaster That Can Compensate For Poor Price Performance
- 03/29/2022
|
Why Moderna and BioNTech Were Winners Today
- The FDA expands its authorization for both companies' coronavirus vaccines.
- 03/29/2022
|
FDA Authorizes Fourth Dose Of Moderna, Pfizer/BioNTech COVID-19 Vaccines For Older People
- The FDA has approved a second round of the Moderna Inc (NASDAQ: MRNA) or Pfizer Inc (NYSE: PFE), and BioNTech SE (NASDAQ: BNTX) COVID-19 vaccines for older people and certain immunocompromised individuals. The agency said the new boosters would be.
- 03/29/2022
|
FDA authorizes fourth Covid vaccine dose for people age 50 and older
- The U.S. Food and Drug Administration has authorized another Covid-19 vaccine dose from Pfizer and Moderna for everyone age 50 and older, as well as some immunocompromised patients. CNBC's Meg Tirrell reports.
- 03/29/2022
|
Earnings Previews: BioNTech, Chewy, Lululemon, Micron
- Markets were off to a positive start on Tuesday, with the Nasdaq leading the charge with a gain of just over 1%.
- 03/29/2022
|
BioNTech, Chewy, Lululemon, Walgreens, and Other Stocks to Watch
- Chewy, Micron, Walgreens, Lululemon, and BioNTech release results this week. Plus, the March jobs report, February personal income and expenditures, and more economic data.
- 03/28/2022
|
Week In Review: Nuance In-Licenses RSV Vaccine In $225 Million Deal
- Shanghai Nuance Pharma in-licensed China and Southeast Asia rights to a respiratory syncytial virus (RSV) vaccine from Copenhagen's Bavarian Nordic in a $225 million deal.
- 03/27/2022
|
Why Moderna, BioNTech, and Novavax Stocks Are Tumbling Today
- Investors appear to be concerned that Uncle Sam won't foot the bill for additional COVID-19 vaccine purchases.
- 03/25/2022
|
Is It Time to Buy COVID-19 Vaccine Stocks Again?
- The picture is improving for vaccine stocks. But there's still a lot of uncertainty.
- 03/24/2022
|
FDA Panel to Discuss Fourth Booster Dose in April Meeting
- The FDA advisory committee meeting on Apr 6 is likely to give an insight into how the regulatory agency feels about the need for additional boosters of COVID-19 vaccines.
- 03/22/2022
|
Why BioNTech Stock Is Jumping Today
- The momentum from earlier this week continues.
- 03/18/2022
|
BioNTech SE Sponsored ADR (BNTX) Gains But Lags Market: What You Should Know
- BioNTech SE Sponsored ADR (BNTX) closed the most recent trading day at $165, moving +0.66% from the previous trading session.
- 03/17/2022
|
Vaccine Stocks Rising on Booster News
- Pfizer Inc (NYSE:PFE) and partner BioNTech SE (NASDAQ:BNTX) filed an application with the U.S. Food and Drug Administration this morning to approve emergency use authorization for a second booster shot of its Covid-19 vaccine.
- 03/16/2022
|
Pfizer, BioNTech Seek FDA Nod for 4th COVID Shot in Older Adults
- Pfizer (PFE) and BioNTech (BNTX) believe that for individuals to be adequately protected, additional booster doses of COVID vaccines are needed.
- 03/16/2022
|
BioNTech to Report Full Year and Fourth Quarter 2021 Financial Results and Operational Update on March 30, 2022
- MAINZ, GERMANY, March 16, 2022 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the full year and fourth quarter 2021 on Wednesday, March 30th, 2022. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. EDT (2.00 p.m. CEST) to report its financial results and provide a corporate update for the fourth quarter and full year 2021.
- 03/16/2022
|
Vaccine maker stocks rise as China battles worst Covid outbreak since 2020
- Shares of Moderna, BioNTech, Pfizer, Johnson & Johnson and Novavax rose on Monday as China battles its worst Covid outbreak in two years.
- 03/14/2022
|
Here's Why BioNTech Shares Are Rising On Monday
- BioNTech SE - ADR (NASDAQ: BNTX) shares are trading higher by 14.8% at $155.65. Strength is possibly due to a spike in COVID-19 cases in China, which could lift vaccine sector sentiment.
- 03/14/2022
|
Why BioNTech, Dynavax, Novavax, and Pfizer Stocks Are Jumping Today
- The broader stock market bounce and news from China are fueling gains for all four vaccine stocks.
- 03/14/2022
|
Moderna and BioNTech Stocks Rally on Booster Chatter and a China Covid Surge
- Shares of Covid-19 vaccine makers jump on news of climbing Covid-19 cases in China and growing talk of a fourth booster round in the U.S.
- 03/14/2022
|
Is It Too Late to Buy BioNTech Stock?
- The market has probably priced in the impacts of its biggest source of revenue.
- 03/12/2022
|
BioNTech (BNTX), Regeneron Expand Agreement for Lung Cancer Study
- BioNTech (BNTX) expands its strategic collaboration deal with Regeneron to evaluate the combo of BNT116 plus Libtayo for treating advanced non-small cell lung cancer.
- 03/09/2022
|
Regeneron, BioNTech to test experimental combination therapy for lung cancer
- BioNTech SE BNTX, -1.36% and Regeneron Pharmaceuticals Inc. REGN, -0.58% said they plan to test an experimental BioNTech cancer vaccine in combination with Regeneron's Libtayo in patients with advanced non-small cell lung cancer, starting with a Phase 1/2 clinical trial. Libtayo is approved in the U.S. to treat advanced basal cell carcinoma.
- 03/08/2022
|
Why BioNTech Stock Dropped 12.4% in February
- Investors are concerned that the company's revenue will plunge as the need for its COVID-19 vaccine diminishes.
- 03/07/2022
|
SCYNEXIS, Inc.: Speculative Buy, Michael Burry Sold, But I Am Buying
- SCYNEXIS, Inc.: Speculative Buy, Michael Burry Sold, But I Am Buying
- 03/07/2022
|
Why Moderna and BioNTech Tumbled on Thursday
- Investors were spooked by the government's plan to share certain COVID treatment technologies with international health organizations.
- 03/03/2022
|
Is BioNTech Stock a Buy Now?
- Is this company just a coronavirus play?
- 03/02/2022
|
Pfizer/BioNTech vaccine found to be much less affective in preventing infection in children aged 5 to 11: NYT
- The COVID-19 vaccine developed by Pfizer PFE, -1.63% and German partner BioNTech SE BNTX, +0.13% is much less effective in preventing infection in children aged 5 to 11 than in older people, according to a new dataset from health officials in New York state, the New York Times reported. For now, the Pfizer/BioNTech shot is the only one authorized for use in that age group.
- 03/01/2022
|
BioNTech SE Sponsored ADR (BNTX) Gains As Market Dips: What You Should Know
- BioNTech SE Sponsored ADR (BNTX) closed the most recent trading day at $150.81, moving +0.13% from the previous trading session.
- 02/28/2022
|
Got $5,000? These 2 Growth Stocks Are Down 60% From Their Highs
- Both have some promising growth opportunities ahead.
- 02/24/2022
|
BioNTech, Medigene Ink Immunotherapy Pact Against Cancer
- BioNTech SE (NASDAQ: BNTX) and Medigene AG have entered a multi-target research collaboration to develop T cell receptor (TCR) based immunotherapies against cancer. The initial term of the collaboration is three years.
- 02/22/2022
|
Pfizer/BioNTech's Omicron-Targeted COVID-19 To Miss March Timeline: Reuters
- Pfizer Inc (NYSE: PFE) / BioNTech SE's (NASDAQ: BNTX) omicron-targeted COVID-19 vaccine is delayed by several weeks due to a slower-than-expected data gathering process, BioNTech Chief Executive Ugur Sahin told Germany's Bild. Once the vaccine is ready, the company would assess whether it was still needed, Sahin said.
- 02/17/2022
|
BioNTech Unveils First Modular mRNA Manufacturing Facility In Africa
- BioNTech SE (NASDAQ: BNTX), which developed the first widely approved COVID-19 shot together with Pfizer Inc (NYSE: PFE), unveiled plans to establish manufacturing facilities in Africa to boost the availability of much-needed medicines on the continent. The manufacturing solution consists of one drug substance and one formulation module, allowing for mRNA vaccine production in bulk (mRNA manufacturing and formulation).
- 02/16/2022
|
BioNTech COO outlines plan to scale mRNA vaccine production in Africa
- BioNTech Chief Operating Officer Sierk Poetting discusses the vaccine maker's plans to ship mRNA vaccine factory kits to increase production of vaccines on the continent.
- 02/16/2022
|
BioNTech unveils plans to develop mRNA vaccine facilities in Africa
- BioNTech SE BNTX, +5.77% said Wednesday it is developing turkey mRNA manufacturing facilities based on a container solution in an effort to promote scalable vaccine production in Africa. The company is expecting to deliver the first BioNTainer in the second half, comprising one drug substance and one formulation module.
- 02/16/2022
|
What to Expect From Pfizer and BioNTech's Next Meeting With the FDA
- What will result from the anticipated upcoming FDA meeting?
- 02/15/2022
|
Pfizer has pulled its FDA request to authorize a 2-dose shot for kids under 5, saying it will 'wait for the 3-dose data'
- Parents of kids aged 0-5 will have to wait until at least April for a vaccine. Pfizer will keep testing a 3-dose regimen, nixing plans for 2 doses.
- 02/11/2022
|
US Plans COVID-19 Vaccine Roll Out For Kids Under 5 Years This Month
- The U.S. government is planning a COVID-19 vaccine roll out for children under the age of 5 as soon as February 21, according to a document from the U.S. Centers for Disease Control and Prevention. Get the Inside Access Traders Are Using to Profit More and Win Bigger.
- 02/10/2022
|
7 Hot Stocks That Can Win in Either a Bull or Bear Market
- These seven hot stocks are a mix of growth and income plays The post 7 Hot Stocks That Can Win in Either a Bull or Bear Market appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.
- 02/04/2022
|
FDA Asks Pfizer - BioNTech To Submit For COVID-19 Vaccine Emergency Use Nod For Youngest Children
- Pfizer Inc PFE and its partner BioNTech SE BNTX have started a rolling submission to amend its COVID-19 vaccine FDA Emergency Use Authorization (EUA) to include children six months to under five years of age. Thousands of new traders are learning the ins and outs on how to find profitable trades every day with Benzinga Trading School.
- 02/02/2022
|
BioNTech (BNTX) Stock: Why The Price Went Up
- The stock price of BioNTech SE (NASDAQ: BNTX) increased by 4.37% in the most recent trading session. This is why it happened.
- 02/02/2022
|
Pfizer, BioNTech ask FDA to authorize two-dose COVID-19 vaccine for children under 5
- In a Tuesday press release, the FDA said the agency pushed Pfizer and BioNTech to submit the application given the ongoing Omicron surge.
- 02/01/2022
|
Why BioNTech Stock Is Climbing Higher Today
- BioNTech and Pfizer could be about to file for authorization of their vaccine for younger kids.
- 02/01/2022
|
Pfizer may seek FDA's OK for COVID vaccine for kids under 5 as soon as Tuesday: reports
- Federal regulators are expected to be asked as soon as Tuesday to authorize Pfizer's COVID-19 vaccine for children as young as 6 months old, and the first shots could come by the end of February, according to news reports Monday night.
- 01/31/2022
|
Pfizer Could Seek COVID-19 Vaccine Emergency Approval For Children Under 5 This Week
- Pfizer Inc PFE and BioNTech SE BNTX are likely to submit a request for an emergency use authorization to the U.S. Food and Drug Administration on Tuesday for a COVID-19 vaccine aimed at children younger than five years. What Happened: The vaccine, made by the two companies, will be the first such available for that particular age group, according to a Washington Post report.
- 01/31/2022
|
Pfizer-BioNTech COVID-19 vaccine for kids under 5 could be ready by end of February, according to The Washington Post
- A Pfizer-BioNTech two-shot regimen for younger kids could be ready in the coming weeks, people briefed on the situation told the outlet on Monday.
- 01/31/2022
|
Monday's Melt-Up Leaves the Market Muddled
- A huge gain for the day; a big loss for the month.
- 01/31/2022
|
3 Things About BioNTech That Smart Investors Know
- This biotech is maturing quickly, and its future won't look like its past.
- 01/29/2022
|
Pfizer (PFE), BioNTech Begin Omicron-Based COVID-19 Jab Study
- Pfizer (PFE) and BioNTech (BNTX) announce that the first participants in a clinical study on its Omicron-specific COVID-19 vaccine candidate have been dosed.
- 01/27/2022
|
Why Coronavirus Vaccine Stocks Topped the Market Today
- The CDC is making a push for fourth shots for the immuno-compromised.
- 01/26/2022
|
Pfizer and BioNTech set to begin trials of Omicron specific vaccine
- Pfizer Inc (NYSE:PFE) and BioNTech say they have signed up the first participants for a clinical trial of a vaccine tailored to target the specific Omicron variant of Covid. The proposed vaccine will be trialed among 1,420 adults between the ages of 18-55, testing for safety, tolerability and efficacy against Omicron.
- 01/25/2022
|
BioNTech, Google, Deutsche Bahn back African-founded AI firm
- Vaccine maker BioNTech, Google and rail firm Deutsche Bahn are among the companies investing in African-founded artificial intelligence company InstaDeep.
- 01/25/2022
|
Pfizer, BioNTech begin omicron-specific COVID-19 vaccine study
- COVID-19 vaccine-makers Pfizer and BioNTech announced Tuesday that the companies would test an omicron-specific vaccine candidate in healthy adults ages 18 to 55.
- 01/25/2022
|
Clinical Trials Begin For Pfizer And BioNTech's Omicron-Specific Covid Shot
- The study will evaluate the safety and efficacy of a new shot designed to target the omicron coronavirus variant, which can evade some of the protection from existing vaccines.
- 01/25/2022
|
Tunisian enterprise AI startup InstaDeep raises $100M from Alpha, BioNTech, Google
- A recent survey carried out by CNBC reported that 81% of executives worldwide say AI will play a prominent and critical role in how their businesses operate this year. Companies are phasing from the first generation of AI, which deals with pattern, text and image recognition, to decision-making AI, which helps them make timely decisions […]
- 01/25/2022
|
Pfizer and BioNTech launch study to evaluate omicron-based COVID-19 vaccine for adults 18 to 55 years old
- Pfizer Inc. PFE, -2.37% and German partner BioNTech SE BNTX, +2.36% said Tuesday they are launching a trial to evaluate an omicron-based COVID-19 vaccine in healthy adults aged 18 to 55. "While current research and real-world data show that boosters continue to provide a high level of protection against severe disease and hospitalization with Omicron, we recognize the need to be prepared in the event this protection wanes over time and to potentially help address Omicron and new variants in the future," said Kathrin U.
- 01/25/2022
|
Pfizer and BioNTech launch clinical study of Covid vaccine targeting omicron
- Pfizer CEO Albert Bourla has said the company will have the omicron vaccine ready by March.
- 01/25/2022
|
Why BioNTech, Moderna, Novavax, and Ocugen Stocks Are Plunging This Week
- Several factors are dragging down these vaccine stocks.
- 01/20/2022
|
What's Happening With BioNTech Stock?
- BioNTech stock, a leader in messenger RNA technology and Pfizer's Covid-19 vaccine partner, declined by almost 31% over the last month, considerably underperforming the S&P 500 which remained roughly flat over the same period. The stock also remains down by almost 55% from all-time highs seen in.
- 01/20/2022
|
Top Stocks For 2022
- Inflation is on fire, there are labor and supply shortages, and the Fed is hinting at multiple rate hikes. We'll look at how stocks can perform in this environment. In 2021, the market rose on low interest rates, government stimulus, and a big rebound in earnings. The breeze from these tailwinds may still blow into the New Year.
- 01/19/2022
|
After Plunging 37.7% in 4 Weeks, Here's Why the Trend Might Reverse for BioNTech SE Sponsored ADR (BNTX)
- BioNTech SE Sponsored ADR (BNTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 01/19/2022
|
Will 2022 Be a Better Year for Biotech Than 2021? 3 Big Picks
- Regeneron (REGN), Vertex Pharmaceuticals (VRTX) and BioNTech (BNTX) are three large biotech stocks that are worth betting on in the current scenario.
- 01/19/2022
|
Why BioNTech, Moderna, and Novavax Stocks Are Sinking Today
- Investors are weighing results from an Israeli study and recent comments from Moderna's CEO.
- 01/18/2022
|
5 Top Biotech Stocks To Watch In January 2022
- Could these biotech stocks be poised for gains in 2022?
- 01/16/2022
|
Why Pfizer and BioNTech Got Thrashed on Thursday
- A fresh Supreme Court ruling does neither stock any favors.
- 01/13/2022
|
What's Going On With Moderna, BioNTech And Novavax Stock Today
- Shares of vaccine makers, including Moderna Inc (NASDAQ:MRNA), BioNTech SE – ADR (NASDAQ:BNTX) and Novavax, Inc. (NASDAQ:NVAX), are all trading lower as the sector continues to pull back following 2021 strength, with investors continuing to weigh sector outlook going into 2022. The US Supreme Court today blocked President Biden's workplace vaccine-or-test mandate for larger employers.
- 01/13/2022
|
Why Shares of BioNTech Rose 216% in 2021
- The successful rollout of a revolutionary vaccine leaves the immunotherapy specialist primed for further gains.
- 01/13/2022
|
BioNTech SE (BNTX) CEO Ugur Sahin on JPMorgan 40th Annual Healthcare Conference (Transcript)
- BioNTech SE (BNTX) CEO Ugur Sahin on JPMorgan 40th Annual Healthcare Conference (Transcript)
- 01/11/2022
|
BioNTech Partners With London-Based AI Developer To Predict COVID-19 Variants
- BioNTech SE (NASDAQ: BNTX) said it's working with London-based AI developer InstaDeep to develop a new computational method that analyzes sequencing data and predicts high-risk variants SARS-CoV-2. The early warning system combines structural modeling of the SARS-CoV-2 spike protein, and AI algorithms to flag potentially high-risk variants entered into SARS-CoV-2 sequence data repositories “within less than a day,” based on metrics scoring their fitness and their immune escape properties.
- 01/11/2022
|
New Strong Buy Stocks for January 11th
- ANF, ARCO, BNTX, GSL, and KLIC have been added to the Zacks Rank #1 (Strong Buy) List on January 11, 2022.
- 01/11/2022
|
BioNTech eyes up to 17 billion euros in vaccine revenue in 2022
- Germany's BioNTech said on Tuesday it would likely generate up to 17 billion euros ($19 billion) in 2022 revenue from the COVID-19 vaccine it co-developed with partner Pfizer.
- 01/11/2022
|
BioNTech, InstaDeep create new system to identify high risk SARS-CoV-2 variants
- Shares of BioNTech SE BNTX, +8.57% were down 0.6% in premarket trading on Tuesday after the company said it developed a new system with InstaDeep Ltd. that uses a mix of modeling and artificial intelligence to predict high-risk new SARS-CoV-2 variants, based on publicly available virus sequences.
- 01/11/2022
|
Why BioNTech Stock Jumped Today
- Two developments contributed to the stock's nice gain.
- 01/10/2022
|
Pfizer and BioNTech to Make mRNA-Based Shingles Vaccine
- Pfizer (PFE) and BioNTech (BNTX) plan to develop an mRNA-based vaccine for shingles after witnessing success with their COVID-19 vaccine.
- 01/06/2022
|
Pfizer, BioNTech Will Develop mRNA Shingles Vaccine After Covid-19 Shot Success
- If successful, the vaccine could be the first mRNA shot for shingles.
- 01/05/2022
|
There's absolutely Covid stock fatigue, says Jefferies' Michael Yee
- Michael Yee, managing director covering healthcare equity research at Jefferies, joins CNBC's 'Squawk Box' to discuss shares of Covid-19 drugmakers Moderna and Pfizer.
- 01/05/2022
|
After Successful COVID-19 Vaccine, Pfizer, BioNTech Come Together For mRNA-Based Shingles Vaccine
- Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have announced a new research, development, and commercialization collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles. The agreement marks the third collaboration between Pfizer and BioNTech in the infectious diseases field, following influenza and COVID-19 vaccine collaborations initiated in 2018 and 2020.
- 01/05/2022
|
BioNTech: Profit Off Of Next-Gen Vaccines And Therapies
- BioNTech: Profit Off Of Next-Gen Vaccines And Therapies
- 01/05/2022
|
Why BioNTech Stock Tumbled on Tuesday
- The current investor trend isn't the biotech stock's friend.
- 01/04/2022
|
Pfizer, BioNTech Booster Gets FDA Nod for 12 to 15-Year Olds
- FDA authorizes the booster shot of Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine for adolescents 12 through 15 years of age.
- 01/04/2022
|
Why Pfizer, BioNTech, and Moderna Stocks Are Falling Today
- Investors appear to be seeing a future where COVID-19 vaccines aren't needed nearly as much.
- 01/03/2022
|
FDA approves Pfizer's COVID-19 vaccine booster shot for children ages 12 and up
- The new approval comes as the Omicron variant surges through the US, driving up new COVID-19 cases to record highs.
- 01/03/2022
|
Pfizer, BioNTech booster shot EUA expanded to include children 12 years old
- Pfizer Inc. PFE, -3.95% and BioNTech SE BNTX, -4.93% announced Monday that the U.S. Food and Drug Administration has granted Emergency Use Authorization of a booster dose of the companies' COVID-19 vaccine into people ages 12 years and older. Previously, the FDA had only authorized a booster for people aged 16 years and older.
- 01/03/2022
|
mRNA technology has been the story of the year, says Caret Group chairman
- Fred Hassan, Caret Group chairman, joins 'Squawk on the Street' to discuss Hassan's predictions for the omicron variant's longevity. Hassan also discusses the mRNA technology that helped produce Covid vaccines.
- 12/31/2021
|
Will the Stock Market Crash in 2022?
- Whether it happens or not, investors should consider buying this pharma stock.
- 12/31/2021
|
Why Pfizer, BioNTech, and Moderna Shot Higher Today
- One coronavirus vaccine will apparently be authorized as a booster for younger people in the U.S.
- 12/30/2021
|
Vaccine Sector Rally Over for These 2 Stocks
- Vaccine stocks have been in a recent downfall, and getting hit particularly hard are Moderna Inc (NASDAQ:MRNA) and BioNTech SE (NASDAQ:BNTX).
- 12/29/2021
|
Biotech stocks will trade depending on the state of the epidemic, says Bernstein's Ronny Gal
- Ronny Gal, Bernstein analyst, joins 'Closing Bell' to discuss how investors view biotechnology stocks like Pfizer and Johnson and Johnson in 2022.
- 12/28/2021
|
BioNTech to Present at the 40th Annual J.P. Morgan Healthcare Conference
- MAINZ, Germany, December 27, 2021 — BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that CEO and Co-founder Ugur Sahin, M.D., will present a corporate overview and update at the virtual 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 9:45 am ET.
- 12/27/2021
|
Pfizer-BioNTech Reveals Updated Longer-Term Data On COVID-19 Shot In Adolescents
- Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have submitted longer-term follow-up data from the Phase 3 trial of the COVID-19 mRNA vaccine in adolescents to the European Medicines Agency (EMA). The data from 2,228 individuals 12 through 15 years of age aims to support further the favorable safety and efficacy profile of Comirnaty in this age group.
- 12/23/2021
|
5 Biotech Stocks That More Than Doubled This Year
- The biotech sector has been in focus through 2021 as vaccine makers like Moderna (MRNA) BioNTech (BNTX), and other companies like Dynavax (DVAX), Prothena (PRTA) and Intellia (NTLA) put up an exemplary performance.
- 12/23/2021
|
Why BioNTech, Novavax, and Ocugen Stocks Are Slipping Today
- Decreasing concerns about the omicron variant are leading to declining prices for these vaccine stocks.
- 12/22/2021
|
Why Some Coronavirus Stocks Plunged Today
- It had much to do with a certain Greek letter.
- 12/20/2021
|
Pfizer and BioNTech to provide more than 200 million additional COVID vaccine doses to EU in 2022
- Pfizer Inc. PFE, -2.89% and German partner BioNTEch SE BNTX, +1.27% said Monday they have reached an agreement to provide an additional 200 million doses of their COVID-19 vaccine to the European Commission and its member states in 2022. The companies said the 200 million doses are on top of 450 million that are already planned for delivery in 2022 in previous contracts.
- 12/20/2021
|
3 Biotech Stocks That Soared in 2021 and Could Go Even Higher in 2022
- Don't expect the momentum to dwindle for these stocks.
- 12/19/2021
|
BioNTech Has More To Give Than Just Its COVID-19 Vaccine
- BioNTech SE (BNTX) is one of the biggest beneficiaries of the pandemic, as it launched the German company to global success while reporting record revenues quarter after quarter in FY2021. With the billions earned from Comirnaty, BNTX is accelerating its oncology and infectious diseases pipeline for regulatory approval within the next five years.
- 12/17/2021
|
COVID-19 Vaccines: The Big Omicron Reboot For BioNTech, Moderna And Novavax
- The Omicron variant has made Wuhan based vaccines redundant, will replace Delta, and causes a milder version of covid. BioNTech, Novavax and Moderna will need to urgently develop an appropriate 2nd generation vaccine candidate.
- 12/15/2021
|
Pfizer early study shows vaccine is 70% effective against Omicron variant as cases rise globally
- Yahoo Finance's Anjalee Khemlani provides data on the Pfizer vaccine's reported effectiveness against the Omicron variant, which has been detected in 33 U.S. states and 77 countries worldwide.
- 12/14/2021
|
South African Study Shows Omicron Variant Could Escape Pfizer/BioNTech COVID-19 Vaccine Protection
- A new private study by South Africa's Discovery Health suggests that Pfizer Inc (NYSE: PFE) and BioNTech SE's (NASDAQ: BNTX) COVID-19 vaccine is just 33% effective against infections by the omicron variant. However, the Company reported that the variant appears to cause less severe disease.
- 12/14/2021
|
How Much Will COVID Boosters for Teens Impact Pfizer and BioNTech?
- Probably not very much.
- 12/13/2021
|
Why BioNTech, Moderna, and Novavax Stocks Are Jumping Today
- Concerns about the omicron variant as well as some good news are helping drive these vaccine stocks higher.
- 12/13/2021
|
How Quickly Could Vaccines Targeting the Omicron Variant Be Available?
- It depends on what data the FDA requires.
- 12/11/2021
|
What Does the Omicron Variant Mean for Vaccine Stocks?
- It looks like the winners will keep winning.
- 12/11/2021
|
Why BioNTech Stock Is Sinking Today
- Good news from the FDA wasn't enough to outweigh less positive updates this week.
- 12/10/2021
|
Pfizer, BioNTech Booster Gets FDA Nod for 16- & 17-Year Olds
- FDA authorizes the booster shot of Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine for 16- and 17-year olds.
- 12/10/2021
|
FDA authorizes Pfizer boosters for 16- and 17-year-olds
- The CDC still needs to sign off on the boosters for teens.
- 12/09/2021
|
FDA Expands Emergency Use Of Pfizer/BioNTech's COVID-19 Booster To 16 Years & Older
- The FDA has expanded the Emergency Use Authorization (EUA) of a booster dose of Pfizer Inc (NYSE: PFE) and BioNTech SE's (NASDAQ: BNTX) COVID-19 vaccine to include individuals 16 years of age and older. The booster dose will be administered at least six months after completion of the primary series and is the same formulation and dosage strength as the primary series.
- 12/09/2021
|
New studies show Covid boosters drive down mortality risks
- CNBC's Jim Cramer and the 'Squawk on the Street' team discuss new studies out of Israel looking at how well Pfizer and BioNTech's Covid-19 booster works in people over age 50.
- 12/09/2021
|
FDA authorizes BioNTech, Pfizer's COVID-19 booster for 16- and 17-year-olds
- The Food and Drug Administration said 16- and 17-year-olds can now get booster doses of BioNTech SE BNTX, -0.22% and Pfizer Inc.'s PFE, +2.41% COVID-19 vaccine. BioNTech's stock was down 0.1% in trading on Thursday, while Pfizer shares gained 1.7%.
- 12/09/2021
|
MRNA vaccines will stay flexible to respond to omicron, analyst says
- Redburn Head of Global Biopharma Research Simon Baker discusses the impact of the omicron variant on vaccine efficacy and the risk of hospitalization.
- 12/09/2021
|
Why BioNTech Stock Slipped on Wednesday
- Investors were weighing a good news/bad news update about the coronavirus vaccine co-developed by the biotech.
- 12/08/2021
|
Why BioNTech Stock Is Sliding Today
- Good news about a booster dose with the omicron variant could be bad news for the biotech's future sales.
- 12/08/2021
|
Remedies for Omicron Apparent, Markets Up Again
- New forms of Covid-19 appear to be growing more highly infectious, if not necessarily more life-threatening.
- 12/08/2021
|
Markets Upbeat on Vaccine Efficacy Against Omicron Variant
- Markets Upbeat on Vaccine Efficacy Against Omicron Variant
- 12/08/2021
|
Will Omicron Change What ‘Fully Vaccinated' Means? BioNTech CEO Says Full Vaccine Regimen Against Variant Is 3 Doses, Not 2.
- Early lab data released Wednesday suggests a booster shot of the Pfizer-BioNTech vaccine is necessary to ensure protection against omicron, rather than just two doses.
- 12/08/2021
|
BioNTech Stock (BNTX): Why The Price Increased Today
- The stock price of BioNTech SE (NASDAQ: BNTX) increased by over 4% pre-market today. This is why it happened.
- 12/08/2021
|
Bond Report: U.S. Treasury yields steady after Pfizer/BioNTech omicron report
- Yields for U.S. government debt on Wednesday were trading mixed as investors digested news suggesting the omicron variant of coronavirus that causes COVID-19 may not impact the economy as much as feared.
- 12/08/2021
|
Pfizer/BioNTech COVID-19 Shot Provides Partial Protection Against Omicron, Study Shows
- A small study in South Africa shows that the omicron variant can partially evade protection from two doses of Pfizer Inc (NYSE: PFE) / BioNTech SE's (NASDAQ: BNTX) COVID-19 vaccine. But the study did show that blood from people who had received two doses of the vaccine and had a prior infection were primarily able to neutralize the variant, thus suggesting booster doses of the vaccine could help to fend off the infection.
- 12/08/2021
|
Pfizer-BioNTech say booster dose provides high level of protection against omicron variant
|
Pfizer, BioNTech say initial lab study showed 3 doses of COVID-19 vaccine neutralized omicron variant
- Pfizer Inc. PFE, +0.47% and BioNTech SE BNTX, +8.17% said results from an "initial laboratory study" showed that their COVID-19 vaccine neutralized the omicron variant of the coronavirus after three doses, or the full two-dose regimen plus a booster shot. The drug makers said those who received just two does of the vaccine showed, on average, a more than 25-fold reduction in neutralization against the omicron variant.
- 12/08/2021
|
Dow futures pick up steam early Wednesday as Pfizer/BioNTech release preliminary lab study on omicron variant
- U.S. stock-index futures gained some altitude higher Wednesday morning after a preliminary lab study from Pfizer PFE, +0.47% and BioNTech SE BNTX, +8.17% suggested that 3 shots of their COVID vaccines, including a booster, provides the same level of neutralizing protection against the new omicron variant as two doses against the original strain of the coronvirus that causes COVID-19. Futures for the Dow Jones Industrial Average DJIA, +1.40% YMZ21, +0.48% were trading 177 points, or 0.5%, higher at 35,885, those for the S&P 500 SPX, +2.07% ESZ21, +0.43% were up 0.5% at 4,705, while the Nasdaq-100 futures were trading 0.4% higher at 16,375.
- 12/08/2021
|
Vaccine Stocks Down as Omicron May Not Be Too Severe
- Stocks of Moderna (MRNA), BioNTech (BNTX), Novavax (NVAX) and Pfizer (PFE) decline as data suggests that Omicron variant may cause less severe cases of COVID-19.
- 12/07/2021
|
BioNTech Stock (BNTX): Why The Price Dropped Today
- The stock price of BioNTech SE (NASDAQ: BNTX) fell by 18.67% today. This is why it happened.
- 12/06/2021
|
Vaccine Stocks: Why MRNA, BNTX, NVAX, PFE Stocks Are Stumbling Today
- Dr. Fauci has implied that the omicron variant may not be as severe as feared. Vaccine stocks have taken a hit as a result.
- 12/06/2021
|
Why Vaccine Stocks Like BioNTech and Novavax Are Crashing Today
- The global war against COVID-19 has changed over the course of the past week -- and changed dramatically just this past weekend.
- 12/06/2021
|
Vaccine Stocks: The Beginning of the End?
- Big declines show the uncertainty investors have about the future of fighting COVID-19.
- 12/06/2021
|
We're in an era of development and innovation in biotech, says WSJ's Greg Zuckerman
- Greg Zuckerman, special writer at the Wall Street Journal, joins the 'Halftime Report' to discuss why Moderna and Pfizer's underperformance in the markets are causing hedge funds to lose money.
- 12/06/2021
|
Pfizer/BioNTech's COVID-19 Shot Receives Emergency Use Nod In Australia For Kids Aged 5-11 Years
- Australia's Therapeutics Goods Administration provisionally approved Pfizer Inc (NYSE: PFE) / BioNTech SE's (NASDAQ: BNTX) COVID-19 vaccine for children between 5 and 11 years. The health minister said that the rollout could begin from January 10, 2022.
- 12/06/2021
|
7 A-Rated Biotechs to Buy for the Long Run
- The one thing the pandemic has shown us is biotechs are changing the way we treat diseases. These A-rated biotechs are great examples.
- 12/03/2021
|
COVID-19 Vaccine & Drug Makers Gear Up to Fight Omicron
- The Omicron variant ignites fears that currently available COVID-19 vaccines and treatments could be less effective against it. MRNA, PFE, BNTX, REGN and JNJ are some of the industry players gearing up to fight against this new variant.
- 12/03/2021
|
FDA prepares for rapid review of omicron vaccines and drugs: WSJ
- The Wall Street Journal is reporting that the FDA is laying the ground work for a quick review of omicron-targeted vaccines and drugs, if needed.
- 12/03/2021
|
Here's What Vaccine CEOs Have to Say About the Omicron Variant
- Some are more optimistic than others.
- 12/03/2021
|
Hotel Stocks: Why MAR, H, HLT, WH, CHH and IHG Are Booking Gains Today
- Hotel stocks are up across the board after President Joe Biden reiterated his message that the U.S. won't face another lockdown. The post Hotel Stocks: Why MAR, H, HLT, WH, CHH and IHG Are Booking Gains Today appeared first on InvestorPlace.
- 12/02/2021
|
Britain Agrees To New Deals For 114M Additional Moderna, Pfizer/BioNTech COVID-19 Vaccine Doses
- The British government has agreed on deals to buy 114 million more Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) and Moderna Inc (NASDAQ: MRNA) COVID-19 vaccine shots. The new contracts with Pfizer/BioNTech and Moderna were accelerated in light of the emergence of the new Omicron variant.
- 12/02/2021
|
People should get vaccinated and boosted, Dr. Fauci says
- Dr. Anthony Fauci, National Institute of Allergy and Infectious Diseases, speaks from the White House on the omicron variant, which was discovered in a patient in California.
- 12/01/2021
|
Buy BioNTech, Sell Moderna On Omicron Variant Price Volatility
- The emergence of the new Omicron COVID strain is concerning - but has boosted the share prices of Moderna and BioNTech. Omicron may not respond to current vaccines developed by these pioneering companies due to the number of spike protein mutations.
- 11/30/2021
|
Analysis: As Omicron plays havoc with markets, shares of vaccine makers surge
- The emergence of a worrisome coronavirus variant is benefiting shares of vaccine makers Moderna Inc, BioNTech and Pfizer as investors search for winning bets in markets roiled by uncertainty in recent days.
- 11/30/2021
|
FDA May Authorize Pfizer-BioNTech COVID-19 Booster Shots For Age 16-17 Next Week: WSJ
- The FDA could authorize COVID-19 boosters from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) for use in 16 and 17-year olds as soon as next week, reports Wall Street Journal, citing a person familiar with the planning. The agency is planning to rapidly take action on a request by the companies to authorize boosters for 16 and 17 year-olds.
- 11/30/2021
|
Why BioNTech Is Beating the Market Today
- The company is getting a quick start on heading off a potential major global health threat.
- 11/29/2021
|
Covid could become like the flu, creating opportunities in science, says Cantor's Alethia Young
- Alethia Young, senior biotech analyst at Cantor Fitzgerald, joins 'Closing Bell' to discuss the impact of the omicron variant on the overall biotech sector.
- 11/29/2021
|
Omicron Fears Fuel Rally in Vaccine Stocks: Will It Continue?
- Another variant of the coronavirus, Omicron, is up on the WHO-identified list. Several mutations of this variant spark fears of high resistance to the COVID-19 vaccines.
- 11/29/2021
|
Carnival Will Survive the Latest Covid-19 Variant Omicron
- Carnival will survive the effects of the latest Covid-19 variant Omicron. CCL stock is a great buy here even being extremely conservative, putting Carnival's value at $24 per share or 34% over today.
- 11/29/2021
|
5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market
- The omicron variant dealt the stock market a blow, but these vaccine stocks promise investors a way to cash in while combatting Covid-19. The post 5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market appeared first on InvestorPlace.
- 11/29/2021
|
Covid vaccine makers' stocks soar on Omicron variant concerns
- Fears about the Omicron variant of Covid-19 rattled the world's financial markets Friday and early Monday morning. But shares of the major coronavirus vaccine makers were getting a boost from the latest pandemic jitters.
- 11/29/2021
|
BioNTech has already started developing a new Omicron version of its COVID-19 vaccine
- The German biotech, which makes COVID-19 vaccines with Pfizer, said Monday it doesn't want to "waste any time" and is working on an "adapted" vaccine.
- 11/29/2021
|
Specter Of New Covid Lockdowns Can Lift These 5 Stocks
- Stocks sold off sharply on Black Friday with concerns over a new Covid variant adding to macro uncertainties. The potential for new travel restrictions or return of social distancing measures represents a deeply bearish development for the market with risks tilted to the downside.
- 11/27/2021
|
Dr. Gottlieb: The vaccines might be sufficient to control spread of new Covid variant
- Dr. Scott Gottlieb, former FDA commissioner, joins 'Closing Bell' to discuss the new Covid-19 variant. He says if the majority of the population is vaccinated it can be effective in protecting people from the new Covid variant.
- 11/26/2021
|
Pfizer-BioNTech investigating new Covid variant, while J&J say they are testing their vaccine against it
- Pfizer and BioNTech said they expect more data from lab tests in two weeks at the latest.
- 11/26/2021
|
Wall Street Tumbles on Resurgence of Coronavirus
- Wall Street Tumbles on Resurgence of Coronavirus.
- 11/26/2021
|
Forget reopening. The new COVID variant has 'stay-at-home' stocks rebounding.
- Little is known about the new COVID strain emerging in Africa. That hasn't stopped traders from betting big on lockdowns and a return to telework.
- 11/26/2021
|
Pandemic-related stocks from Zoom to Moderna jump as new coronavirus variant raises alarms and triggers lockdowns
- The stock prices of vaccine makers Moderna and Pfizer surged Friday along with stay-at-home stocks like Zoom Video and Peloton.
- 11/26/2021
|
BioNTech says it will know in 2 weeks whether the COVID-19 vaccine it developed with Pfizer works against the new variant rapidly spreading in southern Africa
- The B.1.1.529 variant has been detected in South Africa, Botswana, Hong Kong, and Israel, and is spreading rapidly.
- 11/26/2021
|
Pfizer/BioNTech's COVID Jab Gets CHMP Nod for Kids Aged 5-11
- Pfizer (PFE)/BioNTech (BNTX) COVID-19 vaccine, Comirnaty, if approved for use in children aged five to 11, will be the first vaccine to be approved for administration in this age group in Europe
- 11/26/2021
|
BioNTech (BNTX): Why The Price Jumped Today
- The stock price of BioNTech SE (NASDAQ: BNTX) increased by over 7% pre-market today. This is why it happened.
- 11/26/2021
|
Europe's CHMP Backs Pfizer/BioNTech's COVID-19 Shot For Kids Aged 5-11 Years
- The European Medicines Agency's (EMA) human medicines committee (CHMP) recommended using Pfizer Inc (NYSE: PFE) - BioNTech SE's (NASDAQ: BNTX)'s COVID-19 vaccine, Comirnaty, for children between 5 to 11. Pfizer-BioNTech's vaccine will be given in two 10-microgram doses three weeks apart as an injection in the upper arm, per the EMA recommendation.
- 11/26/2021
|
4 Biotech Stocks To Watch This Week
- Could these biotech stocks be poised for long-term gains?
- 11/22/2021
|
FDA Authorizes PFE & MRNA's COVID-19 Boosters for All Adults
- The FDA authorizes booster doses of COVID-19 vaccines of PFE/BNTX and MRNA for use in all adults irrespective of the risk of exposure to coronavirus.
- 11/22/2021
|
Pfizer-BioNTech's COVID-19 Vaccine Shows 100% Effectiveness In Long Term Analysis In Adolescents
- Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have announced topline results from a longer-term analysis of the safety and efficacy of their COVID-19 Vaccine in individuals 12 through 15 years of age. The updated findings from the Phase 3 trial show that a two-dose series of the Vaccine (30-µg per dose) was 100% effective against COVID-19, measured seven days through over four months after the second dose.
- 11/22/2021
|
3 Healthcare Stocks That Are Too Cheap to Ignore
- These awesome stocks don't need COVID-19 to beat the market.
- 11/22/2021
|
Pfizer and BioNTech say late-stage trial shows vaccine effective for 12- to 15-year-olds
- Pfizer Inc. PFE, -1.19% and BioNTech SE BNTX, +5.73% said Monday that topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in people 12 through 15 show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-ug per dose) was 100% effective against COVID-19. The follow-up test measured seven days through four-plus months after the second dose.
- 11/22/2021
|
How Good Were BioNTech's Q3 Results?
- The German biotech delivered another strong quarter.
- 11/21/2021
|
Why BioNTech Stock Was Blasting 20% Higher This Week
- The FDA's approval of coronavirus vaccine boosters wasn't the only reason for the stock's pop.
- 11/19/2021
|
FDA Authorizes Covid Boosters; New Fed Chair Soon?
- Adults who receive booster vaccine shots will be much more highly immunized from Covid-19 than those simply "fully vaccinated."
- 11/19/2021
|
EQT, Biontech investor family consider Sandoz bid - Handelsblatt
- Investment group EQT and members of the Struengmann family, who are investors in Biontech, are considering a joint bid for Swiss pharmaceutical group Novartis's generics division Sandoz, German newspaper Handelsblatt reported on Friday, citing unnamed sources.
- 11/19/2021
|
COVID-19 Booster Shots From Moderna, Pfizer/BioNTech Score FDA Nod All Adults
- The FDA has authorized Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE) / BioNTech SE's (NASDAQ: BNTX) COVID-19 booster shots for all U.S. adults. The agency extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older.
- 11/19/2021
|
Pfizer, BioNTech COVID-19 vaccine authorized in Canada for children 5 to 11 years of age
- Shares of Pfizer Inc. PFE, +1.56% rose 2.1% and of Germany-based partner BioNTech SE BNTX, +3.44% climbed 4.2% in morning trading Friday, after Health Canada authorized use of the companies' COVID-19 vaccine in children 5 to 11 years old. That's the first vaccine authorized in Canada for that age group.
- 11/19/2021
|
Will Pfizer and BioNTech Win Authorization for Boosters for All Adults?
- Yes -- if the FDA focuses on protection against coronavirus infection.
- 11/19/2021
|
CureVac's COVID-19 Vax Shows Comparable Antibody Levels To Pfizer/BioNTech's Shot In Animal Study
- CureVac BV (NASDAQ: CVAC) has announced the online publication of the extended preclinical study of the second-generation vaccine candidate, CV2CoV, jointly developed with GlaxoSmithKline Plc (NYSE: GSK), in the journal Nature. Related Link: CureVac-GSK's Second-Gen COVID-19 Vaccine Candidate Shows Encouraging Action Against Variants In Animal Study.
- 11/18/2021
|
3 Biotech Stocks That Have More Than Tripled so far This Year
- But can they keep up the momentum?
- 11/18/2021
|
3 Big Pharma Outperformers to Watch Out For in the Near Term
- Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.
- 11/17/2021
|
7 Stocks to Buy That Will Make You Rich by 2030
- Patient investors who overcome short-term distractions will get a windfall with these stocks to buy, as they're set to grow at a faster pace. The post 7 Stocks to Buy That Will Make You Rich by 2030 appeared first on InvestorPlace.
- 11/15/2021
|
BioNTech: The Novavax Fork In The Road
- Political messaging around the necessity of covid booster shots is once again following the “optics” script rather than the scientific script. The SARS-CoV-2 virus is a permanent addition to human infectious viruses. It's here to stay.
- 11/15/2021
|
Brandes: The Staying Power of the Value Run
- The last decade has been a challenging one for value investors. Prior to the fourth quarter of 2020, value stocks (MSCI World Value) had been experiencing their longest and most pronounced underperformance period on record relative to growth stocks (MSCI World Growth).
- 11/10/2021
|
10 Stocks Post-Pandemic: What to Consider, Keep and Run From
- More than a year and a half into the Covid-19 pandemic, the world is changing. More people are returning to the office after months of working at home and restaurants have reopened.
- 11/09/2021
|
Why BioNTech Is Tumbling Today
- It really shouldn't, given its convincing quarterly revenue and earnings beats.
- 11/09/2021
|
BioNTech SE (BNTX) CEO Ugur Sahin on Q3 2021 Results - Earnings Call Transcript
- BioNTech SE (BNTX) CEO Ugur Sahin on Q3 2021 Results - Earnings Call Transcript
- 11/09/2021
|
BioNTech stock reverses lower after earnings report, in which profit and revenue beat expectations
- Shares of BioNTech SE BNTX, -3.36% dropped 2.9% in morning trading Tuesday, reversing an earlier intraday gain of as much as 4.3%, in the wake of the Germany-based biotechnology company's better-than-expected third-quarter earnings report. The company reported before the open that it swung to net income of EUR3.21 billion ($3.72 billion), or EUR12.35 a share, from a loss of EUR210.0 million, or EUR0.88 a share, in the year-ago period, to beat the FactSet consensus for earnings per share of EUR10.54.
- 11/09/2021
|
BioNTech Clocks Q3 Sales Of €6B; Raises FY21 COVID-19 Vax Sales Outlook
- BioNTech SE (NASDAQ: BNTX) reports Q3 FY21 revenues of €6.08 billion compared to €67.5 million a year ago, mainly due to rapid increases in the supply and sales of the COVID-19 vaccine worldwide. As of November 2, BioNTech and its partner Pfizer Inc (NYSE: PFE) have shipped over two billion doses of its COVID-19 vaccine (BNT162b2).
- 11/09/2021
|
Recap: BioNTech Q3 Earnings
- BioNTech (NASDAQ:BNTX) reported its Q3 earnings results on Tuesday, November 9, 2021 at 08:00 AM. Here's what investors need to know about the announcement.
- 11/09/2021
|
Why BioNTech Stock Is Bouncing Back Today
- Investors appear to think last week's sell-off was overdone.
- 11/08/2021
|
Earnings Previews: BioNTech, Palantir, Workhorse
- Nearly 500 companies are reporting quarterly earnings this week. The one in our watch list for Monday morning, Coty, beat estimates on both the top and bottom lines.
- 11/08/2021
|
Is a Surprise Coming for BioNTech (BNTX) This Earnings Season?
- BioNTech (BNTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 11/08/2021
|
Gritstone Poised To Dominate mRNA Market
- Gritstone Poised To Dominate mRNA Market
- 11/08/2021
|
Why BioNTech Stock Is Plunging Today
- Good news for Pfizer was seen as potentially bad news for BioNTech.
- 11/05/2021
|
BioNTech: Expecting A Blowout Quarter
- BioNTech continues to have a lucrative future as the world gets vaccinated and boostered.
- 11/04/2021
|
Why BioNTech Stock Is Falling Today
- Moderna's disappointing Q3 report appears to be dragging BioNTech's shares down with it.
- 11/04/2021
|
Better-Than-Expected Private Payrolls in October
- Better-Than-Expected Private Payrolls in October.
- 11/03/2021
|
5 Blue-Chip Stock to Buy as Dow Crosses a Fresh Milestone
- We have narrowed down our search to five Dow stocks with strong growth potential for the ensuing quarter. These are: CVX, DOW, MCD, HD and MSFT.
- 11/03/2021
|
Biotech Stock Presents Interesting Technical Positioning
- Germany-based biotech stock BioNTech SE (NASDAQ:BNTX) has been struggling to rebound from its late-September bear gap, consolidating above the $240 level for a good portion of October.
- 11/02/2021
|
Why BioNTech Shares Are Trading Higher Today
- BioNTech SE (NASDAQ: BNTX) is trading higher Tuesday in sympathy with Pfizer Inc (NYSE: PFE) after the company reported better-than-expected third-quarter financial results. Pfizer reported quarterly earnings of $1.34 per share, which beat the estimate of $1.09 per share.
- 11/02/2021
|
7 A-Rated Healthcare Stocks to Buy for the Long Haul
- It looks like we're on the back end of the Covid pandemic, so it's a good time to look at healthcare stocks that have a big future. The post 7 A-Rated Healthcare Stocks to Buy for the Long Haul appeared first on InvestorPlace.
- 11/01/2021
|
BioNTech to Present New Clinical Data from First-in-Class CAR-T Program BNT211 in Late-breaking Session at 36th SITC Annual Meeting
- MAINZ, Germany, November 1, 2021 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), a next generation immunotherapy company pioneering novel therapies for cancer and infectious diseases, today announced that new clinical data from the first-in-human Phase 1/2 trial evaluating the Company's novel CAR-T cell therapy candidate, BNT211, will be presented in an oral presentation. The presentation is scheduled for the late-breaking abstract poster session at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held both in person and virtually from November 10 - 14, 2021.
- 11/01/2021
|
Top 6 Momentum Picks for November After a Fabulous October
- We have narrowed down our search to six large-cap momentum stocks that have strong upside left for the rest of 2021. These are: BX, Ce, CLR, XLNX, BG, GPC.
- 11/01/2021
|
Novavax Is Finally Coming For BioNTech's Dominance
- Comirnaty, the COVID-19 vaccine produced by Pfizer-BioNTech, has been recommended for children between 5 and 11 years old. The White House has acquired sufficient vaccines from Pfizer-BioNTech. It is targeted for distribution to more than 25,000 pediatricians' offices, hospitals, and pharmacies.
- 10/28/2021
|
FDA's Adcomm Almost Unanimously Back Pfizer/BioNTech's COVID-19 Shots For Younger Kids
- The FDA's Vaccines and Related Biological Products Advisory Committee voted 17-0 favor Pfizer Inc (NYSE: PFE) - BioNTech SE's (NASDAQ: BNTX) COVID-19 vaccine in younger children. With one panelist abstaining, the FDA Advisory Committee said that the vaccine outweighs the risks for children between five and 12.
- 10/27/2021
|
BioNTech to Report Third Quarter Financial Results and Operational Update on November 9, 2021
- Mainz, Germany, October 27, 2021 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter on Tuesday, November 9th, 2021. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. ET (2.00 p.m. CET) to report its financial results and provide a corporate update for the third quarter 2021.
- 10/27/2021
|
BioNTech SE Sponsored ADR (BNTX) Stock Sinks As Market Gains: What You Should Know
- BioNTech SE Sponsored ADR (BNTX) closed at $292.39 in the latest trading session, marking a -0.86% move from the prior day.
- 10/26/2021
|
FDA advisors recommend BioNTech and Pfizer's COVID-19 shot for children
- A group of scientists who advise the Food and Drug Administration said the benefits of BioNTech BNTX, -0.86% and Pfizer's PFE, +0.95% COVID-19 vaccine outweigh the risks for children between the ages of 5 and 11.
- 10/26/2021
|
BioNTech to build mRNA manufacturing facility in the African Union
- Shares of BioNTech SE BNTX, +5.96% gained 0.7% in premarket trading on Tuesday after the company said it plans to start building a manufacturing facility for its mRNA vaccines in the African Union in 2022. Once completed, the site is expected to have the capacity to produce several hundreds of millions of doses of BioNTech's vaccines, including the ability to produce the products used to make 50 million COVID-19 vaccine doses per year.
- 10/26/2021
|
Why Pfizer and BioNTech Will Be Bigger Winners Than Moderna With Mix-and-Match Boosters
- The FDA's decision to allow mix-and-match boosters shakes up the COVID-19 vaccine market.
- 10/26/2021
|
The FDA is set to review Pfizer's coronavirus vaccine for kids 5- to 11-years old
- These are Insider's biggest healthcare stories for October 25.
- 10/25/2021
|
FDA committee to discuss BioNTech/Pfizer's COVID-19 shot in children 5 to 11
- A Food and Drug Administration advisory committee is set to meet Tuesday to discuss and then recommend whether the benefits outweigh the risks of BioNTech SE BNTX, -2.80% and Pfizer Inc.'s PFE, +0.70% COVID-19 vaccine in children between the ages of 5 and 11 years old. The FDA is not required to follow the advice of the committee but often does.
- 10/25/2021
|
How BioNTech Used Cancer Research To Create Its Covid Vaccine
- Over a month and a half before the World Health Organization officially declared a pandemic, BioNTech CEO Uğur Şahin met with his wife, BioNTech's co-founder and chief medical officer Özlem Türeci, and together they agreed to redirect most of the company's resources to developing a vaccine. Up until that point, BioNTech was little-known internationally and primarily focused on developing novel cancer treatments.
- 10/23/2021
|
How BioNTech went from a little-known biotech company to creating the Covid vaccine
- BioNTech founders were confident in the potential of their mRNA technology, which they knew could trigger a powerful immune response.
- 10/23/2021
|
Pfizer says COVID-19 vaccine is more than 90% effective in 5- to 11-year-olds
- Kid-size doses of Pfizer's COVID-19 vaccine appear safe and nearly 91% effective at preventing symptomatic infections in 5- to 11-year-olds, according to study details released Friday as the U.S. considers opening vaccinations to that age group.
- 10/22/2021
|
Pfizer Covid-19 vaccine shows 90.7% efficacy in 5 to 11 year olds
- Pfizer's Covid-19 vaccine was 90.7% effective in 5 to 11 year olds in clinical trials, according to new FDA documents. CNBC's Meg Tirrell reports.
- 10/22/2021
|
Why BioNTech and RedHill Are Soaring This Week, While Novavax Is Sinking
- All three have COVID-19 connections.
- 10/22/2021
|
Why BioNTech Stock Jumped Today
- BioNTech and Pfizer announced high efficacy for their COVID-19 vaccine booster.
- 10/21/2021
|
Shares of Covid-19 Vaccine Co-Developer BioNTech Have Soared Over Past Year
- On the strength of the Covid-19 vaccine it co-developed with Pfizer Inc. ( PFE , Financial), BioNTech SE ( BNTX , Financial) shares rose about 200% in the past year, making it one of the top European biotech stocks cited by Labiotech.eu.
- 10/21/2021
|
Pfizer-BioNTech's COVID-19 Booster Study Shows Robust Efficacy
- Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) announced topline results from a Phase 3 trial evaluating the efficacy and safety of a 30-µg booster dose of its COVID-19 vaccine. Related: Pfizer/BioNTech COVID-19 Boosters For Seniors, Certain Vulnerable Adults Coming Soon - CDC Panel Recommends.
- 10/21/2021
|
Why BioNTech Shares Are Rising
- BioNTech SE (NASDAQ: BNTX) shares rose on Thursday after the company and Pfizer Inc. (NYSE: PFE) announced that a booster shot of their COVID-19 vaccine was found to have a high efficacy of 95.6%. The companies stated that the vaccine booster's efficacy was strong for different demographic groups, "efficacy was consistent irrespective of age, sex, race, ethnicity or comorbid conditions.
- 10/21/2021
|
Pfizer/BioNTech COVID-19 booster 95.6% effective against disease: study
- A 30-microgram booster dose showed a relative vaccine efficacy of 95.6% in individuals who had previously received the Pfizer/BioNTech primary two-dose series, the companies announced.
- 10/21/2021
|
Novartis Extends Fill/Finish Support For Pfizer/BioNTech COVID-19 Vaccines
- Novartis AG (NYSE: NVS) has agreed to expand its fill-and-finish support for Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) COVID-19 vaccine. Novartis will use its sterile manufacturing facilities at its Novartis Technical Operations site in Ljubljana, Slovenia, to fill at least 24 million doses in 2022.
- 10/21/2021
|
Novartis signs new agreement with BioNTech to help manufacture COVID vaccines
- Novartis AG said Thursday that it has signed a new agreement with BioNTech SE to support the production of the company's and Pfizer Inc.'s Covid-19 vaccine at one of its facilities.
- 10/21/2021
|
Down 34% Last Month, Should You Buy BioNTech Stock For Near-Term Gains?
- BioNTech , a leader in messenger RNA technology and Pfizer's Covid-19 vaccine partner, saw its stock price decline by almost 34% over the last month, considerably underperforming the S&P 500 which remained roughly flat over the same period. There have been a couple of recent developments that hurt.
- 10/19/2021
|
Will New COVID-19 Vaccines Be Needed in 2022?
- One biotech CEO thinks so.
- 10/17/2021
|
We're at a very delicate time in this pandemic: FDA advisory panel member
- Dr. Ofer Levy, a voting member of the FDA vaccine advisory panel, joins Closing Bell to discuss the panel's decision to recommend a booster dose of Johnson & Johnson's Covid vaccine.
- 10/15/2021
|
BioNTech's Pipeline, Children's Vaccines, And Comirnaty Demand
- BioNTech's mRNA technology and bioinformatics will be difficult for competitors to replicate.
- 10/15/2021
|
BioNTech SE Sponsored ADR (BNTX) Gains But Lags Market: What You Should Know
- BioNTech SE Sponsored ADR (BNTX) closed at $250.33 in the latest trading session, marking a +0.37% move from the prior day.
- 10/14/2021
|
Has BioNTech SE Sponsored (BNTX) Outpaced Other Medical Stocks This Year?
- Is (BNTX) Outperforming Other Medical Stocks This Year?
- 10/12/2021
|
Thursday Afternoon Analyst Upgrades and Downgrades: Amazon, Bank of America, BioNTech, Chipotle, Disney and More
- Markets climbed higher on Thursday after lawmakers in Washington reached an agreement to extend the government's debt ceiling, preventing a shutdown.
- 10/07/2021
|
Pfizer, BioNTech file for FDA authorization for their COVID-19 vaccine in children
- Shares of Pfizer Inc. PFE, -0.71% were up 0.1% in premarket trading on Thursday after the company and BioNTech SE BNTX, -5.59% announced they submitted an application for emergency use authorization for their COVID-19 vaccine in children between the ages of 5 and 11 years old. The Food and Drug Administration will review the safety and efficacy of the vaccine before deciding whether to authorize the shot for this age group.
- 10/07/2021
|
Why BioNTech Stock Sank Today
- The move downward follows yet more good news from rivals.
- 10/06/2021
|
BioNTech co-founder Özlem Türeci on how Covid vaccine will help future drug developments
- The scientist behind the Pfizer-BioNTech Covid vaccine, Özlem Türeci, speaks to CNBC's Tania Bryer after the 2021 WIRED Health:Tech event, about what the public and private sectors need to do to achieve vaccine equity and how lessons learned from development and regulatory processes will support future treatments for other diseases. Subscribe to CNBC International TV: http://cnb.cx/2wAkfMv Subscribe to CNBC International: http://cnb.cx/2gft82z Like our Facebook page https://www.facebook.com/cnbcinternational Follow us on Instagram https://www.instagram.com/cnbcinternational/ Follow us on Twitter https://twitter.com/cnbci
- 10/06/2021
|
Could a New COVID Pill Crush Vaccine Sales?
- Moderna depends on its COVID-19 vaccine for revenue and profit.
- 10/05/2021
|
BioNTech: Speculating On New Potential Revolutionary Medical Breakthroughs
- BioNTech was among the first companies in the world to bring a viable COVID-19 vaccine to market. Over the short term, the main reason to buy BioNTech is the overwhelming success of its COVID-19 vaccine.
- 10/05/2021
|
Does the Sell-Off of BioNTech and Moderna Stocks Present a Buying Opportunity?
- These vaccine stocks are now cheaper due to investors' reaction to Merck's COVID-19 pill data.
- 10/05/2021
|
Pfizer/BioNTech COVID-19 Booster Shots Get Recommendation From European Medicine Agency
- The European Medicine Agency's Committee for Medicinal Products for Human Use has recommended COVID-19 booster shots from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) for adults 18 years and older. Related: Johnson & Johnson To Seek FDA Approval For COVID-19 Booster Shot: Report.
- 10/04/2021
|
BioNTech (BNTX) Begins Dosing in mRNA Cancer Vaccine Study
- BioNTech (BNTX) doses the first patient in a phase II study on its mRNA cancer vaccine candidate, BNT122, in patients with colorectal cancer.
- 10/04/2021
|
Pfizer and BioNTech Receive CHMP Positive Opinion for COVID-19 Vaccine Booster in the European Union
- NEW YORK and MAINZ, Germany, October 4 , 2021— Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion on the administration of the companies' COVID-19 vaccine as a booster dose at least six months after the second dose in individuals 18 years of age and older. The European Commission (EC) will review the CHMP recommendation and is expected to make a final decision on a variation to the Conditional Marketing Authorization in the near future. If the EC grants the variation regarding a booster dose, the decision will be immediately applicable to all 27 EU member states.
- 10/04/2021
|
Why BioNTech Shares Are Trading Lower Again Today
- BioNTech SE (NASDAQ: BNTX) is continuing to trade lower Monday amid news surrounding Merck & Co Inc's (NYSE: MRK) oral COVID-19 treatment. Merck, and Ridgeback, on Friday announced its investigational oral antiviral molnupiravir reduced risk of hospitalization or death by about 50% versus the placebo for patients with mild to moderate COVID-19 in Phase 3 interim analysis.
- 10/04/2021
|
BioNTech's CEO says the world might need new COVID-19 vaccines by mid-2022 to protect against emerging variants
- Current COVID-19 vaccines and booster shots may not be enough to protect against future variants of the coronavirus, Ugur Sahin told the FT.
- 10/04/2021
|
After COVID-19, Could This Be the Next Billion-Dollar Vaccine Market?
- Three healthcare giants are vying for the prize.
- 10/04/2021
|
Key Words: BioNTech CEO reportedly says a different COVID vaccine may be needed by next year
- BioNTech's chief executive officer Ugur Sahin told the Financial Times in an interview that COVID-19 is likely to continue mutating to the point where it can escape vaccines and immune systems.
- 10/04/2021
|
BNTX Stock Price: Why It Fell Over 6%
- The stock price of BioNTech SE (NASDAQ: BNTX) fell by over 6% in the previous trading session. This is why it happened.
- 10/02/2021
|
Take a Look at the Top-Performing Biotech ETFs YTD
- The pandemic has triggered a race to introduce vaccines and treatment options, opening up investment opportunities in the biotech sector.
- 10/02/2021
|
New COVID Drug Boosts Merck While Moderna And BioNTech Suffer
- Merck has reported strong data from its MOVe-OUT trial of molnupiravir. Molnupiravir could be an effective and safe treatment option for COVID.
- 10/02/2021
|
Why Pfizer, BioNTech, Novavax, and Vaxart Stocks Are Sinking Today
- Good news from Merck and Ridgeback caused these stocks to fall.
- 10/01/2021
|
Moderna and BioNTech plummet more than 15% following news of Merck's COVID-19 antiviral pill
- The antiviral drug could put a dent into the uptake of COVID-19 vaccines, as countries still struggle to reach herd immunity due to vaccine hesitancy.
- 10/01/2021
|
BioNTech Starts Dosing In Mid-Stage Colorectal Cancer Immunotherapy Trial
- BioNTech SE (NASDAQ: BNTX) has dosed the first patient with its individualized mRNA cancer vaccine BNT122 (autogene cevumeran, RO7198457) in Phase 2 clinical trial. The trial plans to enroll about 200 patients.
- 10/01/2021
|
BioNTech to Present New Clinical and Preclinical Data Across Multiple Immuno-Oncology Programs at 36th SITC Annual Meeting
- MAINZ, Germany, October 1, 2021 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), a next generation immunotherapy company pioneering novel therapies for cancer and infectious diseases, today announced that new clinical and preclinical data will be presented in six posters and one presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held both in person and virtually from November 10 - 14, 2021. The presentations will include new data from multiple programs across various drug classes along with first-in-human data for three programs. This is the largest data collection the company will present at a scientific meeting, showcasing BioNTech's diversified oncology pipeline. “The data we will be presenting at SITC 2021 is indicative of our continued pursuit of pathbreaking science and the development of our platform technologies that tailor anti-cancer therapies to individual patient needs,” said Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “We are encouraged by the considerable progress within our oncology portfolio seeing multiple programs now coming to fruition. They represent critical steps for us towards bringing cancer immunotherapy into the next generation and we are looking forward to sharing the data with the scientific community at a key conference.” Presentation Details:
- 10/01/2021
|
BioNTech Expands Clinical Oncology Portfolio with First Patient Dosed in Phase 2 Trial of mRNA-based Individualized Immunotherapy BNT122 in Colorectal Cancer Patients
- MAINZ, GERMANY, October 1, 2021 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ: BNTX, “BioNTech” or “the Company”), announced today that the first colorectal cancer patient has been treated with its individualized mRNA cancer vaccine BNT122 (autogene cevumeran, RO7198457) in a Phase 2 clinical trial. The trial has been initiated in the United States, Germany, Spain and Belgium. It is planned to enroll about 200 patients to evaluate the efficacy of RO7198457 (BNT122) compared to watchful waiting after surgery and chemotherapy, the current standard of care for these high-risk patients. As the second deadliest cancer worldwide, the medical need for novel therapies to treat colorectal cancer remains high.
- 10/01/2021
|
Why Moderna, BioNTech, and Novavax Stocks Are Tanking This Week
- It's not because any of the vaccine makers reported bad news.
- 09/30/2021
|
3 Big Drug/Biotech Stocks to Boost Your Portfolio's Health
- Sanofi (SNY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that are worth betting on in the current scenario.
- 09/30/2021
|
BioNTech: Stock Price Buoyancy Depends On Comirnaty Sales, But Long Term Value On Pipeline
- BioNTech has been a phenomenal success story for investors, delivering a ~1,900% gain on investment since its 2019 IPO. Sales of its mRNA vaccine Comirnaty will earn the company in excess of $18bn in 2021, management believes - firmly ahead of expectations.
- 09/30/2021
|
BioNTech Co-Founder Says Covid Will ‘Become Manageable' and Be Around for Years
- Dr. Özlem Türeci said she could imagine a scenario in which booster shots were given every 12-18 months, but added that more data were needed.
- 09/30/2021
|
'Covid will become manageable': BioNTech co-founder says the virus will be with us for years
- The co-founder and chief medical officer of BioNTech, the German firm which developed a Covid-19 vaccine alongside Pfizer, told CNBC that the world "should not live in fear" of the virus.
- 09/30/2021
|
BioNTech SE Sponsored ADR (BNTX) Outpaces Stock Market Gains: What You Should Know
- In the latest trading session, BioNTech SE Sponsored ADR (BNTX) closed at $277.44, marking a +0.33% move from the previous day.
- 09/29/2021
|
What's New With BioNTech Stock?
- BioNTech, a leader in messenger RNA technology and Pfizer's Covid-19 vaccine partner, has seen its stock decline by almost 9.4% over the last week (five trading days) and by about 17% over the last month. This compares to the S&P 500 which was up about 2% over the last week.
- 09/29/2021
|
Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Today
- Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.
- 09/28/2021
|
Pfizer and BioNTech seek FDA authorization for vaccination of 5- to 11-year-olds
- Pfizer Inc. PFE, -0.84% and German partner BioNTech SE BNTX, -7.91% said Tuesday they have submitted initial data from the late-stage trial of their COVID-19 vaccine in children aged 5 to 12 to the U.S. Food and Drug Administration, and are seeking an emergency-use authorization to add that patient group to the program. The news comes after the companies released initial data from the trial last week, saying the vaccine had proved safe and effective.
- 09/28/2021
|
Pfizer and BioNTech submit initial data to FDA from trial of COVID-19 vaccine in children aged 5 to 12
- Pfizer Inc. PFE, -0.84% and German partner BioNTech SE BNTX, -7.91% said Tuesday they have submitted initial data from the late-stage trial of their COVID-19 vaccine in children aged 5 to 12 to the U.S. Food and Drug Administration, and are seeking an Emergency Use Authorization to add that patient group to the program. The news comes after the companies released initial data from the trial last week, saying the vaccine had proved safe and effective.
- 09/28/2021
|
Why Are the Nasdaq's Top Growth Stocks Freaking Out Monday?
- None of it has anything to do with business fundamentals.
- 09/27/2021
|
Why BioNTech Shares Are Falling
- Shares of COVID-19 vaccine makers, including BioNTech SE - ADR (NASDAQ: BNTX), are trading lower amid continued volatility in the space as investors weigh booster shot progress. Pfizer CEO Albert Bourla recently predicted a return to 'normal life' within a year with a likely need for annual shots.
- 09/27/2021
|
Why BioNTech, Moderna, and Novavax Stocks Are Sliding Today
- Volatility remains high among vaccine stocks as two CEOs predict the end of the pandemic next year.
- 09/27/2021
|
CDC director overrules advisors, expands booster recommendation
- CNBC's Meg Tirrell reports on CDC director overruling advisers to expand Covid vaccine booster recommendation.
- 09/24/2021
|
CDC Director Backs Pfizer Booster Shots For Seniors, Vulnerable—And High-Risk Workers
- Dr. Rochelle Walensky recommended workers in high-risk settings to also be offered Pfizer Covid booster doses, despite the CDC advisers voting against this group getting the third shot.
- 09/24/2021
|
Will Pfizer ETFs Soar on FDA's COVID-19 Vaccine Booster Approval?
- Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging update in coronavirus vaccine.
- 09/23/2021
|
CDC Advisors Recommend Pfizer Booster Shots for Older Americans
- An advisory committee to the agency rejected a recommendation for boosters for people aged 18 to 64 in an occupational or institutional setting where the risk of transmission is high.
- 09/23/2021
|
CDC advisors vote to recommend Pfizer booster
- Meg Tirrell joins Closing Bell with breaking news from a CDC advisory panel evaluating Covid booster shots.
- 09/23/2021
|
CDC panel endorses Pfizer Covid booster shots for people 65 and older
|
Pfizer (PFE) Booster Dose Gets FDA Nod for High-Risk People
- FDA approves Pfizer's (PFE) COVID-19 vaccine booster shots for older adults and high-risk people amid rising infection rates in the country.
- 09/23/2021
|
Pfizer COVID-19 Vaccine Booster Shot Approved By FDA For High-Risk Individuals, People 65 And Up
- The U.S. Food and Drug Administration on Wednesday authorized a booster dose of the Pfizer Inc. (NYSE: PFE)-BioNTech SE (NASDAQ: BNTX) COVID-19 vaccine for people aged 65 years and older as well as other high-risk Americans. What Happened: The FDA said that the booster dose can be administered to individuals that meet these criteria six months after completion of their first two doses.
- 09/22/2021
|
FDA approves Pfizer COVID-19 boosters for seniors, those at high risk
- The U.S. has moved a step closer to offering booster doses of Pfizer's PFE, +0.07% COVID-19 vaccine to seniors and others at high risk from the virus.
- 09/22/2021
|
FDA Authorizes Pfizer Covid Booster Shots For Seniors And High-Risk Patients — But Not For All Americans
- The FDA greenlit a third dose of Pfizer's coronavirus vaccine for seniors, people with underlying health conditions and people with “occupational exposure” to the coronavirus.
- 09/22/2021
|
FDA authorizes boosters of the Pfizer-BioNTech coronavirus vaccine for older adults and others at high risk from COVID-19
- The hope is that booster shots will help protect those most at risk as the pandemic continues to rage.
- 09/22/2021
|
FDA authorizes Pfizer's Covid booster shots for people 65 and older and other vulnerable Americans
- The CDC's vaccine advisory committee plans to meet this week, and the agency's panel of experts is expected to vote on plans to distribute third shots.
- 09/22/2021
|
BioNTech SE Sponsored ADR (BNTX) Stock Sinks As Market Gains: What You Should Know
- In the latest trading session, BioNTech SE Sponsored ADR (BNTX) closed at $339.26, marking a -0.61% move from the previous day.
- 09/22/2021
|
Pfizer CEO on providing 500 million vaccines to low income countries
- CNBC's "Squawk Box" team discusses the coronavirus vaccine and how it can get to lower income countries to provide equitable access and infrastructure with Pfizer CEO Albert Bourla.
- 09/22/2021
|
CDC committee to meet today and Thursday to again discuss BioNTech and Pfizer's COVID-19 booster
- A Centers for Disease Control and Prevention committee is set to meet Wednesday and Thursday to again discuss the science and possible administration plan for BioNTech SE BNTX, +0.69% and Pfizer Inc.'s PFE, -0.63% COVID-19 booster shot. The CDC's Advisory Committee on Immunization Practices sets out the guidelines for how vaccines should be used in the U.S. The Food and Drug Administration has not approved or authorized an extra dose of the BioNTech and Pfizer vaccine except in people who are immuno-compromised, and an influential FDA committee last week recommended that boosters be limited to older people and those who are at higher risk of severe disease.
- 09/22/2021
|
US To Donate Additional 500M Pfizer-BioNTech COVID-19 Vaccine Doses To Lower Income Nations
- Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) will provide the U.S. government additional 500 million doses of its COVID-19 vaccine. The doses at a not-for-profit price will be used for donations to low- and lower-middle-income countries and the organizations that support them.
- 09/22/2021
|
Pfizer, BioNTech to provide additional 500 million COVID-19 vaccine doses to U.S. government for donation
- Pfizer Inc. PFE, -0.63% and BioNTech SE BNTX, +0.69% announced Wednesday plans to provide an additional 500 million doses of their COVID-19 vaccine to the U.S. government. The additional doses will be sold at "not-for-profit" prices, for donation to low- and lower-middle-income countries, as defined by Gavi's COVAX Advanced Market Commitment (AMC) and the 55 member states of the African Union.
- 09/22/2021
|
U.S. to donate millions more Pfizer-BioNTech vaccine doses to poorer nations
- Pfizer and BioNTech will provide an additional 500 million doses of their Covid-19 vaccine to the U.S. government to be donated to lower income countries.
- 09/22/2021
|
Pfizer and BioNTech Expand Collaboration with U.S. to Provide 500 Million Additional COVID-19 Vaccine Doses at Not-For-Profit Price for Donation to Poorest Countries
- NEW YORK and MAINZ, Germany, September 22, 2021— Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced plans to expand their agreement with the U.S. government by providing an additional 500 million doses of the companies' COVID-19 vaccine at a not-for-profit price for donation to low- and lower-middle-income countries and the organizations that support them. This expanded agreement brings the total number of doses to be supplied to the U.S. government for donation to these countries to one billion.
- 09/22/2021
|
FDA To Probably Decide On Pfizer/BioNTech COVID-19 Booster Shots By Tomorrow: Bloomberg
- Citing people familiar with the matter, Bloomberg reports that the FDA is expected to decide on Wednesday whether to recommend Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) COVID-19 vaccine as a booster shot. Last Friday, an FDA advisory panel recommended against the broader use of the vaccine as an additional shot.
- 09/21/2021
|
For BioNTech, the COVID-19 vaccine was simply the opening act
- Ultimately, BioNTech's mission is to make treatments that are optimized not only to specific patient needs, but also to time and place.
- 09/21/2021
|
2 Outperforming Biotech Stocks to Examine on Covid-19 Vaccine Updates
- With recent updates from Pfizer Inc. ( PFE , Financial) and BioNTech SE ( BNTX , Financial) regarding the effectiveness of their Covid-19 vaccine among children ages 5 to 11 and Johnson & Johnson's ( JNJ , Financial) booster shot announcement, consumers and investors alike are continuing to carefully watch the health care space.
- 09/21/2021
|
Is Now the Time to Ditch Pharma Stocks?
- With drug pricing reform on the horizon, investors may want to analyze their allocation.
- 09/21/2021
|
When can children get the COVID vaccine? Good Pfizer-BioNTech results could mean fast timeline
- How quickly we go from today's announcement to shots in little arms depends on how smoothly the process unfolds. Announcing impressive results from a Phase 2/3 trial on Monday, Pfizer and BioNTech said their two-dose COVID-19 vaccine works very well on children aged 5 to 11, a potential game-changer for people in that age group, their parents and caregivers, and vaccination efforts across the country.
- 09/20/2021
|
September Syndrome Deepens in Markets
- September Syndrome Deepens in Markets.
- 09/20/2021
|
Pfizer, BioNTech Analysts On FDA Panel's COVID-19 Booster Dose Decision
- Pfizer, Inc. (NYSE:PFE)-BioNTech SE (NASDAQ:BNTX) suffered a setback last week after a FDA panel did not recommend a third dose of the duo's COVID-19 vaccine for the broader population. The Pfizer-BioNTech Analysts: Morgan Stanley analyst Matthew Harrison maintained an Equal-weight rating and $45 price target for Pfizer shares.
- 09/20/2021
|
Contagion Fears Squeeze Pre-Market Futures
- It's difficult to know what's going on in the minds of the Chinese market authorities, but for those great American companies less reliant on the Chinese economy, it may be a good time to bring out our wish-list.
- 09/20/2021
|
FDA Panel Vetoes PFE/BNTX Third Jab for All, Vaccine Stocks Down
- Pfizer (PFE) and Moderna (MRNA) are the only two companies that have submitted data and are seeking approval for a booster or "third" dose of their COVID-19 vaccines.
- 09/20/2021
|
Pfizer/BioNTech COVID-19 Vaccine Data For Kids Is Here: What You Need To Know
- Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have announced results from one cohort from a Phase 2/3 trial evaluating its COVID-19 vaccine on a two-dose schedule (approximately 21 days apart). The data from over 2,200 children aged 5 to 11 years showed a favorable safety profile and robust neutralizing antibody responses using a two-dose regimen of 10 µg, a smaller dose than the 30 µg dose used for people 12 and older.
- 09/20/2021
|
Pfizer and BioNTech to seek approval to vaccinate children after Covid study
- Pfizer and BioNTech's intend to apply for approval for their Covid-19 vaccine to be given to children after a trial showed it to be safe and rapidly built up resistance to the virus. Children received two doses of the vaccine 21 days apart in what was the first major trial of a covid vaccine for those under the age of 12, Antibody responses in the participants were comparable to those recorded in a previous Pfizer-BioNTech study in people 16 to 25 years of age immunised with three times larger doses, said the firms.
- 09/20/2021
|
Pfizer and BioNTech to seek approval to vaccinate children after Covid study results
- Pfizer and BioNTech's intend to apply for approval for their Covid-19 vaccine to be given to children after a trial showed it to be safe and rapidly built up resistance to the virus. Children received two doses of the vaccine 21 days apart in what was the first major trial of a covid vaccine for those under the age of 12, Antibody responses in the participants were comparable to those recorded in a previous Pfizer-BioNTech study in people 16 to 25 years of age immunised with three times larger doses, said the firms.
- 09/20/2021
|
Pfizer and BioNTech to seek approval to vaccinate children after study results
- Pfizer and BioNTech's intend to apply for approval for their Covid-19 vaccine to be given to children after a trial showed it to be safe and rapidly built up resistance to the virus. Children received two doses of the vaccine 21 days apart in what was the first major trial of a covid vaccine for those under the age of 12, Antibody responses in the participants were comparable to those recorded in a previous Pfizer-BioNTech study in people 16 to 25 years of age immunised with three times larger doses, said the firms.
- 09/20/2021
|
Pfizer and BioNTech Announce Positive Topline Results from Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years
- NEW YORK and MAINZ, Germany, September 20, 2021— Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced results from a Phase 2/3 trial showing a favorable safety profile and robust neutralizing antibody responses in children 5 to 11 years of age using a two-dose regimen of 10 µg administered 21 days apart, a smaller dose than the 30 µg dose used for people 12 and older. The antibody responses in the participants given 10 µg doses were comparable to those recorded in a previous Pfizer-BioNTech study in people 16 to 25 years of age immunized with 30 µg doses. The 10 µg dose was carefully selected as the preferred dose for safety, tolerability and immunogenicity in children 5 to 11 years of age. These are the first results from a pivotal trial of a COVID-19 vaccine in this age group.
- 09/20/2021
|
4 Solid Stock Picks for the Value Investor
- Benjamin Graham, the father of value investing, recommended investors to look for stocks that have a current ratio higher than 2 and more working capital than long-term debt.
- 09/19/2021
|
FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations
- NEW YORK AND MAINZ, GERMANY, September 17, 2021—Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose of COMIRNATY® (COVID-19 Vaccine, mRNA) in individuals 65 years of age and older and individuals at high risk of severe COVID-19. The committee recommended that the additional dose be administered at least six months after the two-dose series. The panel also agreed that healthcare workers and others at high risk for occupational exposure should be included in this EUA.
- 09/18/2021
|
FDA Advisory Committee Votes Unanimously in Favor Of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-risk Populations
- NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose of COMIRNATY® (COVID-19 Vaccine, mRNA) in individuals 65 years of age and older and individuals at high risk of severe COVID-19. The committee recommended that the ad
- 09/17/2021
|
Influential FDA Panel Votes Down Widespread Pfizer Booster; Approves Third Shot For 65 & Older + Those At “High Risk”
- A month after Joe Biden laid out a plan for Americans to get a vaccine booster shot to help contain the coronavirus pandemic and the deadly Delta variant, a pivotal advisory panel to the Food and Drug Administration today partially kicked the legs out from the President's proposal. In a whirlwind of mixed messages, the...
- 09/17/2021
|
FDA panel votes for Pfizer booster for those 65+ and at higher risk
- Meg Tirrell joins Closing Bell with breaking news. An FDA advisory committee voted to approve an emergency authorization for a booster dose of Pfizer's covid vaccine for those 65 and older.
- 09/17/2021
|
FDA Panel Votes Against Approval Of Pfizer/BioNTech's COVID-19 Booster Shot For General Public
- Pfizer, Inc. (NYSE: PFE)-BioNTech SE (NASDAQ: BNTX) shares are sliding after a Food and Drug Administration panel voted against recommending a third dose of their COVID-19 vaccine, Comirnaty, to the general population. What Happened: FDA's Vaccines and Related Biological Products Advisory Committee met Friday to discuss Pfizer-BioNTech's supplemental biologics license application for Comirnaty for the administration of a third dose, or "booster" dose, of the COVID-19 vaccine, in individuals 16 years of age and older.
- 09/17/2021
|
FDA panel votes against Pfizer booster for general public
- In a follow-up vote, the panel voted that the benefits of a third dose for older adults and individuals at high risk of severe COVID-19 outweigh the risks.
- 09/17/2021
|
FDA panel votes not to recommend booster shots at this time
- Meg Tirrell joins Closing Bell with news from the FDA's outside panel of experts on vaccines.
- 09/17/2021
|
FDA Advisory Panel Recommends Against Pfizer Covid Boosters—Except For People Over 65
- The group of independent experts, which informs the FDA's decision on vaccine approval, argued there isn't enough evidence to support the need for a third dose of Pfizer's vaccine.
- 09/17/2021
|
FDA committee votes against approving BioNTech and Pfizer's COVID-19 booster
- A group of advisors to the Food and Drug Administration said Friday the regulator should not allow Americans to get a third dose of BioNTech SE and Pfizer Inc.'s COVID-19 vaccine.
- 09/17/2021
|
